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SUMMARY
Blood platelets are Important cells in the inflammatory 
process and are useful for investigating receptor-linked 
mechanisms of activation and the effects of drugs*
A number of platelet functions have been investigated in 
groups of healthy individuals and patients with rheumatoid 
arthritis, before and during treatment with D-penioillamine. 
Evidence of abnormal platelet function was found in 
rheumatoid arthritis including, thrombocytosis, reduced 
platelet volume, increased platelet turnover, in particular, 
rheumatoid platelets showed enhanced sensitivity to 
aggregation induced by ADP, adrenaline and especially 
collagen. These data imply consumption of platelets during 
the rheumatoid disease process.
Treatment of rheumatoid patients with D-penlcillamine 
brought about the abolition of the aggregatory response to 
adrenaline and reduced sensitivity to the other agonists. 
There was also a general trend towards normalisation in all 
platelet parameters measured. The loss of repsonse to 
adrenaline was found to be partly due to blockade of platelet 
alpha2 adrenoceptors, and partly to another effect, possibly 
on the G1 coupling protein. The inhibition brought about by D- 
penicillamine on platelet aggregation was reversed by 
incubation with Dithiothreitol in vitro.
Thus, D-penlcillamine may bring about some of its anti­
rheumatic actions through effects on platelets, or by similar 
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An investigation into the mode of action of a drug in a 
pathological process requires some knowledge of the 
physiological and biochemical changes that have occurred in 
the system which differentiate it from the normal state. 
Conversely, investigations into proposed mechanisms of drug 
activity may lead to Important information in the 
understanding of the pathological process.
1.2 The Inflammatory Process
Inflammation has been defined as a response of a tissue to 
sublethal Injury (Houck, 1968) and such a general statement 
adequately summarizes the various forms in which the process 
may be manifested. Heat, redness, swelling, pain and loss of 
function, the cardinal signs of inflammation were first 
described by Celsus (30B.C.-A.D.38) and Galen (129-201A.D.). 
Regardless of the type of injury (traumatic, immunological, 
chemical or thermal) or the particular location of the tissue 
itself, the immediate event is that cells are adversely 
affected by the stimulus and an inflammatory reaction is 
initiated. Typical features of the reaction can be 
recognised at the tissue, cellular and subcellular level.
The events of the inflammatory process, outlined later, may 
follow a simultaneous rather than a sequential and orderly
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pattern. The biochemistry and physiology of the inflammatory 
process is complex, and is still to be fully elucidated at 
many stages, but in vitro methods in correlation with in vivo 
observations appear to be the only way in which a true 
understanding of the underlying cause of the pathological 
Inflammatory response and realisation of the mode of activity 
of anti-inflammatory drugs may be achieved.
The events of the inflammatory process have been the subject 
of numerous books, reviews and papers. Notable amongst them 
are the works of Zwelfach, Grant & McCluskey, ( 1965); Spector 
& Willoughby, (1968); Forscher, (1968); Weiner & Piliero, 
(1970); Chayen $ Bitensky, (1971); Willoughby, (1973)* 
Zvaifler, (1973); Billingham & Davies, (1979); Zvaifler, 
(1979a); & Strober, (1981).
The primary effect of tissue injury is almost always 
manifested by a release of intracellular contents into an 
extracellular environment with a subsequent response in the 
micro-circulation. Cell derived small molecular mediators, 
such as histamine and 5-hydroxytryptamine (5HT), are 
liberated, primarily from tissue mast cells, to promote 
vasodilation and to increase the permeability of the venules 
and capillaries to circulating macromolecules and cells. 
These result in an accumulation of fluid at the injured site. 
The release of proteolytic and other digestive enzymes from 
lysosomes of either tissue cells e.g. synovial lining cells
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in rheumatoid arthritis (Chayen&Bitensky, 1971) or invading 
polymorphonuclear leucoytes (Weissmann, 1967) is considered 
of prime importance in the development of the Inflammatory 
response. Platelets are also capable of releasing 5- 
hydroxytryptamine and acid hydrolases which are mediators of 
inflammation, (Mills, Robb & Roberts, 1968).
As well as promoting tissue degradation, the lysosomal 
contents may also initiate the formation of other 
inflammatory mediators such as the klnlns (Hopsu - Havu 
Makinen & Glenner, 1966); and prostaglandins (Anderson, 
Brocklehurst & Willis, 1971). These agents are considered 
chemotactlc for polymorphonuclear leucocytes (Elsen, 1969; 
Kaley & Weiner, 1971) and, thus, might cause a concentration 
of active phagocytic cells in the Inflammatory lesion (Higgs 
& Youlton, 1972). Furthermore, platelets are capable of 
stimulating chemotaxis via complement activation in a manner 
similar to leucocytes (Veksler & Coupal, 1973; Ruddy & 
Austen, 1975) and may therefore participate in early stages 
of inflammation. (Fig.1.1).
Platelet aggregation and fibrin deposition occur late in the 
Inflammatory response causing thrombi formation, and stasis. 
Ischaemia, anoxia and acidosis of the wounded areas result, 
and tissue necrosis might follow. On the other hand 
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Fig. 1.1 Interaction between Platelets, Coagulation, Fibrinolytic
and Inflammatory Mechanisms.
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proliferate in the injured area to promote repair and 
restoration of function. This then represents the endpoint of 
the Inflammatory reaction.
One of the most important aspects of the acute inflammatory 
response is the pathological development of chronic 
inflammation. Mechanisms of this progression are less well 
understood, but it has been widely accepted that the chronic 
response may result partly from the generation and release of 
autoantigens from the Injured tissue, possibly involving a 
modification of host tissues by lysosomal enzymes.
Since the aetiology of virtually all inflammatory diseases 
remains unknown and cures for conditions such as rheumatoid 
arthritis remain elusive, the control of the Inflammatory 
response with non-steroidal drugs and the use of second line 
drugs such as gold and D-peniclllamine appear to be the most 
efficient therapeutic means of relieving much human 
suffering. Understanding the mode of action of these 
compounds might in turn lead to the development of more 
effective agents in the treatment of rheumatoid arthritis.
In this thesis I have examined D-penlclllamlne, a second line 
drug used in the treatment of rheumatoid arthritis, and its 
effects on blood platelets, the function of which may play a 
critical role in the self sustaining of the Inflammatory 
process.
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PART (1) RHEUMATOID ARTHRITIS
(A) The Pathogenesis of rheumatoid arthritis
1.1 Rheumatoid arthritis
Rheumatoid arthritis is a connective tissue disease of 
unknown aetiology which manifests itself both locally and 
systemically, but is characterised chiefly by an 
inflammatory erosive polyarthritis.
The typical picture of rheumatoid arthritis in a middle-aged 
or elderly woman with hands distorted and deviated to the 
ulnar side is familiar to almost everyone. This is, however, 
merely a common late result of a protean disease which may 
begin acutely or Insidiously and affect almost any pattern of 
Joints and show wide differences in its course and in its 
amenability to conventionally-used therapeutic measures.
There is a relatively rare but well defined childhood form of 
the disease in which the general symptoms of fever and weight 
loss are more conspicuous than in the adult. At all ages the 
most urgent symptoms are associated with synovitis of the 
joints leading to a variety of secondary local changes. 
There are inflammatory lesions of similar character in other 
synovial surfaces, bursae, tendon sheaths etc, and 
subcutaneous nodules are common.
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1.2 Epidemiology
Recent epidemiological surveys in different populations have 
shown that the disease is common, affecting up to 3% of the 
adult population and apparently sparing no racial or ethnic 
group* Anyone at anytime can be stricken with the disease 
although statistically the incidence is 2-3 times higher in 
women than men with a peak incidence between the ages of 25-55 
(Wood, 1977).
1.3 Anatomy
Glynn (1972) described the three outstanding anatomical 
features of rheumatoid arthritis to be (a) inflammation with 
progressive deformity of joints, (b) subcutaneous nodules 
and (c) vascular lesions.
A normal diarthrodial synovial joint consists of two bone 
ends capped with articular cartilage and joined by a fibrous 
capsule which is contiguous with the periosteum of the bones. 
The synovial membrane or "synovium" lines the capsule and is 
composed of a thin layer of cells, (Swinson&Swinburn, 1980). 
The lining layer of the synovium, the intlma, is 1-3 cells in 
thickness and rests on a very vascular subintimal tissue 
which may be adipose, fibrous or areolar. Synovial cells or 
synoviocytes are responsible for the secretion of hyaluronic 
acid into the synovial fluid, the removal of solid particles
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from the joint cavity and the activation of fibrinogen which 
is thought to prevent the accumulation of fibrin in the joint, 
(Fell, 1 978). The intimal cells have been shown to be of two 
types ~ A cells which are phagocytic and resemble macrophages 
and B cells which are characterised by abundant, well 
developed rough surfaced endoplasmic reticulum, and are 
fibroblastic in appearance. The A cells are the predominant 
cell type. It is uncertain which types are responsible for 
specific functions, (Zvaifler, 1973; Fell, 1978).
In health, synovial fluid is thick, clear and viscous and 
contains hyaluronlo acid; normal synovial fluid does not 
clot. Fibrinogen is absent but all the components of the 
fibrinolytic system necessary to produce free plasmin are 
present. Plasmin is the enzyme normally involved in the 
removal of fibrin. The volume of synovial fluid in a normal 
knee joint is quite small, being less than 2ml,(Zvaifler, 
1973; Swinson & Swlnburn, 1980).
1.4 Pathology
Early rheumatoid arthritis is characterised by swollen 
joints and a proliferative synovitis. Within the joint, 
excess connective tissue or Bpannusn is produced by the 
proliferation of synovial lining cells with extensive 
vascularisation and infiltration of lymphocytes, plasma 
cells, polymorphonuclear leucocytes, platelets and 
macrophages (Harvey, 1978). The lining cells increase to a
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depth of 6-10 cells (Zvaifler, 1 973) and the pannus protrudes 
into the joint space, Harris (1976) suggested that 
irreversible joint destruction may begin with the 
degradation of articular cartilage which is mediated by the 
encroaching pannus. Chayen & Bltensky (1971) have 
demonstrated a high lysosome content in rheumatoid synovial 
lining cells and the presence of lysosomal enzymes in 
rheumatoid joints which may contribute to the inflammation. 
In studies of rheumatoid synovial membrane using electron 
microscopy, Kobayashl & Ziff (1973) identified perivascular 
accumulations rich in lymphocytes or plasma cells, or both 
types. Gaucher, Faure, Netter, Pourel & Duhellle (1976) 
characterised cells of various sizes connected by 
Intercellular bridges. Thus the rheumatoid synovial 
membrane presents a villous surface in comparison to the 
smooth flat surface of normal synovial membrane, with 
extensive cellular hyperplasia and hypertrophy.
The synovial fluid also varies considerably from normal 
fluid. The most striking differences are the total volume of 
fluid (200-400 ml in an active knee joint) and the ability of 
rheumatoid synovial fluid to clot, (Zvaifler, 1973)* In 
rheumatoid arthritis synovial fluid protein and lipid levels 
are grossly elevated, while the haemolytic complement levels 
in rheumatoid patients are either normal or slightly 
increased.
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It is obvious that the cells infiltrate the joint from the 
surrounding tissues or blood vessels. Zvaifler (1973) has 
demonstrated that the predominant cell in rheumatoid 
synovial fluids is a mature polymorphonuclear granulocyte, 
accounting for 75-90? of all nucleated cells. The remaining 
cells consist of 5 - 1 0? lymphocytes with some monocytes, 
platelets, macrophages and synovial lining cells, all of 
which may be Involved in the pathogenesis of rheumatoid 
arthritis. (Denman, 1979).
Direct evidence of lymphocytes participating in this process 
was provided by Paulus, Machleder, Levine, Yu & MacDonald,
(1977). Thoracic duct drainage produced a clinical 
Improvement in rheumatoid patients and relnfuslon of the 
cells induced exacerbation of disease activity. Support for 
these experiments from the use of lymphapheresls and 
lymphapla8mapheresis has also Indicated some lymphocyte 
involvement (Tenenbaum, Urowitz, Keystone, Dwosa & Curtis, 
1979; Karsh, Wright, Kllppel, Decker, Deisseroth, & Flye,
1979).
Defects in the function of lymphocyte sub-populations may 
contribute to the pathogenesis of rheumatoid arthritis by 
several pathways. These include both helper and suppressor 
T lymphocytes, with defects leading to an inadequate response 
or to uncontrolled hyper-responsivness respectively (Slavin 
& Strober, 1981). Indeed, cellular abnormalities in
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rheumatoid arthritis were shown to be predominantly within 
the T oell population and impaired T cell funotion has been 
reported in many studies, (Hall & Bacon, 1981). Lack of 
suppressor T cell activity from synovial tissue lymphocytes 
has been demonstrated, (Chattopadhyay, Chattopadhyay, 
Natvig, Hichaelson & Mellbye, 1979)* Abdou, Lindsley, 
Racela, Pascual & Bassanein, (1981) also demonstrated 
suppressor T cell dysfunction and the presence of anti­
suppressor cell antibody in the peripheral blood of active 
early rheumatoid arthritis patients but not in Inactive and 
late inactive disease.
Raised platelet counts have been reported in rheumatoid 
arthritis and a direct relationship noted between 
thrombocytosis and disease activity, (Selroos, 1972; 
Hutchinson, Davis & Jayson, 1976; Colli Maderna, Tremoll 
Colombo & Canesi, 1982). The interaction be tween platelets, 
rheumatoid factor and immune complexes, all implicated in 
rheumatoid arthritis, may represent a conceivable link with 
tissue lesions of Inflammatory origin peculiar to the disease 
(Mueller-Eckardt&Luscher, 1968; Luscher, 1971; Margaretten 
& McKay, 1971; Pfueller & Cosgrove, 1980).
Hutchinson, Davis & Jayson (1976) also noted a significant 
correlation between thrombocytosis, vasculitis and other 
extra-articular manifestations and concluded that a 
compensatory over production, secondary to increased 
platelet consumption via intravascular coagulation may be
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involved. This supports the work of Bennett, Eddie-Quartey 
& Holt (1972); Selroos & Wegelius (1973b); Selroos, 
Petterson, & Vegelius (1973c). Biochemical changes are 
common in rheumatoid arthritis (Kendall, 1977)* However 
most of these are symptoms of an unhealthy state with little 
specificity for the condition.
1.5 Humoral Immunity
The presence of antibodies against the Fc region of 
autologous IgG (Rheumatoid Factor) in the serum of 
approximately 80$ of patients with rheumatoid arthritis has 
been well documented for many years, (Waaler, 1940; Rose, 
Ragan, Pearce & Lipman, 1948); and has been extensively 
reviewed (Zvaifler, 1973; Johnson & Faulk, W.P, 1976; Ziff, 
1980).
Classical IgM rheumatoid factor (IgMRF) led to the definition 
of seropositive and seronegative rheumatoid arthritis. No 
correlation was found between IgMRF and raised 
immunoglobulin levels in rheumatoid patients, (Barden, 
Mullinay & Waller, 1967)* More recently IgG rheumatoid 
factor has been demonstrated in both seropositive and 
seronegative rheumatoid patients but not in other 
seronegative rheumatoid diseases (Allen, Elson, Scott, Bacon 
& Bucknall, 1981). High levels are associated with
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rheumatoid vasculitis and IgA rheumatoid factors have also 
been described (Johnson & Faulk,W.P, 1976; March, Reebaek, 
Holborow & Coombs, 1981).
Rheumatoid factors could contribute to the presence of 
circulating antigen antibody complexes and rheumatoid 
arthritis is often termed an "Immune Complex Disease". 
Complexes can interfere with Fc receptor meditated functions 
and, when deposited in the tissues , may have pathological 
effects. Glomerulonephritis is probably immune complex 
induced (Wiggins & Cochrane, 1981), although this is rare in 
rheumatoid arthritic.
The rheumatoid synovial membrane is known to synthesise 
immunoglobulin of mainly IgG class (Smiley, Sachs & Ziff, 
1 968). IgG and IgG complexes can be synthesised 
intracellularly and not secreted. Approximately 5 0% of 
plasma cells are synthesising IgG (Natvig & Munthe, 1975). 
Immune complexes containing IgM, IgG and complement have been 
detected in synovial fluids, (Zvaifler, 197*0. Britton & 
Schur (1971) described intracytoplasmio inclusions of 
Immunoglobulins and complement in synovial fluid leucocytes, 
they suggested that immune complexes within the synovial 
fluid fix complement and through activation of C3 are 
phagocytosed by synovial fluid leucocytes. This may provide 
an explanation for the low levels of complement found in the 
joints of rheumatoid patients (Winchester, Agnello & Kunkel,
-14-
1969; Winchester, Agnello & Kunkel, 1970; Ruddy & Austen,
1975).
Other autoantibodies have been demonstrated in rheumatoid 
arthritis e. g.anti-nuclear antibodies (ANA) or anti-nuclear 
factors (ANF) (Holborow, 1979). These antibodies are found 
mainly in patients vlth systemic lupus erythematosus (SLE) 
although they are sometimes found in rheumatoid patients. 
Grennan, Sloane, Behan & Dick (1977) showed that rheumatoid 
patients with antibodies to double stranded DNA are more 
likely to have severe disease and extra-articular 
complications. Anti-collagen antibodies have been detected 
in both rheumatoid sera and synovial fluid, and collagenase 
activity has been proven in synovial membranes and fluid 
(Steffen, 1980).
1.6 Aetiology
The search for a primary antigen in rheumatoid arthritis has 
so far proved negative. It was originally postulated that 
the "Rheumatoid Factor" was the cause of rheumatoid arthritis 
but the discovery of high titres in other diseases dispelled 
this assumption (Zvaifler, 1973; Johnson & Faulk,W.P, 1976; 
Carson, Lawrance, Catalano, Vaughan & Abraham, 1977).
Using the human leucocyte migration inhibition test (LMT) 
some researchers have demonstrated a specific response by
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rheumatoid patients to synovial eluates (Bacon, Cracchiolo, 
Bluestone, & Goldberg, 1973)* Other investigations 
however, using very large numbers of patients have shown this 
effect to be non-specific (Morgan, Hall Collins, & Bacon,
1980).
An infectious agent has been implicated as the instigator of 
rheumatoid arthritis since many lmmunopathological features 
resembling those of connective tissue disease are associated 
with infeotions. It is known that arthritis complicates 
many bacterial and viral Infections such as rubella, although 
it is nearly always short lived and non erosive. A wide 
variety of autoantibodies are produced in some Infectious 
disease e.g. subacute bacterial endocarditis and anti IgG can 
neutralise infectious complexes of antigen found in viruses 
such as herpes simplex. Thirdly, virus infection has been 
implicated in some degenerative diseases of the central 
nervous system i.e. slow virus infection and influenza virus 
has been shown to precede Goodpastures syndrome :- an 
autoantibody induced glomerulonephritis in which antibodies 
to glomerular basement membrane are produced . There is 
commonly an Immune complex nephritis in infection including 
sub acute endocarditis. This subject is reviewed by Denman 
(1975) and Denman, Appleford, Imrie, Kinsley, Felton & 
Schnitzer, ( 1977)* These authors favour a viral aetiology for 
rheumatoid arthritis but this is not proven.
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Following many viral infeotions, viral antigens are 
expressed on the surface of the infected cells and the viral 
genome may become Integrated into host DNA, thus persisting 
in the host cell. Norval & Smith ( 197 9) » found no evidence of 
viral genomes in the DNA and RNA of synovial fibroblasts, 
synovial membranes or peripheral blood lymphocytes from 
patients with rheumatoid arthritis or other Joint 
conditions.
Appleford & Denman (1979a) Isolated lymphocytes from the 
peripheral blood and synovial fluid of rheumatoid patients 
and showed that only peripheral blood lymphocytes support the 
growth of Herpes Simplex Virus (HSV) . The same workers 
showed that the T lymphocytes Isolated from synovial fluid 
could support the growth of HSV but the readditlon of non-T 
lymphocytes again caused non permissiveness. However, if 
synovial fluid non-T lymphocytes were added to autologous 
peripheral blood T cells no such effect was noted and the 
virus grew normally. Removal of glass adherent cells from 
non-T Synovial fluid lymphocytes did not remove inhibition. 
The authors suggest that synovial non-T cells may be 
producing anti viral factors (Appleford & Denman, 1979b). 
Other investigators suggesting a viral aetiology for 
rheumatoid arthritis described the presence of a serum 
antibody in rheumatoid patients which is reactive with a 
soluble nuclear antigen extracted from human lyphoblastold 
lines infected with Epstein Barr Virus (EBV), but not those
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infected with other Herpes type viruses. Thus rheumatoid 
arthritis associated nuclear antigen (RANA) appears to be 
distinct from Epstein Barr Nuclear Antigen (E.B.N.A.) 
(Alspaugh, Jensen, Rabin & Tan, 1978). A high frequency of 
anti-RANA antibody was shown to occur in both seropositive 
and seronegative rheumatoid arthritis . Normal controls and 
patients with other arthritic conditions had low levels of 
antibody (Ng, Brown, Perry & Holborow, 1980). Catalano, 
Carson, Niederman, Feorino & Vaughan (1980) studied healthy 
individuals and showed that those having antibodies to Viral 
Capsid Antigen (VCA) whioh is expressed during EBV infection, 
also had anti- RANA antibodies, while anti-VCA negative 
individuals were anti-RANA negative. They therefore 
concluded that anti-RANA antibodies are produced only after 
EBV Infection. Ferrell, Aitcheson, Pearson & Tan, (1981) 
confirmed the high incidence of anti-RANA antibodies in RA 
patients and its distinction from anti EBNA. Other EBV- 
assoclated antibodies were also detected. Rheumatoid 
arthritis suppressor cells are poor regulators of EBV 
outgrowth (Depper & Zvaifler, 1981) but this effect is not 
specifio for rheumatoid arthritis .
1.7 Genetic Factors
Rheumatoid arthritis is a disease of relatively recent origin 
(Bywaters, 1975). It has been suggested that enviromental 
factors may operate in genetically predisposed individuals
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to promote development of the disease. Interest In the role 
of genetic factors in rheumatoid arthritis was generated 
through the work of Brewerton, Caffrey, Hart, James, Nlcholls 
& Sturrock (1973) Schlosstein, Terasaki, Bluestone & Pearson
(1 9 7 3 ) who demonstrated a very strong association between 
Ankylosing Spondylitis and the presence of an 
Histocompatibility Antigen (HLA-B27)• The HLA antigen DR4 
has been found in a higher proportion of rheumatoid patients 
than in healthy controls (Panayl & Wooley, 1977; Stastny, 
1978; Glbofsky, Winchester, Pafarroyo, Fotino & Kunkel, 
1978; Stastny & Fink, 1979). However, Jones, Jacoby, 
Johnson, Phua & Welsh (1983) suggested that HLA-DR4 is a 
marker of disease severity in rheumatoid arthritis rather 
than of suceptibility to arthritis.
Hence it appears that rheumatoid arthritis may be due to the 
exposure of individuals with a particular genetic 
constitution including HLA-DR4 to an infectious agent. The 
Illness may result from an Inappropriate immune response to a 
ubiquitous agent, or conversely, the individual who develops 
rheumatoid arthritis may be less able to withstand Infection 
by an uncommon pathogen, (Zvaifler, 1979a).
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(B) Treatment of Rheumatoid Arthritis
1.1 First line drugs
a. Non-steroidal anti-inflammatory drugs (NSAIDs)
The major classes of non steroidal anti-inflammatory drugs 
are (a) salicylic acids e.g. aspirin, (b) carboxylio acidss- 
1 . acetic acids e.g. indomethacin, 2 . propionic acids e.g. 
ibuprofen, 3 . fenamlc acids, mefenamlo acid, (o) enolic 
acids:- 1 . pyrazolones e.g. phenylbutazone 2 . oxicams e.g. 
piroxicam (Nickander, McMahon & Ridolfo, 1979)*
The NSAIDs can provide symptomatic relief, i.e. relief of 
pain, stiffness and swelling but are not thought to have any 
influence on the actual disease process ( Vane, 1971; Smith & 
Willis, 1971; and Hart, Huskisson & Ansell, 1982). Vane 
(1971) was the first worker to show that NSAIDs such as 
aspirin and indomethacin inhibited prostaglandin synthesis 
by blocking the cyclo-oxygenase pathway. However, their 
potencies as cyclo-oxygenase inhibitors vary widely (Crook, 
Collins, Bacon & Chan, 1976). It is now thought that some of 
the NSAIDs may have specific effects upon the lipoxygenase 
pathway as well. The lipoxygenase pathway releases potent 
lnflammogenlo components from platelets and leucocytes 
(Moncada & Vane, 1979). Blockade of the cyclo-oxygenase 
pathway could result in increased activity of the 
lipoxygenase pathway and thus enhance inflammation, (Humes,
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Winter, Sadowski & Kuehl, 1981), prostaglandin E2 and 
prostacyclin are the chief components of this kind. All 
NSAIDs exhibit not only analgesic, anti-inflammatory and 
anti-pyretic actions but also characteristic 
gastrointestinal side effects, possibly related to their 
common modes of action.
The effect of NSAIDs on prostaglandin production is now well 
documented, although other potential sites of action are 
numerous e.g. kinins, leukotrienes and oxygen radicals. 
Indeed non steroidal anti-inflammatory drugs have been shown 
to be Inhibitors of chemiluminescence generated by H2 O2 - 
myeloperoxidase C1, the major cytoxic system of neutrophils 
(Pekoe, Van-Dyke, Mengoli, Peden & English, 1982). Thus part 
of the Inflammatory effect of NSAIDs may be due to 
interference with the oxidative metabolism of neutrophils.
1*2 Second line drugs
Second line drugs are "disease modifying" or "slow acting" 
which are used generally in patients with severe active 
rheumatoid arthritis only after an adequate trial of first 
line NSAIDs has failed to relieve symptoms satisfactorily. 
Gold and penicillamine are examples of these and actually 
suppress disease activity in some patients with rheumatoid 
arthritis, slowing down the rate of progression of Joint 




Gold compounds are actually administered intramuscularly as 
aqueous sodium aurothiomalate or as an oil-based 
aurothioglucose. The mode of action of gold in rheumatoid 
arthritis is not known, but it may possibly act via thiol 
groups on the surface of cell membranes.
Gold has been used in the treatment of rheumatoid arthritis 
for over fifty years (Forestier, 1929). Its efficacy is well 
established in rheumatoid arthritis when disease activity 
cannot be controlled with NSAIDs (Empire Rheumatism Council, 
1960; and 1961 ; American Rheumatism Association, 1973; Walz, 
DiMartino & Sutton, 1974). The results of these studies were 
confirmed by Sigler, Bluhm, Duncan, Sharp, Ensign & McCrum
(1974). In a double blind trial they extended these findings 
to positive radiological evidence, proving that gold therapy 
significantly slowed the progression of disease activity in 
the joints of rheumatoid patients.
Clinical improvements are seen in 60-70$ of patients with 
reductions in circulating immune complexes in advance of 
rheumatoid factor decrease (Nlneham, Hay, Male & Roitt, 
Young & Perumal, 1979). The majority of gold injected is 
sequestered throughout the body tissues and has been 
demonstrated in lysosomes of macrophages and lining cells of 
the synovium, where it may inhibit the release of lysosomal
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enzymes, (Welssmann, 1972). A variety of enzyme systems are 
influenced by gold, particularly those requiring free SH 
groups (Zvaifler, 1979b). Comparisons of thlomalate with D- 
penicillamine, also an effective drug in rheumatoid 
arthritis, have led to the intriguing proposal that they may 
act by a common mechanism. Both are sulphydryl compounds 
(Munthe, Jellum & Aaseth, 1979) and there are similarities in 
their clinical effects - slow response, prolonged 
effectiveness and their side effects,
b. D-penlolllamlne (D-pen)
Penicillamine was discovered in acid penicillin hydrolysates 
(Abraham, Baker, Chain, Florey Holliday A Robinson, 1942); 
and was shown to be a fundamental part of the penloillln 
molecule. It was later given the name penicillamine because 
of its close relationship to penicillin and because it was an 
amino acid (Abraham, Chain, Baker & Robinson, 1943). The 
presence of a sulphydryl group on the beta carbon led to the 
structural formula of penicillamine (Chain, 1949). Much work 
was carried out on O-pen treatment of patients with Wilsonfs 
Disease due to its copper-chelating properties (Valshe, 
1956). Deutsch & Morton (1957) observed that certain thiols 
dissociated maoroglobulins, and this ultimately led to the 
considerable and subsequent study of the treatment of 
rheumatoid arthritis with penicillamine (Jaffe, 1962; Jaffe, 
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Mode of Action
Its mode of action in rheumatoid arthritis remains unknown, 
but it may act upon disulphide bonds and thiol groups, on cell 
membranes or on metallo-enzymes. The usual Initial dose of 
penicillamine Is 125mg/day, increasing by 125mg in steps 
every month until there is a clinical response. Some patients 
who fail to respond benefit from higher doses, occasionally 
up to 1,000mg/day. However, the incidence of side-effects 
increases rapidly at this dose level. Side effects of 
penicillamine are similar to those of gold and include 
thrombocytopenia, neutropenia and gastric irritation. 
Proteinuria, taste loss and skin rashes are common and may 
occur at any stage of therapy.
Penicillamine is an amino acid with thiol, amino and carboxyl 
functional groups. Three types of reaction play an important 
role in explaining the pharmacological and possible 
therapeutic actions of this drug:-
(a) Thiol-disulphide exchange, (b) Thiazolldine formation,
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(c) Metal ohelation (Friedman 1977; Nimni 1977; Sarkar, Sass- 
Kortsak, Clarke, Laurie & Wei, 1977).
In human blood, penicillamine forms complexes with various 
metals including lead and zinc (Balogh, El-Ghobarey, Fell, 
Brown, Dunlop & Dick, 1980) but its complexes with copper may 
have a more important role in changing or reducing 
inflammation in rheumatoid arthritis (Jaffe 1979; Munthe, 
Jellum & Aaseth, 1979; Greenwald, 1981; Clark, 1983; Davis, 
1984; Staite, Zoschke & Messner, 1984). The D-pen-copper 
complex possesses superoxide dismutase activity, in that it 
removes superoxide radicals generated by macrophages by 
catalysing the reaction to hydrogen peroxide. The hydrogen 
peroxide liberated is itself harmful to cell membranes and 
this is further removed by the enzyme catalase, (Greenwald 
1981; Clark, 1983; Staite, Zoschke & Messner, 1984).
The reaotivity of penicillamine with natural thiol compounds 
is not necessarily restricted to mixed disulphide formation 
with extracellular cysteine or with circulating 
macroglobulins like IgM. The drug may also react with free 
SH groups in other proteins such as serum albumin, resulting 
in the displacement of bound low molecular weight compounds 
(Stanworth, 1984). Hall & Gillan (1979) have shown that 
penicillamine enhances SH-SS exchange reactions and Gerber
(1978) reported that D-pen inhibits the SH-dependent heat 
aggregation of IgG in vitro and possibly the formation of auto 
IgG aggregates in vivo.
Many observations have been made on the long term action of
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penicillamine on plasma immunoglobulins and rheumatoid 
factors. Immunoglobulin levels of all classes are affected by 
penicillamine and IgA deficiency has resulted in some cases 
(Hjalmarson, Hanson & Nibson, 19 7 7 ;Stanworth, Johns 
Williamson, Shadforth, Felix-Davies & Thompson, 1977? Mbuyi- 
Muamba, Stevens & Decqueker, 1981; Gul, Corke, Huskisson & 
Holborow, 1984). Stanworth & Hunneyball (1979) have linked 
the tendency of penicillamine Induced Class A 
Immunoglobulinaemia to possession of the HLA A3B40 
haplotype.
Penicillamine responders who are initially classical 
seropositive, will demonstrate a fall in serum IgMRF levels, 
(Gul, Corke, Huskisson & Holborow, 1984). It is possible 
that the IgG complex becomes a stimulus to IgMRheumatoid 
factor production because of sulphydryl-disulphide 
rearrangements within the IgG molecule. Penicillamine by 
cross-linking with the sulphydryl groups, might prevent 
these rearrangements and so IgM antibodies to IgG are no 
longer produced (Pritchard & Nuki, 1978; Wollheim, 1981).
Lipsky(1 9 8 l) proposed that penicillamine might exert an 
immunosuppressive action and inhibit the function of cells 
involved in humoral immune responses.
Penicillamine, in the presence of copper, has been shown to 
inhibit the proliferative response of human peripheral blood 
T cells to non-specific phytomitogens (Lipsky & Ziff, 1978).
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In these experiments, the T cell function appeared to be 
specifically inhibited while the monocyte accessory function 
was not affected. Later, Lipsky & Ziff (1982) found that 
penicillamine also inhibited the capacity of peripheral 
blood mononuclear cells to generate immunoglobulin- 
secreting cells in response to in vitro stimulation with T 
cell-dependent polyclonal B cell activators. Again, 
inhibition was observed only when cells were incubated with 
penicillamine in the presence of copper ions. Other compounds 
such as 2 -mercaptoproprionylglycine and 5 -thiopyridoxine 
also inhibited responsiveness in the presence of copper in 
this system (Lipsky & Ziff, 1982). The observation that pre­
incubation with penicillamine and copper ions did not alter 
the capacity of B cells to form immunoglobulin-secreting 
cells after appropriate stimulation, but rather diminished 
helper T cell activity, implies that the action of 
penicillamine and other thiols results from a selective 
inhibition of T cell function, (Lipsky, 1981; Lipsky, 1984).
In addition to these effects, wide ranging actions of 
penicillamine have been reported, reduced levels of 
complement that may demonstrate an effect of the drug on the 
macrophage (Pritchard & Nukl, 1978; Munthe, Jellum & 
Aaseth, 1 979); an effect on neutrophils possibly due to the - 
COOH group on the penicillamine molecule activating 
granulocytic chemotactic response (Davis, 1984) and the 
stabilisation of lysosomal membranes and increases of lysyl
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oxidase activity, thereby leading to increased repair of 
collagen, (Munthe, Jellum & Aaseth, 1979; Davis, 1984). 
Thrombocytopenia is a fairly common side effect of 
penicillamine therapy and it has been estimated that between 
8 and 3 1 £ of patients will show a fall in their platelet count 
(Camp, 1981; Lyle, 1983; Thomas, Gallus, Brooks, Tampi, 
Geddes & Hill, 1984). This is of great interest in that a very 
large proportion of untreated rheumatoid patients present 
initially with a thrombocytosis. The mechanism causing a 
reduction in total platelet count remains unknown. It has 
been suggested it may be an auto immune reaction (Pegels, 
Ament, Van Der Plass Den Dalen, Van Dem Borne & Feltkamp, 
1982). Conversely, it has been shown that penicillamine 
alters platelet production rather than damaging existing 
platelets, (Thomas, Gallus, Brooks, Tampi, Geddes & Hill, 
1984).
The only conclusion that can be drawn about the mode of action 
of penicillamine is that it is very complex. It may not be 
simply explained by immunomodulation; but, all three types of 
reaction outlined may play a role in its pharmacological 
actions.
1.3 Third line drugs 
a. Cortieosteroids
There is no convincing evidence that corticosteroids modify
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the course of rheumatoid disease, and they are now used with 
caution and in defined limited circumstances. Non-specific 
immunosuppression results in the risk of infection as well 
as vascular necrosis, osteoporosis and vertebral collapse. 
However, these side effects are only relevant to high doses.
Mode of Action
Corticosteroids are the most powerful anti-inflammatory 
drugs available and their pharmacological effects are 
extensive. They have wide ranging effects on all aspects of 
humoral and cellular immunity and the reticuloendothelial 
system, with no specificity for those cells involved in 
pathogenesis. Corticosteroids inhibit vascular responses 
to chemical mediators preventing increased permeability and 
vasodilation seen in acute inflammation. The accumulation 
of platelets, neutrophils, monocytes, macrophages and T and B 
lymphocytes is inhibited (Fauci, Dale & Balow, 1976 ; Parrillo 
& Fauci, 1979) and antibody production is reduced and 
clearance of Immune complexes by the reticulo-endothelial 
system is lowered. Suppression of arachidonic acid 
release and resultant lack of synthesis of the cyclo- 
oxygenase and lipoxygenase products such as leukotreine B4 
(LT B4) and interference with the generation of platelet 
aggregating factor (PAF), results in an overall reduction in 
pro-inflammatory activity, (Lewis & Piper, 1975; Hirata, 
Schiffmann, Venkatasubramanian, Saloman & Axelrod, 1 980).
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These effects on mediator production are secondary to 
inhibition of phospholipase Ag by a steroid-induced protein, 
lipocortin (Flower, 1984; Flower, 1985).
The effect on the production of the inflammatory mediators 
may help to explain the potency of corticosteroids compared 
to other treatment. Important actions on carbohydrate, lipid 
and protein metabolism are reflected in the clinical 
appearance of patients receiving steroid therapy. The growth 
of fibroblasts is inhibited by glucocorticoids resulting in 
thinning of the skin, loss of protein, muscle proteolysis and 
very poor wound healing.
Since synovial fluid cells have been shown to concentrate 
steroids from solution at relatively low concentrations, the 
ability of the drugs to stabilize lysosomal membranes and 
prevent enzyme release may be an important feature, (Lewis & 
Day, 1 972). This however is unlikely to be a definite 
mechanism of action.
(b) Cytotoxic agents
The immunosuppressive agents azathioprine, cyclophosphamide 
methotrexate and chlorambucil can suppress both immune and 
non immune inflammation in experimental models and it has 
been suggested that this may be their primary mode of action 
in rheumatoid arthritis. However, evidence of immune 
suppression in rheumatoid patients on these drugs is
-30-
conflicting. Cell mediated responses have been reported as 
depressed or unaltered ( Currey, 1 978) , although azathioprine 
(Hurd & Ziff, 1974) and cyclophosphamide, (Campbell, 
Skinner, McLennan, Hersey, Waller, Wood, Jewell & Truelove,
1976) are known to deplete lymphocyte populations. High 
doses primarily cause reduction of B lymphocytes, plasma 
cells and antibody productivity, whereas smaller doses can 
actually enhance the production of antibodies and 
autoantibodies in experimental models by a differential 
effect on T suppressor lymphocytes, (Chanmougan & Schwartz, 
1966). All four drugs have severe toxic effects and long 
term treatment is prevented by the anxiety over late toxicity 
e.g. the likelihood of developing malignancy, especially 
Hodgkins lymphoma, mutagenesis, bone marrow and renal 
toxicity, (Bertino, Hurd, Decker & Steinberg, 1973).
1.4 Experimental therapies
(a) Plasmapheresis
Researchers have attempted to modulate the Immune system in 
rheumatoid arthritis by plasmapheresis. This has been 
beneficial in some immune complex diseases e.g. systemic 
lupus erythematosus (Hay, Nineham, Male, Roitt & 
Parry,1979a; Verrier-Jones, Cumming, Bacon, Evers, Fraser, 
Bothamley, Tribe, Davis & Hughes, 1979). Goldman, Casey, 
Mcllwain, Kirby, Wilson & Miller (1979) and Bacon (1979) have
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treated vascultis in rheumatoid arthritis by plasmapheresis. 
This resulted in a fall in circulating immune complex levels 
but symptoms reappeared when plasmapheresis was discontinued 
and no improvement was found in five other patients.
(b) Total Lymphoid Irradiation
Irradiation of total lymphoid tissue has been tried in 
several uncontrolled studies and in some instances symptoms 
have improved, (Kotzin, Strober, Engleman, Calin, Hoppe, 
Kansas, Terrell & Kaplan, 1981). However the results of 
controlled studies are awaited and since there is a high 
morbidity risk from such therapy it should be confined to 
specific centres conducting carefully controlled research 
and only involving patients where all conventional therapy 
has failed.
1.5 Alternative Medicine
Many homeopathic and diet regimes have been postulated in 
treating rheumatoid arthritis but there is little evidence 
that they have any beneficial effect in controlling the 
disease. However, Heptinstall, White, Williamson & 
Mitchell (1985) and Heptinstall (personal communication) 
have examined extracts of feverfew (tanacetum parthenium), a 
herbal remedy used since ancient times as a remedy for fever, 
arthritis and migraine. These extracts were found to
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inhibit secretory activity in blood platelets and 
polymorphonuclear leucocytes. Release of serotonin from 
platelets induced by various aggregating agents (ADP), 
adrenaline, sodium arachidona te, collagen and U46619 v/as 
inhibited. Platelet aggregation was consistently inhibited 
but thromboxane synthesis was not. Feverfew also inhibited 
release of vitamin B12 binding protein from 
polymorphonuclear leucocytes induced by seeretagogues N- 
for my 1-methiony 1-1 eucyl-pheriyl alanine, sodium ara chi do nate 
and zymosan-activated serum. Feverfew did not inhibit the 
secretion induced in platelets or polymorphonuclear 
leucocytes by the calcium ionophore A23187-
The pattern of the effects of feverfew extracts on platelets 
is different from that obtained with other inhibitors of 
platelet aggregation and the effect on polymorphonuclear 
leucocytes more pronounced than that which has been obtained 
with very high concentrations of non-steroidal anti­
inflammatory agents. These findings are extremely 
interesting and may relate to the inflammatory process and 
the claimed benefit for feverfew treatment in rheumatoid 
arthritis.
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PART (II) BLOOD PLATELETS
(A) Introduction
1.1 General Introduction
The mechanisms of physiological haemostasis, pathological 
thrombosis and Inflammation have received much attention in 
recent years. These processes involve the interaction of a 
number of factors including platelets and (a) Neutrophils, 
Lymphocytes and Monocytes, (b) The Blood Coagulation system
(c) The Fibrinolytic System, (d) The Complement System and 
(e) Vascular contraction and altered haemodynamic 
mechanisms.
1.2 History
In 1842 George Gulliver and William Addison provided the 
earliest drawing of cells that appear to be platelets. Max 
Schultze (1865) using a method for keeping the blood cells 
warm during microscopic examinations observed that platelets 
could coalesce into granular masses. In the following year 
Booth and Hlmmelburgh (1866) introduced the concept that 
platelets play an important primary role in the formation of 
the haemostatic plug. Their experiments demonstrated that 
on cut carotid arteries in the dog, the platelets plugged the 
gap in the vessel wall, formed aggregates and fused into one
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another. It was William Osier in 1874 who described resting 
platelets and their ability to aggregate and clump which are 
consistent with today's current concepts. He suggested, 
however, that the cells he observed were possibly types of 
bacteria. Platelet clumping was also noted by Georges Hayem 
(1 8 7 8 ) but he failed to understand their significance and 
concluded that platelets served as precursors of 
erythrocytes. Julius Bizzozero (1882) made several 
remarkable contributions by accurately illustrating the 
appearance of activated platelets, describing their adhesive 
properties and recognizing that these cells participated in 
blood coagulation and thrombosis. He had previously 
reported in 1868 that blood cells originated in the bone 
marrow.
The functions of platelets were clearly demonstrated by Karl 
Eberth and Curt Schimmelbusch in 1886. They described changes 
in the morphology of platelets that had come in contact with 
foreign surfaces or damaged vessels as "viscous 
metamorphosis" a term which is still used in medical 
practice. J. Homer Wright ( 1906 ) used his famous stain to 
study bone marrow cells and established that platelets 
originated in megakaryocytes.
Despite these elegant scientific observations and studies 
made in the nineteenth century, the platelet and its 
physiological significance were not appreciated during the
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first half of the twentieth century. Unfortunately interest 
turned from the platelet to other components of blood 
coagulation, in particular those related to the formation of 
fibrin clot.
Current appreciation of the biology of platelets and their 
integral role in haemostasis and inflammation can be 
attributed to the talent and dedicated efforts of a number of 
investigators over the last twenty five years. Of these, 
Arvid Hellem is chiefly noted for developing innovations in 
methodology and for devising a useful quantitative test of 
platelet function:- Platelet adhesiveness (Hellem, 1960). 
This test undoubtedly stimulated the development of the 
method for studying platelet aggregation which is now an 
important diagnostic and investigative tool. Hellem applied 
the test to demonstrate that erythrocytes contained a 
substance that caused platelets to become sticky' and to 
adhere to glass and to each other. He named this substance 
"Factor R" and characterized it as a small acid molecule that 
was heat stable.
Hellem participated in further investigations (Gaarder, 
Jonsen, Laland, Hellem & Owren, 1961) and identified "Factor 
R" to be adenosine diphosphate (ADP). It is accepted today 
that platelets contain and secrete ADP and that ADP is pivotal 
for platelet physiology. The enormous proliferation of 
research during the last decade as well as the understanding
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of the role of blood platelets both In health and disease, In 
vessel-wall Injury, arterial and venous thrombosis, 
atherosclerosis and antiplatelet therapy, can In large part 
be related to Hellemfs contributions.
(B) Thrombokinetics
1.1 Platelet Production
Platelets are formed in the bone marrow by fragmentation of 
the cytoplasm from giant precursor cells (megakaryocytes). 
Although megakaryocyte production is normally confined to 
the bone marrow it has been known for many years that 
megakaryocytes are present in large numbers in the lungs. 
There is evidence to suggest that the pulmonary 
megakaryocytes originate from the bone marrow and are carried 
to and retained in the lungs via the venous return (Kaufman, 
Airo, Pollack, Crosby ADoberneck, 1 965). The contribution of 
the pulmonary megakaryocytes to the body platelet pool has 
been calculated to be as much as 7—17% (Kaufman, Airo, 
Pollack, Crosby & Doberneck, 1965).
Till and McCulloch (1961) showed that the megakaryocytes 
share a common precursor with the myeloid and erythroid 
series the pluripotent stem cell. They designated this cell 
CFU-S (spleen colony forming unit). In these now classic 
experiments, mice receiving lethal marrow irradiation and
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injected with normal bone marrow cells showed macroscopic 
colonies on the splenic surface seven to ten days after 
transplantation, the number of colonies being proportional 
to the number of marrow cells injected. If these 
excrescences were dissected out and stained, haematopoietic 
colonies containing megakaryocytes, granulocytes, macro­
phages and erythroid cells were observed. Studies 
employing genetic markers have shown that each cell of an 
individual spleen colony arises from a single cell, thus the 
colony is a clone (Becker, McCulloch & Till, 1963)* If the 
colonies are removed, dispersed into a suspension and 
subsequently Injected into another group of recipients given 
lethal marrow irradiation, new splenic colonies appear, 
(Siminovitch, McCulloch & Till, 1963).
These experiments Indicate that there are single cells which 
have the capacity for both self renewal and differentiation. 
The nuclei of the megakaryocytes are multilobed and exhibit 
polyploidy, the lobulated mass contains 2 , 4, 8 , 16, or 32 
times normal diploid content of DNA. They have a unique 
pattern of cellular motivation in that, although DNA 
synthesis is completed at an early stage cells appear to 
undergo a series of nuclear divisions with a progressive 
Increase in the volume of cytoplasm but without cell 
division. The earliest recognisable type of megakaryocyte 
found in the marrow has a nucleus which has undergone three 
divisions (8 n cell). The nuclei of the megakaryocyte again 
divide several times to form I6 n, 3 2 n and then a 64n cell with
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all the nuclei in a single megakaryocyte dividing 
synchronously.(Fig. 1 .2) . Successive nuclear division 
results in an increase in cytoplasmic volume, which in turn 
Increases the number of platelets formed. One single 
megakaryocyte is calculated to produce at least 2 , 0 0 0  
platelets.
Formation of blood platelets in the bone marrow does not 
appear to be by a simple shedding or disintegration but rather 
by projection of the cytoplasm through the sinusoidal 
endothelium. It has been suggested that newly produced 
platelets are larger and more dense than those that have aged 
in the circulation (Karpatkin, 1 9 6 9 a & Karpatkin, 1 9 6 9 b). 
However, the majority of evidence supports the view that 
platelet volume and density are independent of age and are 
determined by the stage of megakaryocyte development 
(Paulus, Bre ton-Gorius, Kinet-Denoel & Boniver, 197*1; 
Penington, Streatfield & Roxburgh, 1976; Corash & Shafer,
1 9 8 2 ).
1.2 Regulation of Platelet Production
The blood platelets in man circulate as flattened cytoplasmic 
discs with a mean platelet volume (MPV) of 9.5 femtolitres in 
a concentration of 250 x 10 ^/1 (range 150 - 400 x 1 0 ^/1 ). 
Although there is considerable interspecies variation 
(concentration of rodent platelets is four times that of
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Fig.1.2 Schematic model of platelet production.
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man) the intraspecies variation in the platelet count is 
minor and the day-to-day individual variation is minimal. 
The maintenance of the platelet count within such narrow 
boundaries, together with the initiation of compensatory 
changes in the megakaryocytic lineage subsequent to 
perturbations in the count, indicate that platelet 
production is a regulated process. It would appear that a 
regulatory hormone analogous to erythropoietin named 
"thrombopoietinw (Evatt & Levin, 1969) is responsible, 
mediating its effects by (a) increasing the number of 
megakaryocytes formed from precursor cells and (b) 
increasing the rate of both cytoplasmic maturation and 
platelet release. The site of synthesis of thrombopoietin 
appears to be the kidney and liver.
1.3 Platelet Kinetics
After their release from the bone marrow, the life span of the 
platelet is regulated by a very finite internal metabolism 
and its dynamic interaction with the vascular endothelium, 
the inflammatory response, and the coagulation and 
fibrinolytic systems.
The total body platelet mass is split between the splenic pool 
(approx 30$) and the blood circulation (approx 7 0 %), Platelet 
survival studies using various isotopes indicate a survival 
time in the circulation of between 10 - 14 days (Harker & 
Finch, 1969) whilst the workers using a non radio-isotope
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technique such as aspirin acetylation of the platelet enzyme 
cyclo-oxygenase gave a figure of 8 - 11 days (Harker, 1 968). 
The spleen has an effect on the platelet distribution by 
sequesting approximately 3 0 ? of labelled platelets into the 




The circulatory platelets in man are non-nucleated bodies of 
discoid shape measuring on average 2 - 4jJim in length and 1um in 
thickness with a volume of 9.5+ 1 .3fl. Mature platelets stain 
pale blue with a granular core on a Romansky stained 
peripheral blood smear (Erslev & Gabuzda, 1975). They do not 
normally adhere to other platelets, endothelium, or other 
blood cells. Platelet fine structure has been the subject of 
several reviews (White, 1 979; White, Clawson&Gerrard, 1981; 
White & Gerrard, 1982).
On Electron Microscopy the anucleate platelet is seen to be an 
extremely complex cell with systems of membranes, 
microtubules, microfilaments and organelles. (Fig.1.3).
As a result of these findings the ultrastructure revealed by 
electron microscopy can be divided into four distinct regions 
and these are shown in Table I.
-42-
(1) The peripheral zone.
(2) Sol-gel zone.
(3) Organelle zone.
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1.3 Platelet Ultrastructure: (a) Equatorial Plane
(b) Cross Section. Peripheral Zone: EC = Exterior Coat 
CM = Trilaminar Membrane. Matrix Sol Gel Zone:
SMF = Submembrane Filaments; MT = Microtubules;
GLY = Glycogen. Organelle zone: M = Mitochondria;
G = Alpha Granules; DB = Dense Bodies; DTS = Dense 
Tubular System.
1.2 The Peripheral Zone
The peripheral zone constitutes the platelet wall and 
invaginates extensively into the interior of the cell to form 
the surface connecting or open canalicular system. The 
peripheral zone plays an important role in maintaining 
platelet integrity, providing receptor sites for various 
stimulatory or inhibitory agents e.g. collagen, ADP, 
adrenaline and is responsible for platelet adhesion and 
providing a phospholipid surface to accelerate blood 
coagulation. (Fig.1.4). The peripheral zone is composed of 
three morphological areas, (a) exterior coat, Glycocalyx, 
(b) the unit membrane and (c) the submembrane region.
(a) The exterior coat is rich in glycoproteins, several of 
which are unique to platelets. Five major platelet 
glycoproteins (GPI-V) have been characterised (Inter­
national Committee on Thrombosis and Haemostasis, 1981). A 
deficiency of certain of these glycoproteins in congenital 
disorders of platelet function provides evidence for their 
role in adhesion and aggregation (Nurden & Caen, 1 976) GPI is 
necessary for normal adhesion and G P U  & GPIII for normal 
aggregation. (Fig.1.4). The surface glycoproteins contain 
terminal sialic acid molecules contributing to a large 
negative surface charge which could help, by electrostatic 
repulsion, to prevent platelets sticking to one another or to 
the normal intact endothelium (Gorog, Schraufstatter & Born, 
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DISORDERS OF SECRETION 
a Storage pool deficiency
b. Primary secretion defects
c. Abnormalities of 
thromboxane synthesis
DEFICIENCY OF PLATELET  
COAGULANT ACTIVITIES
Fig. 1.4 Schematic representation of the normal platelet responses 
and currently recognised types of defects in platelet 
function. Adhesion of platelets to subendothelium is 
mediated by the interaction of factor VIII - von Willebrand 
Factor and a membrane glycoprotein (GP-I) on the platelet.
Interaction of agonists such as ADP, Adrenaline, Thrombin, 
Collagen and platelet activating factor with specific 
membrane receptors (R) results in platelet activation.
This leads to mobilisation of calcium from intracellular 
stores. Aggregation of platelets involves glycoproteins 
lib and Ilia on the platelet surface and the plasma factor 
Fibrinogen.
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(b) The unit membrane consists mainly of a phospholipid 
bilayer with transmembrane protein compartments randomly 
dispersed. The phospholipid molecules, which are distributed 
asymmetrically on the two sides of the ailayer are able to 
diffuse laterally or become translocated from one side to the 
other. Important components of the platelet unit membrane 
include the membrane endoenzymes, the enzymes involved in 
membrane transport and cyclic AMP metabolism.
(o) The submembrane region constitutes the space between the 
unit membrane and the circumferential band of microtubules 
and contains a system of filamentous elements. Functionally 
the submembrane filaments may be involved in maintaining the 
platelet discoid shape, pseudopodal formation and clot 
retraction.
1.3 The sol-gel-zone
This zone comprises the viscous matrix inside the platelets 
and is composed mainly of proteins that can be assembled into 
fibrous elements. The microtubules are arranged in a 
circumferential band just beneath the cell wall in the non­
activated platelet. They are composed of tubulin, 
polymerized into a single tubule of 25nm in diameter that is 
coiled to form a group of 10-24 circular profiles (Nachmias, 
1980). These tubules appear to maintain discoid shape and are 
involved in internal contraction of platelets when 
stimulated.
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1.4 The Organelle Zone
Several different types of organelles including mitochondria 
can be seen in the cytoplasm of platelets. They have a random 
distribution in non-activated platelets, but centralize upon 
activation. The main function of the organelle zone is to 
store important physiological substances in the granules. 
The electron dense granules contain calcium, adenosine-5- 
diphosphate, (ADP), adenosine triphosphate (ATP) and 
serotonin. Approximately 7 0% available ATP/ADP is stored in 
granules and is secreted during platelet aggregation. The 
non-dense granules are the most numerous, and cell fractions 
and cytochemical techniques have revealed that they can be 
divided into alpha granules, lysosomes and peroxisomes 
(Bentfeld-Barker and Bainton, 1982). Alpha granules are 
either Type I or II, examples of Type I (20-200 per platelet) 
are Beta Thromboglobulin (B-TG), Platelet Factor 4 (P.F.4), 
Platelet Derived Growth Factor, thrombin-sensitive protein 
and fibrinogen. Examples of Type II (2-10 per platelet) are 
lysosomal enzymes,
1.5 The Membranous System
Two Important anatomical connecting systems are found in the 
platelet, the surface connecting system, and the dense 
tubular system. The former consists of a network of channels 
spreading throughout the cytoplasm. These channels greatly 
enlarge the platelet surface area and allow blood borne 
substances easier access to the inner parts of the platelets.
-48-
They also serve as conduits to convey substances released by 
the platelets. Externallzation of the internalized platelet 
membrane appears to take place during platelet shape change 
(Frojmovic & Hilton, 1982) possibly resulting in the 
exposure of functional sites.
The dense tubular system is composed of smooth endoplasmic 
reticulum and is very pronounced in the vicinity of the 
microtubules (Werner & Morgenstern, 1980). It is the major 
storage site for calcium which can be mobilised to regulate 
platelet activation, shape change and aggregation. Calcium 
is the pivot ion that regulates many of the cellular functions 
of the platelets. It is involved with initiating changes 
leading to adhesion, secretion and contraction. During 
these exchanges the resting cytoplasmic level of calcium is 
raised by an influx of calcium which Increases cell 
activation via calmodulin and other proteins (Gerrard, 
Peterson & White, 1981). Prostaglandin metabolism also 
appears to be localised in this region.
Platelets have associated internal and external platelet 
coagulation factors. Some of these, fibrinogen and Von- 
Willebrand factor are necessary for normal platelet function 
e.g. platelet adhesion to exposed endothelial surfaces via 
Von-Willebrand factor, (Sakariassen, Bolhuis & Sixma, 1979; 
Sixma, 1981b) (Fig.1.4). Others, such as factor V on release 
from internal alpha granules attach to the platelet 
phospholipid interphases, thus enhancing prothrombin via
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Factor X interaction. Specific proteins such as platelet 
derived growth factor play a significant role in tissue 
repair and healing (Ross & Vogel, 1 978; Raines & Ross, 1982) 
by their effect on endothelial cells, smooth muscle cells and 
fibroblasts.
(D) Platelets and the Vascular System
1.1 The Interaction of blood platelets, vessel wall and 
coagulation
Whenever blood vessels are damaged there is an immediate 
physiological response designed to minimize and eventually 
arrest the loss of blood. This involves the interaction 
between vessel walls, circulating platelets with normal 
function and the coagulation plasma proteins (Fig. 1.5). 
In addition to the interaction of these three compartments 
further mechanisms are involved:- physiological, inhibit­
ory and fibrinolytic systems which maintain a balanced 
equilibrium (a) localized vasoconstriction following 
damage, (b) platelet adhesion to injured blood vessels, (c) 
platelet shape change and aggregation, (d) fibrin formation 
via the coagulation cascade system, (e) activation of the 
fibrinolytic system and (f) regulation of a series of 
physiological inhibitors.
In this manner coagulation balances the physiological 
requirement of no blood loss from damaged vessels and of 
greater importance, no thrombosis in intact vessels.
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Haemostasis


















Fig. 1 .5 Balanced Equilibrium between the platelet system, vascular 




Under normal physiological conditions white cells and fluids 
are allowed to pass through the capillary wall whilst blood 
and other cellular elements, in particular, platelets are 
retained within. In the intact microcirculation platelets 
circulate in close proximity to the vessel wall without 
adhering to each other or to the endothelium. However, 
following injury there is a transient vascular constriction 
causing turbulent blood flow, conditions which aid the 
‘deposition of platelets at the injured site. The precise 
mechanism that induces the vasoconstriction is not fully 
understood, but it is possible that the scale of response to 
trauma is proportional to the size and physiological site of 
the damaged vessel and is possibly regulated by internal 
pressure, exposure of subendothelium and the release of 
vasoactive amines from the circulating platelets.
1.3 Blood Platelets and the Vascular System
Tissue damage as seen in rheumatoid arthritis leads to the 
disruption of endothelial lining and permits platelets to 
adhere to the subendothelial tissue (Caen, 1972). 
Investigations have shown that endothelial cells (a) 
physically monitor vessel wall integrity, (b) synthesise and 
store important haemostatic components, (c) produce 
























Fig. 1.6 Interaction between Platelets, Plasma Factors and 
Vessel Wall.
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and subsequent aggregation (Caen, 1972). In a pathological 
state, damage to the vessel wall exposes collagen fibres. 
Platelets adhere to the collagen and release adenosine 
diphosphate and platelet degranulation occurs. This 
process accelerates and more and more platelets arrive, 
attach to the adhered platelets and platelet aggregation is 
initiated. Degranulation of platelets enhances further 
platelet aggregation and a feedback loop is maintained. 
These changes are accompanied by a pronounced infiltration of 
polymorphonuclear leucocytes, lymphocytes and monocytes 
thus leading to the Inflammatory response.
Such events are demonstrated schematically (Fig.1.6).
1.4 Interaction between antl-aggregatlon activity of vessel 
wall prostacyclin and pro-aggregating production of platelet 
thromboxane Ag
The most important product of the endothelial cell is 
prostacyclin (PGI2 ) (Moncada & Vane, 1979) an endogenous 
inhibitor of platelet aggregation and a very labile 
metabolite of arachidonic acid. It is a circulating hormone 
generated in venous and arterial endothelial cells from 
arachidonic acid via prostaglandin endoperoxides G2 and H2 • 
Since the platelet has the ability to form the pro- 
aggregating substance thromboxane A2 (TXA2 ) from its own 
arachidonate pathway, there is a potential dynamic 

























Fig. 1.7 Interaction between anti-aggregating activity of vessel 
wall prostacyclin and pro-aggregating production of 
platelet thromboxane A^.
-55-
wall prostacyclin and the pro-aggregating production of 
platelet TXA2 (Fig.1.7). There appears to be a balanced 
equilibrium between vessel wall PGI2 and platelet TXA2 which 
regulates platelet aggregation and therefore influences 
haemostasis and thrombosis.
Moncada & Vane (1979) suggested that there is continuous 
production and release of PGI2 by the endothelial cells and 
one of the consequences of tissue damage is that not only is 
the subendothelial collagen exposed, but there is loss of 
released prostacyclin, enabling more platelet aggregates to 
form. This can lead to further tissue degeneration and 
activation of the coagulation and fibrinolytic systems.
(E) Platelet Adrenoceptors
1.1 Platelet Alpha*, Adrenoceptors
In common with cells in many peripheral tissues the blood 
platelet carries receptors on its plasma membrane that enable 
this cell to respond to blood borne catecholamines, in 
particular to adrenaline and noradrenaline. Human 
platelets contain alpha-adrenergic receptors and when 
exposed to agonists such as adrenaline, these receptors 
promote platelet aggregation and secretion; enhance 
aggregation caused by unrelated agents e.g. ADP and thrombin 
(Mills & Roberts, 1967)» increase calcium influx (Grant &
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Scrutton, 1979; Grant & Scrutton, 1980; Owen, Feinburg & Le 
Breton, 1980; Owen & Le Breton, 1980) and inhibit adenylate 
cyclase (Jakobs, Saur & Schultz, 1 976; Hsu, Knapp & Halushka, 
1979). The alpha adrenoceptors of numerous tissues have been 
characterised according to the potency of various agonists 
and antagonists (Langer, 197*1; Starke, Endo & Taube, 1975). 
These receptors have also been classified on a morphological 
basis as presynaptic (alpha2 ) and postsynaptic (alpha.,) 
(Langer, 1977; Starke, 1977; Starke, 1981; Langer, 1980). 
Within a series of agonists, clonidine, oxymetazoline and 
adrenaline preferentially act presynaptically, while 
phenylephrine and methoxamine preferentially act 
postsynaptically (Starke, Endo & Taube, 1975). Within 
antagonists yohimbine preferentially acts on alpha2 
receptors and phenoxybenzamine and prazosin on 
alpha., receptors, (Cavero, Gomeni, Lefevre-Borg & Roach, 
1980; Starke, 1981).
1.2 Adrenoceptor Stimulus - Response Coupling
Alpha2 receptors can therefore be studied on platelets using 
selective radioligands such as (3h) yohimbine, (Motulsky & 
Insel, 1 9 8 2 ).
In a number of systems e.g. hamster adipocytes, frog skin and 
rat glial cells, agonist occupancy of an alpha adrenoceptor 
causes inhibition of adenylate cyclase and decrease in tissue 
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Fig- 1.8 Proposed mechanism for transmembrane coupling of Alpha 
adrenoceptors to adenylate cyclase. Adrenaline is 
designated as H, the alpha adrenoceptor as R, the 
nucleotide (GTP) binding protein as N, and the catalytic 
subunit of adenylate cyclase as C.
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adenylate cyclase also results from interaction of alpha 
adrenergic agonists with the platelet alphag adrenoceptor, 
(Lasch & Jakobs, 1979). Transmembrane coupling involving 
inhibition of adenylate cyclase by occupancy of an alpha 
adrenoceptor appears to occur by a receptor/nucleotide 
regulatory protein/catalytic moiety mechanism as 
illustrated (Fig.1.8). This is very similar to that proposed 
by Lefkowitz (1982) and Lefkowitz, Stadel & Caron (1983), 
although some observations suggest that there may be 
differences in the nature of the nN n proteins involved, 
(Nahorski, 1982). It is now well established that the 
presence of both extracellular divalant cations and also 
fibrinogen are required to observe an aggregatory response to 
adrenaline, (Peerschke, 1982). These requirements can be 
understood in the context of the exposure of fibrinogen 
receptors on stimulation by adrenaline, (Bennett & Villaire, 
1 979; Peerschke, 1982) and of the role of divalent ions in 
either formation of or interaction of fibrinogen with the 
receptor.
1.3 Responses of Platelets to Adrenaline
Several responses can result from exposure of platelets to 
adrenaline, depending on the species being examined. O'Brien 
(1 9 6 3 ) showed a direct aggregatory response to adrenaline 
when added in the absence of another agonist. A 
proaggregatory response was noted by Mills & Roberts (1967)
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in which adrenaline enhanced aggregation caused by addition 
of suboptimal concentrations of an excitatory agonist acting 
at the ADP receptor. Alternatively Yu & Latour (1977) 
demonstrated an inhibitory response in which adrenaline 
reduces the aggregatory response to a second agonist acting 
at a different receptor e.g. thrombin. Jakobs, Saur & Schultz 
(1 9 7 6 ) found an inhibition of adenylate cyclase which in the 
intact cell is expressed as a prevention of the increase in 
cyclic AMP levels induced by an inhibitory agonist such as 
prostaglandin .
(F) Platelet Aggregation Pathways
1.1 Platelet aggregation
Platelets respond to a number of stimuli including 
adenosine diphosphate (ADP) and collagen by changing shape 
from discoid cells to spherical spiny cells and aggregating 
into large clumps. Adrenaline differs from other aggregating 
agents in that there is no shape change and no increase in the 
concentration of free calcium ions within platelets 
(Westwick, Poll & Kakkar, 1984).
Shape change to stimuli is rapid and is associated with the 
exposure of previously cryptic receptors for fibrinogen, 
(Mustard, Kinlough-Rathbone, Packham, Perry, Harfenist & 
Pai, 1979; Leung & Nachman, 1982; Phillips & Baughan, 1983); 
and the expression of procoagulant activity which has both a
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phospholipid and protein receptor component (Tracy & Mann,
1983). Finally they secrete the contents of the different 
storage organelles. During the late stages of the aggregation 
step arachidonate is liberated from certain phospholipids 
and rapidly converted to prostaglandins and thromboxanes 
which are themselves potent platelet agonists, and further 
activate the platelets (so called positive feedback loops, 
Holmsen, 1977). This response sequence results from 
interactions between platelet surface receptors and 
corresponding agonists. Since the receptors have a high 
degree of specificity, the sequential execution of the same 
responses suggest that the receptors share a common part of 
the signal pathway, (Holmsen, 1976; Holmsen 1978; Holmsen & 
Karpatkin, 1 983) •
Experimentally, a platelet suspension is stirred and a 
stimulus is added, and the coalescence of the individual 
platelets into aggregates is measured. The extent of 
aggregation depends on the concentration of the stimulating 
agent, the anticoagulant, the shape of stirrer bar, the rate 
of stirring, pH and temperature. All these parameters must be 
standardised to obtain reproducible results.
The three most studied pathways of autoactivation of 
platelets are (1) the release of ADP, (2) the liberation and 
metabolism of arachidonate and (3 ) the synthesis of Platelet 
Activating Factor (PAF, 1-0-alkyl-2- acetyl glycero-
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phosphocholine). Each one of these pathways generates 
compounds which act as intercellular mediators to propagate 
the rapid activation of the platelets. Until recently it had 
been widely assumed that an increase in cytosolic Ca2 + 
concentration was the mechanism of stimulation by endogenous 
pathways through a common intracellular trigger, possibly 
calcium (Gerrard, Peterson & White, 1981; Rittenhouse, 
1982). In this context, induction of aggregatory response to 
a weak partial agonist at the alpha2 adrenoceptor by a 
divalent cation ionophore (Grant & Scrutton, 1 980a); as well 
as stimulation by adrenaline of ^^Ca^ + influx (Owen, Feinberg 
& Le Breton, 1 980) ; and of intracellular Ca2 + mobilisation as 
monitored by changes in fluorescence in platelets loaded with 
chlortetracycline (Owen & Le Breton, 1981). This was readily 
accepted as an indication of a role for Ca2 + in the 
aggregatory response induced by adrenaline. However, recent 
observations have confused the situation and may necessitate 
revaluation of this postulate.
Hallam & Rink (1985) found adrenaline induces no detectable 
increase in cytosolic Ca2 + concentration in platelets 
treated with aspirin and loaded with the intracellular Ca2+ 
indicator Quin II. **5ca2 + influx induced by adrenaline can 
only be detected in association with a secretory response 
when these two parameters are evaluated in the same sample 
(Clare & Scrutton, 1983b; Clare & Scrutton, 1984). Using a 
different protocol, Brass & Shattil (1982) and Brass & 
Shattil (1984) also failed to show stimulation of net Ca2+
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uptake by adrenaline although both these agonists and ADP 
increased Ca^+ redistribution across the plasma membrane.
1.2 ADP Pathway
The addition of exogenous ADP to platelet rich plasma 
stimulates shape change and aggregation. In washed platelet 
suspensions, when physiological concentrations of calcium 
and magnesium ions are present, this primary aggregation is 
followed by spontaneous disaggregation with no release of 
dense granules. In platelet suspensions with Ca2+ 
concentrations of 30-50/iM, such as citrated platelet rich 
plasma and within a narrow range of concentration of ADP, a 
second stage of aggregation follows the primary aggregation 
and a biphasic aggregation curve is recorded. The liberation 
of arachidonic acid and its subsequent metabolism as well as 
the release of granules are associated with the second burst 
of aggregation. The ability of acetylsalicylic acid and 
scavengers of released ADP to inhibit this second phase of 
aggregation suggests that both the release of ADP and 
arachidonate metabolites are involved (Packham, Guccione, 
Chang & Mustard, 1973).
There are at least two hypotheses on the nature of the 
receptor for ADP and the mechanism of transmission of the 
stimulatory signal into the cell. The first is the binding of 
ADP to a nucleotide diphosphokinase (NDK) on the platelet
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surface. This is consistent with the conversion of exogenous 
ADP to ATP during platelet aggregation (Mustard, Packham, 
Perry, Guccione & Kinlough-Rathbone, 1975).
Mechanistically, the shunting of endogenous ATP to act as 
phosphate and energy donor to this process and away from 
normal phospholipid synthesis or cyclic adenosine 
monophosphate (cAMP) production, could trigger the cellular 
response (Lam, Guccione, Packham & Mustard, 1 982). Vithin the 
inositol phospholipids, a decreased synthesis of 
triphosphatidylinositol upon stimulation has been reported 
(Lapetina, 1982). However, photocoupling of an ADP analogue 
to the receptor for ADP has located a protein that is 
different from the NDK enzyme, suggesting that indirect 
effects on the NDK, or perhaps a molecular complex may be 
operative (MacFarlane, Mills & Sorivastava, 1982).
A second hypothesis is the reduction of cAMP levels within the 
platelet by the binding of ADP to a regulatory portion of the 
adenylate cyclase complex (MacFarlane, Mills & Srivastava,
1982). The cAMP levels in platelets drop slightly upon 
stimulation, and large Increases of cAMP inhibit platelet 
stimulation by powerful stimuli. However it is not clear how 
decreases in cAMP would initiate the intracellular events 
that occur prior to aggregation (Haslam, 1 973 ; Haslam, 1 975).
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1.3 Arachidonic Acid Pathway
The second pathway of platelet stimulation is the release of 
arachidonic acid from membrane phospholipids by the direct 
action of phospholipase A2 or by the indirect action of 
phospholipase C, diglyceride lipase and monoglyceride lipase 
(Prescott & Majerus, 1 983). The intracellular location of the 
phospholipid pool that donates arachidonate and the species 
of phospholipid remain controversial.
The arachidonic acid is metabolised via the cyclooxygenase 
pathway with the formation of prostaglandins (PG) G2 H2 and 
E2 , thromboxane A2 (TXA2 ), and malondialdehyde, (MDA) or via 
the 1 2-lipoxygenase pathway with the formation of 1 2 -L- 
hydroxy-5,8 ,10-heptadecatrienoic acid (12-HETE) (Marcus, 
1978). Platelet stimulation by thrombin, calcium ionophore, 
collagen and ADP or adrenaline in low calcium conditions, is 
associated with activation of membrane phospholipases. 
Platelets can also metabolize exogenous arachidonate to 
produce PGH2 and TXA2 , both of which are stimulants of 
platelet aggregation (Marcus, 1978). Platelets can also 
produce PGE2 , which inhibits platelet aggregation by raising 
intracellular cAMP concentrations. There is a range of 
arachidonate concentrations ( 100 - 300)iM) that inhibit
platelet aggregation, while both lower and higher values have 
no apparent effect. The reason for this anomaly is unknown.
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One important consideration when inhibitors of one pathway of 
arachidonate metabolism are used is that metabolites from the 
other pathway will be increased. Thus the inhibition of 
cyclooxygenase by acetylsalicylic acid causes an elevation 
in 12-HETE products (Marcus, 1978).
1*4 Ether Phospholipid Pathway
A third pathway of platelet activation has been suggested to 
be the formation of Platelet Activating Factor (PAF), 
although the site of synthesis and catabolism and mechanism 
of stimulation within platelets remains unknown. Other blood 
cells such as macrophages, neutrophils, basophils and 
monocytes produce PAF (Pinckard, McManus & Hanahan, 1982). 
The chemical structure of PAF has been determined to be 1-0- 
alky 1-2-ace tyl-sn-glycerophosphoryl choline (Demopoulos,
Pinckard & Hanahan, 1979) and is therefore related to other 
phospholipids. Phospholipids in human platelets consist of 
phosphatidylcholine, phosphatidylethanolamine, phospha- 
tidylserine, phosphatidylinositol and sphingomyelin (Cohen 
& Derksen, 1969; Owen, Hutton, Day, Bruckdorfer & McIntyre, 
1981; Mahadevappa & Holub, 1982). The synthetic pathways of 
PAF are emerging, one suggestion is that the action of 
phospholipase Ag forms 1-0 -alkyl-2 phosphatidylcholine 
(lyso-PAF) with subsequent acetylation to form PAF (Albert & 
Snyder, 1983; Albert & Snyder, 1984). The activation of
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platelets by PAF has been suggested to be through a receptor 
binding and initiation of the phosphotidylinositol cycle 
(Lapetina, 1982; Billah & Lapetina, 1982a; Billah & Lapetina,
1983); or the inhibition of adenylate cyclase (Haslam & 
Vanderwel, 1982). Platelet activation by thrombin, collagen, 
ADP and adrenaline have all been shown to activate the 
phosphatidylinositol cycle similarly ( Rittenhouse-Simmons & 
Deykin, 1981; Leung, Vickers, Kinlough-Rathbone, Reimers & 
Mustard, 1 9 8 3 b)* Once the synthesis and catabolism of PAF and 
the effects of various inhibitors are classified, a fourth 
pathway of platelet activation may well emerge.
1.5 Synerglsas
Platelet stimuli when used together, result in stronger 
aggregation responses than those observed independently. 
This synergistic phenomenon, while not understood has been 
repeatedly observed for almost all pairs of activating 
stimuli (O'Brien, 1964a; Mills & Roberts, 1967* Grant & 
Scrutton, 1980b; Huang & Detwiler, 1981; Cameron & Ardlie, 
1982). An Important distinction must be made between 
synergistic actions that yield enhanced primary aggregation 
and eventual secondary aggregation and release of granules. 
Huang & Detwiler (1981) stimulated platelets with two stimuli 
such as ADP and high concentrations of thrombin. They found 
enhanced primary aggregation but no secondary aggregation or 
release of granules even when 30juM ADP was employed as long as
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the thrombin concentrations remained fairly low. Increasing 
thrombin levels, at low ADP concentrations induced secondary 
aggregation. A closely related situation has been reported in 
which platelets become refractory to a second stimulation by 
the same agent after disaggregation (Rao & White, 1981). 
However, if sub-activating concentrations of adrenaline are 
added before the second stimulation by the same stimulus, 
reaggregation will result (Rao, Reddy & White, 1981). Clearly 
more than just simple convergence of excitation pathways to a 
common intracellular event is in operation.
1.6 Beta-Thromboglobulin (B-TG)
When blood platelets aggregate several proteins and other 
factors are liberated. One of the platelet proteins released 
is B-thromboglobulin (B-TG) (Moore, Pepper & Cash, 1975; 
Bolton, Ludlam, Moore, Pepper & Cash, 1976; Moore & Pepper 
1976). This protein has been purified and characterized, 
(Begg, Pepper, Chesterman & Morgan, 1978) although its 
function is, as yet, not perfectly clear. The protein has a 
molecular weight of 36,000 and is thought to comprise six 
identical subunits. It is probably located in the alpha 
granules of the blood platelets (Moore, Pepper & Cash, 1975). 
It is the most abundant platelet specific protein and is 
possibly a "granule packing protein" stablising the active 
constituents in the alpha granules (Moore & Pepper, 1976). 
B-TG is only present in minute amounts in other tissues and 
can therefore be considered to be a platelet specific
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protein, the release of which is a clear marker of platelet 
release and aggregation (Zahavi & Kakkar, 1980).
When B-TG is released from platelets its retention time in 
plasma is relatively short, with a half life of around 100 
minutes (Dawes, Smith & Pepper, 1978). Therefore, a 
measurement of its concentration in platelet poor plasma 
represents a dynamic equilibrium between release and 
clearance. If the phenomenon responsible for its release is 
only transitory, as in formation of thrombi in deep vein 
thrombosis or myocardial infarction, then concentrations may 
rise only transiently, (Pepper & Ludlam, 1977; Denham, 
Fisher, James & Hassan, 1977). However, a more continuous 
lesion such as vasculitis or chronic inflammation may well 
give rise to a "steady state", thus reflecting constantly 
elevated rates of platelet aggregation or destruction.
(G) Platelets and Inflammation
1.1 Immune Complexes
The contribution of platelets to the inflammatory process 
associated with immunological injury has been suggested by 
several workers (Pfueller & Luscher, 1974; Nachman, 1978). 
Although human platelets participate in the inflammatory 
process, little attention has been paid to their possible 
involvement in the pathogenesis of rheumatoid arthritis (RA) 
(Colli, Maderna,Tremoli, Colombo & Canesi, 1982). Previous 
studies have described an increase in platelet count in a 
large percentage of rheumatoid patients, as well as an
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apparent relationship between thrombocytosis and several 
biological and clinical markers of active disease (Bean, 
1965; Selroos, 1972; Hernandez, Rowan, Kennedy & Buchanan, 
1975; Hryszko, Pietruska, Bernacka & Bogdanikowa, 1975).
Several aggregating agents e.g. collagen, thrombin, ADP, and 
adrenaline may induce aggregation and the release of platelet 
contents from storage granules (Holmsen, Salganicoff & 
Fukami, 1977). Also, aggregated IgG and immune complexes, 
unrelated to platelet antigens or other platelet 
constituents can induce aggregation and release of platelet 
contents (Pfueller & Luscher, 1 972; Pfueller & Luscher, 1 974; 
Luscher & Pfueller, 1978). Immune complexes may also be 
phagocytosed by platelets (Zimmerman & Kolb, 1976). 
Depending on the nature of the inducer, the substances which 
may be released or secreted from platelets include ADP, 5- 
hydroxytryptamine 5HT, calcium, acid hydrolases and other 
mediators of inflammation.
Human platelets have receptors for the Fc region of 
aggregated IgG (Kulka, Booking, Ropes, & Bayer, 1 955 ; Weksler 
& Coupal, 1973)t and the interaction with IgG/immune 
complexes appears to be a direct binding of the Fc region of 
IgG to the platelet Fc receptors.
There is also evidence of receptors for complement factor C3 
on human platelets (Zimmerman & Kolb, 1976) thus (Ab-Ag) 
complexes may induce platelet activation both directly and
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via the complement system resulting in platelet aggregation 
and release, followed by toxic events on endothelial cells 
(Henson & Cochrane, 1 969a; Henson & Cochrane, 1 969b; Henson, 
1970; Jorgensen, Hovig, Rowsell & Mustard, 1970; Israels, 
Nisli, Paraskevas & Israels, 1973). Furthermore, platelets
are capable of stimulating chemotaxis via complement 
activation in a manner similar to leucocytes (V/eksler & 
Coupal, 1973) and therefore may participate in the early 
stages of inflammation in rheumatoid arthritis or any other 
connective tissue disease. Thus human platelets are both 
haemostatic and inflammatory cells which can be activated by 
immunological and inducer mechanisms. Platelet activation 
could therefore play a very important role in the 
pathogenesis of rheumatoid arthritis (Fig.1.9).
The contribution of platelets to the inflammatory process, 
linked to immunological injury, may lead to the formation of 
microthrombi and the exposure of platelets to insoluble 
antibody-antigen (Ab-Ag)complexes, and subsequent release 
of biologically active components and lysosomal enzymes, 
which in turn increase vascular permeability. ( Nachman & 
Ferris, 1968; Henson & Cochrane, 1969a; Henson & Cochrane, 
1969b; Henson, 1970; Chesney, Harper & Colman, 1974).
1.2 Thrombocytosis
Hutchinson, Davis & Jayson (1976) suggest that 
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Fig. 1.9 A proposed model of the possible roles of platelets in 
the pathogenesis of synovitis in Rheumatoid Arthritis
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to a compensatory increase in platelet production associated 
with active intravascular coagulation. Platelet thrombi, 
together with obliterative microangiopathy and platelet 
aggregation on altered endothelial surfaces, have been 
demonstrated in histological studies of active lesions in 
synovial tissue obtained from patients with early and chronic 
rheumatoid arthritis (Schumacher, 1975).
Fink, Piening, Fricke & Deicher (1979) found that the 
addition of sera from patients with sero-positive classical 
rheumatoid arthritis to platelet rich plasma taken from 
normal patients will also induce platelet aggregation. 
Several other studies implying that the reactivity of blood 
platelets is altered by immune complexes in some types of 
arthritis have been suggested. (Pfueller & Luscher, 1972; 
Weksler & Coupal, 1973; Luscher & Pfueller, 1978).
Biochemical analysis of platelets obtained from patients 
with rheumatoid arthritis has shown increased content of acid 
mucopolysaccharide together with low 5HT levels, a 
diminished protein content, a possible decrease in acid 
polysaccharide activity and reduced amounts of connective 
tissue activating peptide III (Smith & Castor, 1 978). Along 
with increased platelet counts the turnover of plasma 
fibrinogen was found to be elevated in patients with 
rheumatoid arthritis as well as increases in fibrin 
degradation products (Barnhart, Riddle & Bluhm, 1967; 
Bennett, Eddie-Quartey & Holt, 1972; Selroos, & Wegelius,
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1973b; Selroos, Petterson & Wegelius, 1973c» Hutchinson, 
Davis & Jayson, 1976).
Thus the presence of an over-compensated intravascular 
coagulation and fibrinolytic system may make a significant 
contribution to the inflammatory process in patients with 
rheumatoid arthritis, and may be brought about by over-active 
platelet aggregation in the synovial fluid (Endresen, 
1 9 8 1).
In the authors view, the likely systems for the action of 
penicillamine must have exaggerated aotivity in the 
inflammatory process and be influenced in vitro at drug 
levels achieved in vivo.
Many of the cellular and subcellular mechanisms of the blood 
system have been examined in rheumatoid arthritis, however, 
one of the cellular aspects that requires intensive studies 
is the blood platelet. This cellular consituent of blood was 
chosen, since, as discussed, is probably intimately involved 
in the acute inflammatory reaction found in rheumatoid 
arthri tis.
The aim of this thesis was (1) to determine the possible role 
and significance of increased platelets in rheumatoid 
arthritis, and (2) to identify the effects of D-pen 







All chemicals except where 
otherwise stated:
4ml Labco blood tubes 
(B.S.4851)
Final concentration of 1.5mg/ml 
of EDTA Potassium Ethylene- 
Diamine-Tetra-Acetic Acid:




60ml plastic syringes 
+ 19g Sabre hypodermic 
needles:
Precision micropipettes:
Sigma Chemical Co. Ltd.,










Gillette UK Ltd., 
Isleworth, Middlesex.
B . C . L . ,




Blood diluent Isoton III 
Lyslng agent Lyse S III 
Detergent Isoterge III 
(1.2 dilution with Isoton III) 
Bleaching agent. Hypochlorite 
(255V/V solutions)
4c Plus blood control:
Scintillation vials:
& plastic tubes. 75x12mm











Coulter Electronics Ltd., 
Northwell Drive,
Luton, Beds.
Richardsons of Leicester, 
Leicester.
Radiochemical Centre Ltd., 
Amersham, Bucks.
Packard Instrument Ltd., 
Caversham, Berks.
Radiochemical Centre Ltd., 
Amersham, Bucks.
Dista Products Ltd., 
Basingstoke, Hampshire.
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Myocrisin: Hay & Baker Ltd.,
(sodium aurothiomalate) Dagenham, Essex.
2.2 Equipment
Coulter S Plus III 
+ Data Terminal:
Platelet Aggregometer AT8:
I.E.C. Centra 4 X centrifuge:
I.E.C. Centra 7R refrigerated 
centrifuge:
L.K.B. Flat Bed 
Chart Recorder:
L.K.B. Ultrospec U050 
U.V. Spectrophotometer:
L.K.B. 1260 Multigamma 
II Counter:
Grant water bath:
Grant boiling water bath:
Suppliers
Coulter Electronics Ltd., 




Damon/I.E.C. (UK Ltd)., 
Chestnut House,
North Dunstable, Beds.








Gallenkamp vortex mixer: Gallenkamp,




Tri-Carb 400 series Packard Instrument Ltd.,
Liquid scintillation counter: Caversham, Berks.
2.3 Routine buffers and reagents
2.3*1 Phosphate buffered saline (PBS) x 10
Sodium chloride 
Potassium chloride 







The above were dissolved in 1 litre of distilled water, filter 
sterilised (millipore filter 0.45 um pore size) and stored at 
4°C until required.
Before use, the solution was diluted to ten times its volume 
with distilled water. To this was added the equivalent of:
0.1 g/litre calcium chloride 
0.1 g/litre magnesium chloride 




Sodium chloride 1 6 0 . 0 0
Potassium chloride 4.00
Sodium bicarbonate 20.00
Sodium dihydrogen phosphate 1 . 0 0
The above were dissolved in 1 litre of distilled water,filter 
sterilised (millipore filter 0.45 pm pore size) and stored at 
4®C until required.
Before use the solution was diluted to twenty times its volume 
with distilled water. The pH was adjusted to 7.35 with 0.1N 
hydrochloric acid.
2.3-3 Thiobarbiturate reagent
2 - Thiobarbituric acid 40.Og
5N Sodium hydroxide 250ml
The pH was adjusted to pH 12.0 with 70J6 perchloric acid. 
Distilled water 250ml
final volume 500ml
and stored at 4°C until required. Fifteen minutes before use, 




3.2$ Sodium citrate anticoagulant (buffered) was used for 
studies on platelet function in the proportion of 1 vol of 
citrate to nine volumes of blood.
g/li tre
Tri sodium citrate dihydrate 32.00
N-2-hydroxyethy1-piperazine-
N-2-ethane sulphonic acid (HEPES) 50.00
The above were dissolved in 1 litre of distilled water, filter 
sterilised (millipore filter 0.45/Jm pore size) and stored at 
4°C until required.
This maintains the pH of the anticoagulated plasma at 7.4 the 
optimal pH for platelet aggregation studies.
The storage of platelet rich plasma results in loss of 
dissolved carbon dioxide and a rise in pH, the use of HEPES and 
capped plastic tubes prevents this.
2.4 Platelet aggregation reagents
2.4.1 ADP:- Adenosine-5-diphosphate
The stock solution of ADP 1raM/l was stored at -20^0 in 0.5ml 
aliquots. Working solutions were prepared by diluting the
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stock solution with 0.15M NaCl to give appropriate final 
concentrations. One volume of aggregating agent was added to 
10 volumes of platelet rich plasma. All dilutions were made 
in 0.15M NaCl immediately before use and kept on ice during 
experiments.
2.4.2 Adrenaline:- Epinephrine bitartrate
The stock solution of adrenaline 1mg/ml was stored at 4^C. 
Working solutions were prepared by diluting the above stock 
solution with 0.15M NaCl to give appropriate final 
concentrations. One volume of aggregating agent was added 
to 10 volumes of platelet rich plasma. All dilutions were 
made in 0.15M NaCl immediately before use, kept on ice and 
protected from sunlight.
2.4.3 Collagen:- (calf skin - Type 1)
The stock solution of collagen 1mg/ml was stored at 4°C and 
working solutions were made in Tyrodes buffer to the desired 
concentrations. One volume of aggregating agent was added 
to 10 volumes of platelet rich plasma. All appropriate 
dilutions were made in Tyrodes buffer immediately before use 
and kept on ice during experiments.
"Final concentration" refers to concentration of reagent 
after the addition of platelet rich plasma.
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METHODS
(A) Measurements of haemoglobin and platelet parameters
Haemoglobin:- g/dl, platelet count:- x 10^/1, platelet 
crit:- (?ct)% and mean platelet volume (MPV):- femtolitres 
were measured on the coulter model S-Plus III using a fresh 
homogenised E.D.T.A. sample of whole blood and examined 
within two hours of venepuncture.
2.1 Haemoglobin concentration
This was measured photometrically as cyanmethaemoglobin 
after exposure to a combined lysing haemoglobin conversion 
reagent for at least twenty three seconds. All tests were 
performed in triplicate and the mean value recorded.
2.2 Platelet count
The model S-Plus III separates platelets by differential 
gating, measured by electrical Impedance and uses the log 
normal principle to derive all the platelet parameters. 
Particles of 2-20 femtolitres are channelised from the red 
blood cell / platelet line and a histogram generated. The 
smoothed distribution curve is then scrutinised between 3-15 
femtolitres for the mode.
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2.3 Mean platelet volume
The model S-Plus III in addition to the platelet count, 
generates the platelet crit (Pet) and the mean platelet 
volume (M.P.V.)
The M.P.V. is calculated from the following formula:
M. P. V . = exp(p + <$ 2 )
2
where u is the log median and (S the log standard deviation.
2.4 Platelet crit
The platelet crit is the product of the platelet count and the 
mean platelet volume. Platelet crit correlates closely with 
the platelet count, which indicates that the number of 
platelets is the major determinant. There is an inverse 
relationship between platelet size and count which leads to a 
constant Pet.
The (Pet) is calculated from the following formula:-
Pct = platelet count x M.P.V. %
10000
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(B) Determination of platelet aggregation
2.1 Preparation of platelet rich samples from controls 
and various patient groups
40ml of venous blood was taken from an antecubital vein by 
clean venepuncture and with minimum stasis. The blood was 
mixed with an anticoagulant 3*2£ sodium citrate (HEPES) in 
the proportion of one volume of citrate to nine volumes of 
blood•
Platelet rich plasma (PRP) and platelet poor plasma (PPP) was 
prepared by centrifugation at room temperature at 120g for 
fifteen minutes and 2,000g respectively for twenty minutes. 
Platelet suspensions were prepared by removing PRP with 
plastic transfer pipettes to a second plastic universal 
container. The platelet rich plasma was then counted in a 
model S Plus III Coulter Counter and diluted if necessary with 
autologous PPP to give an average platelet count containing 
200-250x10^/1. All plastic containers of platelet rich 
plasma were capped Immediately after counting to maintain pH 
and to minimise any loss of carbon dioxide. All measurements 
were performed within three hours of blood collection.
2.2 Platelet aggregation
Platelet aggregation was measured in vitro according to the 
turbidometrie method of Born (1962). The measurements were
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performed in a single channel aggregometer (Accutech) 
utilising 1ml of platelet rich plasma and 100jil of the 
standard aggregating agents, ADP, adrenaline and collagen. 
Platelet rich plasma was placed in a plastic cuvette warmed to 
37°C in the heating block of the instrument and constantly 
stirred at 900 r.p.m. by use of a siliconised magnetic stir 
bar. Light transmission was monitored continuously on a chart 
recorder. The addition of the aggregating agent results in 
the formation of increasingly larger platelet aggregates 
with a corresponding decrease in optical density. The change 
in optical density was recorded as a tracing by the chart 
recorder for all the various concentrations of agonists, 
controls, and patient groups, and was standardised for each 
sample.
The transmission was adjusted to 0% for platelet rich plasma 
and to 100$ with the corresponding platelet poor plasma. The 
platelet rich plasma was incubated at 37°C for exactly two 
minutes before the various concentrations of ADP, adrenaline 
and collagen were added. Maximum time for aggregation was 
five minutes and all traces were plotted on a chart recorder 
as a percentage transmission.
Dose response curves to increasing concentrations of ADP, 
adrenaline, and collagen were obtained in all groups and the 
concentration inducing 50$ aggregation was calculated and 
used as an index of aggregability. E.C.50: the estimated 
concentration at which primary aggregation occurs at half its 
maximum velocity.
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(C) Determination of beta-thromboglobulin
2.1 Preparation of plasma samples from controls and 
rheumatoid groups
2.5ml of venous blood was taken from an antecubital vein by 
clean venepuncture and with minimum stasis. The blood was 
immediately transferred to a cooled plastic tube containing 
powdered E.D.T.A. 2.75mg/ml and Theophylline 0.15mg/ml. 
These tubes were stoppered, mixed gently and cooled in 
crushed ice for 30 minutes. The samples were then 
centrifuged at 4°C at 3,000g for 30 minutes.
All sample tubes were performed in duplicate.
Centrifugation must be carried out within three hours of 
blood collection otherwise platelets may disrupt releasing 
their contents and giving false high levels of Beta- 
thromboglobulin. After oentrifugation the top 500^1 was 
carefully removed and transferred to a second plastic tube.
2.2 Standards
The aluminium closure foil and rubber stopper was carefully 
removed from the Beta-thromboglobulin human reference 
standards and 500^1 of distilled water added with a precision 
micropipe tte.
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The stopper was then replaced and the contents of each vial 
mixed by gentle swirling and inversion until the contents had 
dissolved completely and a homogenous solution obtained.
Standards contained 10ng/ml, 20ng/ml, 50ng/ml, 100ng/ml, and 
225ng/ml Beta-thromboglobulin.
2*3 Antiserum
10ml of distilled water was added to 1 vial containing anti 
Beta-thromboglobulin and mixed by gentle inversion.
2.4 125j labelled Beta-thromboglobulin
10ml of distilled water was added to 1 vial containing 2pCi 
labelled Beta-thromboglobulin, and again mixed by 
gentle inversion.
2.5 Total Beta-thromboglobulin Assay (B-TG)
The B-TG was measured by radioimmunoassay using Amersham 
Beta-thromboglobulin reagents according to the method of 
Ludlam, Moore, Bolton, Pepper & Cash, (1975).
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Assay Procedure was as follows:-
Standard tubes containing Test tubes containing
10, 20,50, 100, 225ng/ml
50/il of above standards 50/il of unknown
plasma
ZOOpl 125I labelled B-TG 20 0/il 125I labelled 
B-TG
200/il of anti B-TG serum 200/11 of anti B-TG
serum
The above sets of tubes were vortex mixed, and incubated for 1 
hour at room temperature. After incubation and the addition 
of 500/il ammonium sulphate solution to standards and tests, 
all tubes were again vortex- mixed, and then centrifuged for 
15 minutes at 1,500g at 15°C
All supernatant fluid was decanted and allowed to drain 
inverted for 5 minutes. After draining the radioactivity in 
the precipitates was counted in a LKB 1260 Multigamma II 
Counter.
Based on this method a calibration curve for the total Beta- 
thromboglobulin was determined using the known standards and 
calculating the means of the duplicate standards. The total 
Beta-thomboglobulin was determined for the various patient 
groups and control group by reading directly from the 
calibration curve and recorded as ng/ml Beta- 
thromboglobulin.
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(D) Determination of malonyldialdehyde
2.1 Preparation of platelet samples from controls and 
rheumatoid groups
15ml of venous blood was collected into 3.2$ sodium citrate 
and centrifuged at 150g for 15 minutes at 20°C to obtain 
platelet rich plasma (PRP) and a platelet count performed on 
the coulter S Plus III. Samples of PRP (0.9ml) were 
transferred to four tubes and the platelets sedimented by 
further centrifugation at 1,500g for 15 mins at 20°C.
The supernatant platelet poor plasma (PPP) was decanted off 
and the platelet count performed again and recorded. The 
tubes were then inverted to drain for 2 minutes to remove all 
plasma, and the platelet buttons were resuspended in 0.9ml of 
phosphate buffered saline (PBS).
2.2 Assay of malonyldialdehyde
For each normal control or patient, two platelet samples 
(0.9ml) were treated with 100)il of PBS as blank, and two 
samples with 100jul of one of the stimulating reagents, 
adrenaline, collagen and ADP. The suspensions were then 
incubated for 60mins at 37°C in a waterbath.
After incubation, 1ml of the 2-thiobarbituric acid solution 
was added to each tube which was vortex mixed to terminate the
-90-
reaction, and after capping, the tubes were transferred to a 
boiling waterbath for 10 minutes. The tubes were then 
removed, cooled on ice, and centrifuged at 2,000g for 15 
minutes at 4°C. The supernatants were then decanted and 
absorbance measured at 532nm against the appropriate blank in 
an L.K.B. ultrospec U.V. spectrophotometer.
2.3 Calculation
The number of n moles of malonyldialdehyde / 10^ platelets 
were then calculated by the following formula:-
A *vf* x 109 
N.Vi.E
Where A = optical density of samples at 532nm 
Vf = final volume of sample (1ml)
Vi s initial volume of sample (0.9ml)
N = number of platelets in sample (platelet count of 
PRP-platelet count of PPP)
E = Molar extinction coefficient of
malonyldialdehyde (1.55x10^)n moles
The results were expressed as mean ± SD of the duplicates.
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(E) Determination of alpha2 platelet adrenoceptors
following the method of Boon and Elliott (1981)
Anticoagulation mixture 1.0? disodium E.D.T.A
0.7? NaCl pH = 7.4
Incubation medium 0.1? (w/v) disodium E .D . T. A
150mM NaCl pH7.5
2.1 Preparation of platelet samples
40ml of venous blood was taken from an antecubital vein by 
clean venepuncture and with minimum stasis. The blood was 
immediately transferred into a plastic universal container 
containing the above anticoagulant mixture in a ratio of ten 
volumes of blood: one volume of anticoagulant.
These samples were then centrifuged at 180g for 15 minutes at 
20°C to obtain platelet rich plasma. The platelet rich 
plasma, was then decanted using plastic transfer pipettes 
into a second plastic universal container and further 
centrifuged at 1 ,700g for 10 minutes at 10°C. After 
centrifugation the plasma was discarded, and the platelets 
resuspended in 200pl of incubation buffer medium 0.1? (w/v 
disodium EDTA and 150mM NaCl pH 7*5) by use of a vortex mixer. 
The platelets were then diluted by further addition of 
incubation medium and counted in a Coulter S Plus III, 
adjusting the count if necessary with further additions of
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incubation medium to yield platelets of approximately 
10® cell s/ml.
2.2 Assay of alpha2 platelet adrenoceptors with (^H)
yohimbine
The experimental design was as follows:-
The stock solution of (^H) yohimbine was diluted in a mixture 
of 90% incubation medium and 10$ ethanol in a ratio of 
15pl(^H) yohimbine plus 1.5ml of ethanolic medium. This 
constitutes the highest concentration in the assay 
(designated F). Dilutions were then made from solution F into 
tubes A, B, C, D, and E using the ethanolic medium as below:-
F-Dilute (3h ) yohimbine 












Six sets of tubes for each dilution were made at this stage (A- 
F).
A solution of 50/uM of Phentolamine was also prepared for the 
use of non specific binding in the assay.
-93-
The assay tubes were then set up each containing 50jj1 of the 
diluted ( ) yohimbine, six samples at each dilution (A-F).
To three samples at each concentration of (^H) yohimbine 50)il 
of incubation medium was added and to the other three samples 
at each concentration, 50fil of phentolamine solution was 
added.
Incubations were started by adding to each of these assay 
tubes kOQfil of platelet suspensions containing 
approximately 10®cells/ml. These tubes were then incubated 
for twenty minutes at 37°C in a shaking water bath. 
Incubations were terminated by centrifuging the assay tubes 
at 6,000g for two minutes at 20°C.
A 100jil sample of the supernatant from each assay tube was 
removed carefully and added to a scintillation vial 
containing 5ml of scintillation fluid (Insta-gel), these 
were then counted in a scintillation counter to estimate the 
free concentration of (3h ) yohimbine in the incubation. 
Any remaining supernatant was poured off and 500/il of 
distilled water added to each assay tube and sonicated to 
resuspend the platelet pellet. 400f»l of this mixture was then 
taken from each tube, put into a scintillation vial with 5ml 
of scintillation fluid (Insta-gel) and again counted. The 
three tubes in the assay containing (^H) yohimbine and 
incubation medium measure total binding.
The three tubes in the assay containing (3h ) yohimbine and 
phentolamine measure the non specific binding.
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Specific binding of (^H) yohimbine = total counts - non 
specific binding counts.
Scatchard plots (Scatchard 1949). This is a manipulation of 
the "specific binding" data used to produce a linear 
equation. The relationship between bound and free 




B - Specific Bound radioligand
F - Free concentration radioligand
Bmax - Maximum binding capacity (number of receptors)





So by plotting B/F against B, the result is a straight line 
with the slope = 1/Kd and the x - intercept = Bmax.
The radioligand binding was analysed by Scatchard plot 
analysis using linear regression with all assays having 
correlation coeficient greater than 0.9 (for plots of 
Bound/Free V.S. Bound (3h ) yohimbine.
Results were expressed as mean ± S.D. and affinity (Kd) and 
capacity (Bmax) calculated from the Scatchard plots.
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(F) In Vitro platelet studies with thiol reactive compounds
2.1 D-pen
Normal citrated platelet rich plasma (PRP) suspensions were 
prepared as described in (B) 2.1 and platelet aggregation as 
in (B) 2.2.
The platelet suspensions were adjusted to 250x10^/1 from 
healthy normal controls (no drugs) and divided into 1ml 
aliquots.
The experimental design was as follows:
(a) 1ral PRP + 5>ig/ral D-pen ) 10 mins
i
(b) 1ml PRP + 10jig/ml D-pen ) incubation
(c) 1ml PRP + 20pg/ml D-pen ) 37°C
(d) 1ml PRP - no D-pen control )
These experiments were repeated at 30mins and 60mins 
incubation respectively.
Following the incubations of the platelet suspensions with 
the three drug concentrations of D-pen, they were immediately 
stimulated with 100jal of (a) ADP 2.5/Jmol/l, (b) collagen
4jig/ml, (c) adrenaline 5pmol/l and examined for aggregation 
for up to five minutes at 37®C.
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The capacity of each agonist to either induce or inhibit 
platelet aggregation was calculated from the aggregomoter 
tracings and recorded as a percentage.
Each of the drug concentrations were studied on platelets 
coming from the same donor, thus eliminating incidental and 
individual variations in platelet aggregability.
2.2 Sodium aurothlomalate
Exp erimental design was as follows:
(a) 1 ml PRP + 1.5jug/ml aurothlomalate ) 1Omins
(b) 1ml PRP + 3jig/ml aurothlomalate ) incubation
(o) 1 ml PRP + 5/ig/ml aurothlomalate ) 37°C
(d) 1 ml PRP - no aurothlomalate control )
The above experiments were repeated at 30mins and 60mins 
incubations and at the above drug concentrations. The 
experimental design was then exactly as for D-pen as 
described in (F) 2.1.
Percentage aggregation to each agonist was calculated from 
the aggregometer tracings and recorded.
2*3 phydroxymercuriphenylsulphonate (pHMPSA) + L-cysteine
pHMPSA an irreversible non penetrating SH blocking agent and 
L-cysteine - a sulphydryl containing compound able to compete 
with the cellular sulphydryl sites for the pHMPSA on
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platelets were used in this in vitro system. Working 
solutions of pHMPSA 10“^M and L-cysteine 10“^M were prepared 
fresh for each set of experiments.
The citrated platelet rich plasma (PR?) suspensions were 
prepared as described in (B) 2.1 and platelet aggregation as 
in (B) 2.2.
The platelet suspensions were adjusted to 250x10^/1 from 
healthy normal controls (no drugs) and divided into four 1ml 
aliquo ts.
The experimental design was as follows:
(a) 1ml Control PRP - no additions )1 minute
(b) 1 ml PRP + 10"4M pHMPSA )incubation
(c) 1ml PRP + L-cysteine ) 37®C
(d) 1 ml PRP + lO-^M pHMPSA + 10“^M L-cysteine)
Following the incubation at 37®C of the normal platelet rich 
suspensions (PRP) with pHMPSA 10“^M and L-cysteine 10"^M 
either singly or in combination they were immediately 
stimulated with 100jil of (a) adrenaline 5/imol/l, (b) collagen 
4jig/ml (c) ADP 2.5 Jimol/l and examined for aggregation at 
5mins, 10mins, 15mins, 20mins, 25mins, and 30mins at 37^C.
The capacity of each agonist on the platelet suspensions to 
either induce or inhibit aggregation was calculated from the 
aggregometer tracings and reported as a percentage.
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2.4 Dithiothreitol (DTT)
DTT a potent reducing agent was used in this in vitro system. 
The stock solution was kept for one week at 4^C as a 100mM 
solution in isotonic saline, working solutions of 0.5mM and 
1.0mM were prepared fresh in isotonic saline for each 
experiment.
The citrated platelet rich plasma (PRP) suspensions were 
prepared as described in (B) 2.1 and platelet aggregation as 
in (B) 2.2.
The platelet suspensions were adjusted to 250 x 10^/1 from 
both rheumatoid patients receiving daily doses of D-pen and 
normal healthy controls, then split into 3 and 2 aliquots 
(1ml) respectively.
The experimental design was as follows:
(a) 1 ml RA - D-pen PRP - no DTT ) 1 minute
(b) 1 ml RA - D-pen PRP + 0 .5mM DTT ) incubation
(c) 1 ml RA - D-pen PRP + 1 . OmM DTT ) 37°C
(d) 1 ml Control PRP + 0. 5mM DTT )
(e) 1 ml Control PRP — no DTT )
These experiments were repeated at 2mins and 5mins incubation 
respec tively.
Following the various incubations at 37^C the above platelet 
suspensions were immediately stimulated with 100jil of
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adrenaline 5pmol/l and examined for aggregation for up to 
5mins at 37®C.
The capacity of 5jJmol/l adrenaline on the platelet 
suspensions to either induce or inhibit platelet aggregation 
was calculated from the aggregometer tracings and reported as 
a percentage.
(G) Groups of patients studied
2.1 Spot studies
2.1.1 Normal controls:- n=20
These were twenty laboratory staff: ten male and ten female, 
mean age 31-5 years, range 18-45 years, not taking any drugs, 
oral contraceptives and free from intercurrent and chronic 
disease. All were sero-negative for classical rheumatoid 
fac tor.
2.1.2 Chronic inflammatory disease:- n=20
These were twenty patients: twelve female and eight male, 
mean age 41.6 years, range 18-74 years, and were sero­
negative for classical rheumatoid arthritis. Their disease 
states included ulcerative colitis, Crohns disease and 
ankylosing spondylitis. Treatment included steroids, 
sulphasalazine or azathioprine.
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2.1.3 Rheumatoid patients NSAIDs:- n=20
These were twenty patients 8 male and twelve female, mean age
45.5 years, range 22-70 years, receiving NSAIDs but no second 
line treatment with D-pen. All patients were sero-positive 
for classical rheumatoid factor.
2.1.4 Rheumatoid patients treated with D-pen:- n=20
These were fifteen females and five males, mean age 50.5 
years, range 25-74 years, receiving doses of D-penicillamine 
375mg-750rag/day All patients were sero-positive for 
classical rheumatoid factor.
2.2 Serial studies
2.2.1 Normal controls:- n=20
These were the twenty laboratory staff used in the spot 
studies.
2.2.2 Rheumatoid patients NSAIDs:- ns20
These were 11 females and 9 males mean age 47.3 years, range 
27-72 receiving NSAIDs, (Naprosyn, Voltarol, Flurbiprofen, 
Ibuprofen, Sulindac and Indomethacin), no second line 
treatment with D-pen. All patients were sero-positive for 
classical rheumatoid factor.
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2.2.3 Rheumatoid patients Pre-D-pen 
(untreated -0 months):- n=20
These were twenty patients: fourteen female and six male, 
mean age 47*9 years, range 28-62 years, having received no 
second line treatment with D-pen. All patients were sero­
positive for classical rheumatoid factor.
2.2.4 Rheumatoid patients
(treated with D-pen 0-18 months):- n=20
The same twenty of the above group after two and three months 
treatment with D-pen (final dose 375mg-750mg/day) and 
examined at two, four, six, eight, twelve, fourteen, sixteen 
and eighteen months.
Any patient receiving aspirin was excluded from the study.
(H) Measurement of disease activity (rheumatoid arthritis)
2.1 Assessment
The activity and severity of the disease was assessed by an 
Activity Index compiled using, morning stiffness, grip 
strength, articular index, onset of fatigue and ESR as 
described by Wallace & Ragan (1958). See Table A. This 
protocol was also used to identify responders and non­
responders to D-pen therapy, a fall of 1 or more in the 
activity index being regarded as a positive response.
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None Less than 30 mins
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220 -  280 
mm. Hg.





FATIGUE None Slight Moderate Pronounced
ESR Less than 20mm/hr 20-35m m /hr 35-50m m /hr
Greater 
than 50mm/hr
TABLE A Assessment of Disease Activity in Rheumatoid A rthritis
These values were used as guidelines for allocating patients 
to an overall activity score. The assessment also included 
analysis of functional status (Steinbrocker) and anatomical 
stage (Radiological).
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2.2 Grade of activity
Patients were then graded as:-
Inactive = 1
Mildly active = 2
Active = 3
Very active = 4
All controls were graded ,0* as they were all sero-negative 
for classical rheumatoid factor.
The assessment of the activity of the disease in the patient 
was carried out by one Medical Officer, therefore, removing 
as far as possible, any discrepancies in the scoring.
(I) Induction regime of D-pen
2.1 Starting dose
Starting dose 125mg x 2:- 250mg/day
after 1 month 125mg x 3:- 375mg/day
2.2 Maintenance dose
after 2 months either remain:- 375mg/day
or 125mg x 4:- 500mg/day
occasionally higher to a maximum:-750mg/day
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(J) Statistical methods
2.1 Mean values, standard deviation, linear regression 
and coefficent of variation were calculated 
according to conventional methods (Armitage, 1977).
2.2 Statistical analysis:- Mann-Whitney-U-Test.
(Mann & Whitney, 1947).
Data obtained from patients in this study were not 
normally distributed. Therefore, non-parametrie 
tests (Mann-Whitney-U-Test) were used to compare 
results from the various patient and control groups. 
This method involves ranking data points from the 2 
groups being compared and summing the ranks for each 
set. The smaller rank total is compared with values 
published in tables for differing sample sizes. In 
this thesis, the Mann-Whitney-U-Test was carried out 




RESULTS - SPOT STUDIES
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3.1 Comparison of haemoglobin, mean platelet volume,
total platelet count and platelet crit in (a) healthy 
controls, (b) RA-NSAIDs, (c) RA-D-pen treated, (d) 
Inflammatory disease states
In a wide series of observations the platelet count in healthy 
individuals remains within a fairly narrow range of 150 - 
400x10^/1 and the day-to-day individual variations are 
minimal. This study was designed to compare the haemoglobin 
and platelet parameters in a group of patients with 
rheumatoid arthritis with an observed thrombocytosis (range 
357-7^0x10^/1) subsequently treated with D-pen and with 
healthy controls and other RA patients NSAIDs treated and 
with a group of inflammatory disease states.
Haemoglobin and platelet parameters
The methods used to derive the haemoglobin and platelet 
parameters are refinements of the well established Coulter 
principle of counting and sizing in combination with an 
automatic diluting and mixing device for sample processing 
and a single beam photometer for haemoglobinometry:- the 
Coulter S Plus III and data terminal. Calibration, linearity, 
accuracy, reproducibility and precision were maintained 
throughout all the experiments on the Coulter S Plus III by 
performing strict quality control on reagents and standards 
and in measuring the haematological parameters in triplicate
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between one and three hours and recording the means.
The Coulter S Plus III measured the haemoglobin as 
cyanmethaemoglobin in gms/dl at 525 nanometers, the 
absorbance of which was directly proportional to the 
haemoglobin concentrations of the sample in the test system. 
This compares to the reference material for haemoglobin 
recommended by the International Committee for 
Standardisation in Haematology, (ICSH, 1978).
Platelet volume analysis used in this study was also 
performed on the Coulter model S Plus III, an instrument which 
separates platelets by differential gating measured by 
electrical impedance and uses the log normal principle to 
derive the platelet parameters. For total platelet count, 
mean platelet volume and platelet crit the Coulter S Plus III 
produced logarithmic transformation which generated data 
that fitted the Gaussian distribution.
The haemoglobin values for the various patient groups and 
controls are shown in Fig.3.1.a Two hundred and forty 
Coulter counter measurements were made from the four groups 
studied and in all three disease states the mean haemoglobin 


































Fig. 3 .1.a Haemoglobin levels gms/dl in (A ) Normal Controls, (B) R .A . NSAIDs 
treated, (C ) R .A . D-pen treated, (D ) Chronic Inflammatory 
diseases. The results are expressed as mean -  S.D. (n = 20).
Statistical analysis shows:- a highly significant difference between 
A vs B, C & D (P < 0.001).
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The results in Fig.3.1.b and Table 1 show the mean level of 
platelet counts within the four groups investigated. 
Compared to the normal control mean 288±54x1o9/l both 
rheumatoid groups showed a significant elevated mean 
platelet count. 500i88x10^/l and 461±14 2 x 10^/1 respectively 
(P < 0.001, P < 0.001). There was no significant difference 
between normal controls and the platelet counts in the 
inflammatory disease group.
Mean platelet volume analysis
Mean platelet volumes measured in femtolitres (f 1) were also 
studied and these results are illustrated in Fig 3.1.C and 
Table 1. The mean platelet volume in the RA groups, RA-NSAIDs 
7.5±0.7 fl; RA-D-pen 7.8±0.9 fl were significantly lower than 
the MPV of the control group 9.3-0.9 f 1 > or the inflammatory 
disease group, 9.3-1*2 fl (P < 0.001), RA-NSAIDS and (P < 
0.001) RA-D-pen. However, there was a considerable overlap 
between the various groups. Histograms producing platelet 
volume distribution were plotted using an X-Y recorder 
(results not shown) from data generated from the Coulter S 
Plus III. Variables of platelet volume analysis were detected 
by measuring their relative surface area in the histograms, 
then calculating the percentage of microthrombocytes and 
mega thrombocytes present. Microthrombocytes were defined as 
particles with a volume between 2-5fl and mega thrombocy tes as 
















A B C D
9
.b Platelet counts x 10 /I  in (A ) Normal Controls, (B) R .A . NSAIDs 
treated, (C) R .A . D-pen treated, (D ) Chronic inflammatory 
diseases. The results are expressed as mean - S.D. (n = 20). 
Statistical analysis shows:- a highly significant difference between 
A vs B (P < 0.001) and A vs C (P < 0.001).
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Fig 3.1.c Mean platelet volume (M PV) fl. In (A ) Normal Controls,
(B) R .A . -  NSAlDs treated, (C) R .A . D-pen treated, (D ) Chronic 
inflammatory diseases. The results are expressed as mean -  S.D. 
(n = 20). Statistical analysis shows:- a highly significant 
difference between A vs B (P < 0.001) and A vs C (P < 0.001).









IN FLA M M A TO R Y
DISEASES
Pit Qpunt 288 -  53 500 -  88* 461 -  142** 338 - 123
x 10/ 1
M P V (fl) 9.3 -  0.9 7.5 -  0 .7* 7.8 t  0 .9 ** 9.0 -  1.2
PDW 16.A -  0.7 16.2 -  0.5 16.1 i  0.4 16.2 -  0.6
Pit Size 22.5 -  3.7 31.4 -  4 .4* 32.1 -  4 .2 ** 21.2 -  3.9
2-5fl%
Pit Size 8.8 -  1.8 4.2 -  2 .1* 4.5 -  2 .0 ** 6.9 -  2.6
TABLE 1 Variables of p latelet volume analysis in normal subjects 
and d ifferent patient groups. The results are expressed 
as mean -  S.D. (n=20). Statistical analysis shows: -  
a highly significant difference between Normal vs 
R A -N SA ID s* (P < 0.001) and Normal vs R A -D -p e n **
(P < 0.001).
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Table 1 shows the results of determining the percentage of 
micro thrombocy tes 2 - 5fl and mega thrombocy tes 13 - 20fl from 
the platelet volume distribution histograms. Compared with 
normal healthy subjects, the RA group with thrombocytosis had 
a substantially increased number of small platelets, mean 
32.li4.2$ compared to normal controls 22.5^3*7? (P < 0.001) 
and fewer larger platelets, mean 4.5±2$ compared with 
controls 8.8il.8/t, these results show that the percentage of 
megathrombocytes in rheumatoid patients was significantly 
lower than in normal subjects. (Table 1) (P < 0.001).
Platelet crit
As shown in Fig.3.1.d the third platelet parameter 
investigated in this study was the platelet crit %. Any 
expansion of the platelet count and the mean platelet volume 
is an expression of the platelet crit. The platelet count is 
the prime determinant in the platelet crit and an abnormality 
in the MPV produces only comparatively minor differences. 
Platelet crit was calculated from the following formula:-
Plt count x MPV
Platelet crit %= ------------------ —  %
1 0 , 0 0 0
In the four groups of patients studied, the rheumatoid groups 
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Fig. 3.1.d Platelets Crit (%) In (A ) Normal Controls, (B) R .A . NSAlDs 
treated, (C ) R .A . D-pen treated, (D ) Chronic Inflammatory 
diseases. The results are expressed as mean -  S.D. (n = 20). 
Statistical analysis shows:- a highly significant difference  
between A vs B (p < 0.001) and A vs C (P < 0.001).
- 1 1 4 -
platelet crit, 0.378-0.060$ NSAIDs, and 0.338*0.084$ RA-D- 
pen compared to the normal controls 0.268*0.055$ (P < 0.001). 
The inflammatory disease group did not differ significantly 
from the control group, mean 0.300±0.065$. There were no 
differences between groups of patients in terms of age or sex, 
and these factors did not influence the platelet parameters 
measured.
3.2 Platelet aggregation with ADP, adrenaline and
collagen
Platelets are known to aggregate under a variety of 
conditions and in the presence of a number of different 
reagents. For conventional aggregation ADP, adrenaline and 
oollagen were extensively used. For the purpose of 
comparison, the changes in light transmission during the 
first five minutes of aggregation was used for maximum 
aggregation results with the three platelet agonists. This 
protocol gave more consistent results, as the first two 
minutes could vary considerably between individual samples 
and with the particular agonists used.
Quantitation of Aggregation results
Changes in $ Transmission (T) of various PRPs during 
aggregation were recorded with the aggregation controls 
adjusted to give 100$ T with water in the cuvette and zero T
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with no input into the chart recorder.
The recorded T values were then treated in the following 
manner. The apparatus was adjusted so that PRP and PPP read 0% 
and 100? T respectively. To facilitate comparison with this 
approach the recorded T values were converted to T^  values by 
the following equation:-
T(?) - T(?) (PRP)
T1 % = ------------------------  x100
T( ? ) ( PPP) - T( ? ) ( PRP)
T(?) (PRP) is the T? value of the PRP before the addition of 
the agonist. The rate of aggregation was then recorded as the 
maximal increase in T(?) over the five minute time interval.
Typical representative traces are shown in Fig.3*2.a.
3.2.1 Illustrations of actual traces of normal platelet 
aggregation to agonists ADP9 adrenaline and collagen
Primary aggregation or the first wave of aggregation refers 
to the direct aggregation of platelets by adenosine 
diphosphate (ADP) and other aggregating agents. Primary 
aggregation is accompanied by shape changes and is a 
reversible process, this is normally followed by a secondary
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or second wave of aggregation. Secondary aggregation is 
irreversible and is accompanied by the extrusion of the 
content of the granules found in the platelet cytoplasm. 
For the purpose of comparison the changes in transmittance of 
the platelet suspension with various concentrations of the 
agonists were measured for up to 5 mins for maximum 
aggregation and the percentage aggregation calculated from 
the results of the tracings.
Aggregation by ADP
Increasing concentrations of ADP were added to aliquots of 
the same platelet rich plasma (0.01 Jimol/1 - 4.0 jimol/1 ADP) 
and Fig.3.2.a records a typical family of traces. It will be 
seen that aggregation begins at once and with increasing 
concentrations the initial slope increases indicating more 
rapid aggregation. The initial slope of these curves which 
are almost linear are proportional to the log of the dose of 
ADP added. With concentrations of ADP between 0.2 pmol/l and 
0.5 )Jmol/l a primary wave was observed followed by 
disaggregation, however, concentrations of ADP above 
1.0jumol/l produced the secondary wave of aggregation which 
blended with the primary wave forming a single broad wave of 
aggregation. This at 2.0 /imol/1 concentration represented 
approximately 50% platelet aggregation. When ADP 
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Fig. 3.2.a Agqregometer tracings of ADP induced aggregatiun by 
increasing concentrations of agonist.
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Aggregation by adrenaline
Inspection of the traces in Fig.3.2.b produced by adding 
increasing concentrations of adrenaline (0.1 pmol/l >8.0 
praol/1) to aliquots of the same platelet rich plasma shows 
that aggregation began immediately and that the initial slope 
depends on the concentration of the adrenaline added, as with 
ADP, the slope was proportional to the log of the dose. 
With smaller doses 0.1 jimol/1 >1.0 jimol/1 aggregation ceased 
after about 70 seconds, a time that was constant over this 
range, but some disaggregation occurred.
Following this plateau there was a delay of several minutes 
which appeared to be dose dependent. Aggregation increased, 
became rapid, and was always complete and irreversible.
Thus adrenaline concentrations <0.4 /imol/1 induced only a 
weak reversible aggregation response. However, with 
concentrations ranging between 1.0 jimol/1 and 8.0 jimol/1 the 
aggregatory response was monophasic and irreversible 
reaching approximately 50J5 aggregation between 2.0 jimol/1 
and 4.0 jLimol/1 with maximum aggregation at a concentration of 
adrenaline 8.0 pmol/l (see Fig 3.2.b).
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lim e in Minute*.
Fig. 3.2.h. Aggregometor tracing?, of Adrenaline induced aggregation 
by inrrea?.ing concent ration?; ol agonist.
Aggregation by collagen
Collagen induces only a secondary wave of aggregation which 
corresponds to the release reaction of the platelets.
A typical collagen curve was characterised by a lag phase 
before aggregation occurred. Typical aggregation traces are 
shown in Fig.3 .2.c. At concentrations of collagen between 0.2 
-0.4 pg/ml no aggregation was observed. However, between 0.8 
jig/ml and 1.6 jug/ml concentration there was a delay period of 
1 - 2  minutes (the lag phase) followed by aggregation to 
approximately 50%. As the concentration of collagen was 
increased between 4.0 - 8.0 jig/ml aggregation
correspondingly increased to a maximum level. The range of 
concentrations used in this study were later utilised to 
determine the ED^q for each of the agonists studied in the 
various patient groups.
3*3 Representative sigmoid dose response curves and
calculation of ED50 results, showing aggregation 
responses to increasing concentrations of ADP, 
adrenaline and collagen within the various patient 
groups
In order to establish the optimum dose of agonist needed for 
platelet aggregation in the various disease states dose 
response curves were produced for each individual within that 
group and plotted versus increasing concentrations of the 
agonist. By examining the curves and plotting concentration
-121-





















Fiq. 3.2.C Aqgreqometer tracings of Collagen induced aggregation 
by increasing concentrations of agonist.
versus aggregation, ED^q values for each agonist could be 
produced thus allowing standardisation within the 
experiments. Following this procedure these conditions 
would then allow the test system to detect any possible 
increases or decreases of sensitivity to platelet 
aggregation with ADP, adrenaline, and collagen within 
control and patient groups studied.
ADP
Increasing concentrations of ADP (0.1 jimol - 4.0^imol/l) were 
added to aliquots of the various platelet rich plasmas and 
Fig.3.3.a illustrates typical sigmoid representative curves 
for (a) healthy normal controls, (b) RA-NSAIDs (c) RA-D-pen 
treated and (d) chronic inflammatory diseases. Platelets 
from both the rheumatoid groups showed increased sensitivity 
(RA-NSAIDs > RA-D-pen treated) to low concentrations of ADP. 
When the ED^q's were calculated and plotted as shown in 
Fig.3*3*h there were significant differences in ADP 
concentrations required for 50% aggregation in controls 
versus RA-NSAIDs (P < 0.005 )» RA-NSAIDs versus RA-D-pen 
(P < 0.05 ), RA-NSAIDs versus inflammatory disease states 
(P < 0.01). The ranges of ADP ED^q concentrations in all 
groups overlapped considerably, normal controls 0.3 Jimol -
1.5 yumol/1, RA-NSAIDs 0.15^mol - 1.0yumol/1, RA-D-pen 0.15 
^lmol - 1.5 ^imol/1, and inflammatory group 0.3 /imol - 1.5 
yumol/1. There was no correlation between platelet 
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Fig 3.3.b A.D.P. Concentrations inducing 50% aggregation (ED^q ) 
in (A ) Normal Controls, (B) R .A . -  NSAIDs treated.
(C) R .A . D-pen treated, (D ) Chronic Inflammatory disease. 
Bars indicate means (n -  20). Statistical analysis shows:- 
a significant difference between A vs B (P < 0.005);
B vs C (P < 0.05) and B vs D (P < 0.01).
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Adrenaline
Increasing concentrations of adrenaline (0.1 jimol “ 100
jimol/1 ) were added to the patient group platelets and these 
results are shown in Fig.3 .3 .c. The dose response curve 
indicates that there was a dramatic decrease in adrenaline 
stimulated responses with rheumatoid platelets treated with 
D-pen. Even with concentrations of 100 jimol/1 adrenaline, the 
dose response curve was shifted far to the right, with a total 
loss of sensitivity to adrenaline. When compared with the 
normal group, RA-NSAIDs and inflammatory disease groups 
showed a slight increase in sensitivity to adrenaline.
The ranges of adrenaline ED50 concentration overlapped in 
three of the groups i.e. normal controls 0 . 2 jumol - 5.0 
Jimol/l, RA-NSAIDs 0.1 /imol - 4.0 jimol/1, and inflammatory 
disease group 0.1 jumol - 5.0  ^ imol but there was no overlap in 
the RA-D-pen treated group.
Two patients only showed some aggregation at 10^umol/1 but the 
remaining eighteen patients failed to aggregate, even at a 
concentration of 100 jimol/1 adrenaline. This was obviously 
highly significant (P < 0.001). There was no correlation 











A . Healthy Normal Controls.
B. R .A . -  NSAIDs treated.
C. R .A . -  D-pen treated.
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Fig.3.3.c Representative curves showing aggregation responses to 
increasing concentrations of adrenaline.
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Fig- 3.3.d Adrenaline concentration inducing 50% aggregation (E D ™ ) 
in (A ) Normal Controls, (B ) R .A . -  NSAIDs treated,
(C ) R .A . D-pen treated, (D ) Chronic inflammatory disease. 
Bars indicate means (n = 20). Statistical analysis shows:- 




As illustrated in Fig.3.3«e increasing concentrations of 
collagen (0.2 /Jg - 8.0 jxg/ml) were added to aliquots of 
platelet rich plasma from the various patient groups and dose 
responses calculated for collagen gave sigmoid dose response 
curves.
Platelets from both the rheumatoid groups showed increased 
sensitivity to low concentrations of collagen (< 1.5 /ig/ml ). 
The results of the ED^q plots for collagen shown in Fig.3.3.f 
Indicate a significant decrease in the amount of collagen 
required for 50% aggregation with RA-NSAIDs compared with any 
group. (Controls versus RA-NSAIDs (P < 0.001), RA-NSAIDs 
versus RA-D-pen (P < 0.001) and RA-NSAIDs versus
inflammatory diseases (P < 0.001).
There was slight overlapping of the ranges of collagen ED^q 
values in all groups. Results for controls (2.0 - 5.0 jig/ml) , 
RA-NSAIDs (0.5 - 1.5 Jig/ml), RA-D-pen (1.0 - 3.0 ^ ig/ml) and 
inflammatory diseases (1.5 - 4.0 jig/ml). Again there was no 
correlation between age or sex in the patient groups and the 
sensitivity of aggregation with collagen.
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Healthy Normal Controls.
R .A . -  NSAIDs treated.
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Fig. 3.3.e Representative curves showing aggregation responses to 
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Fig* 3.3.f Collagen Concentrations inducing 50% aggregation (ED,-n) 
in (A ) Normal Controls, (B) R .A . -  NSAIDs treated,
(C) R .A . D-pen treated, (D ) Chronic Inflammatory disease. 
Bars indicate means (n = 20). Statistical analysis shows: -  
a highly significant difference between A vs B (P < 0.001); 
B vs C (P < 0.001) and B vs D (P < 0.001).
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CHAPTER FOUR:
RESULTS - SERIAL STUDIES
-132-
4.1 Serial Studies
Twenty patients, fourteen female and six male, mean age 47-9 
years, range 28-62 years were included in the study and age- 
matched to a control group of healthy volunteers. The twenty 
patients all had classical rheumatoid arthritis and showed 
evidence of moderate to severe disease activity as defined by 
the assessment of duration of involvement, presence of extra- 
articular manifestations, morning stiffness, grip strength 
and joint score. Prior to entry, patients had been taking a 
variety of non-steroidal anti-inflammatory drugs (NSAIDs) 
but none had previously received specific anti rheumatoid 
drug therapy (i.e. D-pen or gold). During the initial month 
all patients were treated on daily doses of 250 mg followed at 
month 2 by 375 mg/daily and finally with a range of (250-750 
mg/day) depending on clinical assessment over an 18 month 
period. The patients were followed at 2 monthly intervals 
for clinical assessment and examination of laboratory 
parame ters.
4.1.1 Effects of D-pen treatment on platelet parameters in 
rheumatoid patients
Serial studies showing the effects of D-pen on platelet 
parameters, mean platelet volume, total platelet count and 
platelet crit are illustrated in Fig.4.1.a. No significant 
difference was noted between male and female or age of the
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patients in the rheumatoid group in all of the parameters 
studied. On examination of the individual platelet results 
the mean platelet volume (MPV) at 0 months was 7.5 fl. 
Following six months treatment with D-pen a significant 
increase was noted in the MPV, mean 8.5 fl (P < 0.001). The 
increase in platelet volume was maintained at this level for 
the full 18 month period, mean 8.6fl. As shown in Fig.4.1. a 
the total platelet count had a mean value of 593 x 10^/1 in the 
rheumatoid group at month 0, compared with normals 288 x 10^/1 
(P < 0.001). This level of thrombocytosis had decreased 
significantly to a mean of 402 x 10^/1 at month 8 of D-pen 
treatment (P < 0.001) and had decreased slightly further at 
month 18 to a mean of 384 x 10^/1. The control group remained 
within normal platelet limits during the whole series.
Similarly the platelet crit at month 0 (0.425? ) had decreased 
at 6 months to a mean of 0.338?, compared to a normal value of 
0.268?. This decrease in platelet crit ? was maintained over 
18 months (P < 0.001). There appeared to be very minimal 
variation in the control group for all three parameters 
examined over the 18 month period.
Disease activity.
Analysis was carried out in small sub-groups of patients with 
differing levels of disease activity. These group sizes were 
small so that statistical analysis shows trends rather than 
significant differences. These comments are also applicable 
to analysis of differences between RA-responders and the 
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Fig.4.1.a Serial studies showing the effects on Platelet Parameters: -  
Mean platelet volume (M PV), Platelet count and Platelet 
c rit % (P et), in •  Normal Healthy Controls, o R .A . D-pen  
treated ( 0 - 1 8  months). The results are expressed as means 
-  S.D. (n=20). The S.D. bars are om itted for c larity . 
Statistical analysis shows:- a highly significant difference  
between Month 0 vs Month 6 R .A . D -pen* (P < 0.001);
Month 0 vs Month 8 R .A . D -p en ** (P < 0.001) and Month 
0 vs Month 6 R .A . D -p e n ***  (P < 0.001).
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4.1.2 Effects of D-pen treatment on platelets from 
rheumatoid patients at various stages of disease 
activity
The results presented in Table 2.a show that there was no 
significant association of platelet parameters with disease 
activity prior to D-pen treatment. However, post D-pen 
treatment all groups show changes in platelet parameters 
irrespective of initial score of disease activity. These 
results are shown in Table 2.b. All the platelet parameters 
differ significantly in the rheumatoid groups compared with 
controls, irrespective of disease activity scores.
For example, MPV values pretreatment disease activity - (2) 
MPV 7.82-0.32 fl versus MPV post treatment 8.64*0.21 fl 
(P < 0.001), similarly platelet count pre - treatment 
586*59 x 1 0  ^ /l versus platelet count post - treatment 
385*52 x 10^/1 (P < 0.001), and thirdly platelet crit pre 
treatment 0.421*0.018$ versus post treatment 0.357*0.052$ 
(P < 0.001).
4.1.3 Effects of time course on D-pen dosage, ESR/hour and 
disease activity in rheumatoid patients
Serial changes in disease activity, mean daily dose of D-pen 
and ESR/hour are shown in Fig.4.2.a These were examined at two 
monthly intervals and up to a period of eighteen months 
duration in the rheumatoid group. A favourable clinical
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DISEASE A C TIV ITY  
R .A . SCORE




PLT CRIT % 
(Pet)
1 (n=0) - - -
2 (n=5) 7.82 -  0.32 586 -  59 .421 -  0.018
o' II 7.35 -  0.31 567 - 5 1 .423 ± 0.046
4 (n=11) 7.39 -  0.70 605 i  95 .427 -  0.054
Control (n=20) 9.20 -  0.87 280 - 5 3 .268 -  0.055
TABLE 2.a Pre D-Penicillam ine Treatm ent
DISEASE A C TIV ITY  
R .A . SCORE 
Pre D-pen
M EAN PLATELET  
VO LUM E  
(M P V )/fl
PLATELET COUNT 
x 1071
PLT CRIT % 
(Pet)
1 (n=0) - - -
2 (n=5) 8.64 -  0 .21* 385 -  52* .357 - 0 .052*
3 (n=4) 8.40 - 0 .35* 380 -  75* .328 -  0.052*
4 (n=5) 8.48 - 0 .38* 391 -  100* .350 -  0.057*
Control (n=20) 9.20 -  0.87 288 -  53 .268 -  0.055
TABLE 2.b Post D-Penicillam ine Treatment (18 months)
Mean values of P latelet Param eters:- (M PV) P latelet Count and Pet % in R .A . 
patients Pre and Post D-pen treatm ent at d ifferent levels of disease activ ity , 
compared to controls. The results are expressed as means -  S.D. (n=20). 
Statistical analysis shows:- a highly significant difference between Pre vs 




























□ A. Index of disease activity  
•  B. ESR mm/hour.
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Time in months
Fig»4.2.a Serial studies showing e ffec t of tim e(0 -  18 months) in R .A . 
patients on (A ) Index of disease activity, (B ) Erythrocyte  
sedimentation rate (ESR mm/hour), (C) Mean daily dose of 
D-pen (m g/day). The results are expressed as means 
-  S.D. (n=20).
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response to D-pen was observed with an index mean of pre
drug decreasing to 2.0 at six months. Although generally 
patients were given D-pen in increasing doses up to 
750mg/day, several patients had their doses reduced because 
of various side effects including three cases of nausea and 
vomiting, four with loss of taste and one a skin rash in which 
the drug was stopped for a fortnight. However, restarting 
D-pen on a lower dose in this patient caused no further 
complications or recurrences. The clinical response (disease 
activity) was reflected by rapid improvement in the clinical 
measurements described in section 2.2, which reached 
statistical significance by 6 months compared to month 0 
(P < 0.001). The mean level of clinical response maintained 
this index over the following twelve months.
The results expressed in Fig.4.2.a for the erythrocyte 
sedimentation rate (ESP) also showed a gradual and 
significant decrease from month 0 - month 18. The mean ESR 
pretreatment 58±25mm/hour fell by month 18 to 25t12mm/hour. 
This decrease was first noted after two - three months of D- 
pen treatment and correlated well with clinical index of 
disease ac tivi ty. Mean daily doses of D-pen (250 - 750 mg) were 
either increased by 125mg/daily or correspondingly reduced 
by 125mg/daily depending on clinical assessment at each 
clinic visit and the corresponding laboratory results. These 
are illustrated in Fig.4.2.a Initially all rheumatoid 
patients commenced on levels of 250mg/daily at month 0 and
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375mg/daily at month 2. There was an increase in D-pen dosage 
with a peak at month 14, mean 482mg/daily this very slowly 
decreased to month 18 with a mean daily dose of 443mg. As shown 
by the SD bars the standard deviations were very wide and 
there was marked variation between each individual studied. 
On clinical examination at 18 months the twenty patients in 
the series studied were assessed for their response to an 
active and fairly aggressive regime of D-pen therapy.
4.1.4 Effects of D-pen treatment on ESR/hour and platelet 
parameters in rheumatoid patients, showing good or 
poor clinical responses
After eighteen months of continual D-pen therapy clinical 
appraisal of the patients studied showed that out of twenty 
patients sixteen could be classified into responders and four 
into non responders. On examination of all data collected 
from patients and shown in Table 3 the mean daily dose of D-pen 
in the responder group was 406±97mg compared to the non 
responder group value of 593±120mg. (P < 0.05).
The erythrocyte sedimentation rate in the responder group had 
decreased with D-pen treatment to a mean of 2li8mm/hour, but 
remained high in the non responder group 42i7mm/hour. This 
compared to a pre-D-pen treatment mean at month 0 
58±25mm/hour. Closer observations of platelet data derived 
from the responder group showed that platelet counts had 






Mean Daily  
Dose of D-pen  
mg/day
406 t 97 • 593 ± 120
ESR
mm/hour 2 1 - 8 4 2 - 7
Platglet Count 
x 1071 363 -  7 3 ** 482 -  29
MPV
fl 8.62 -  0 .2 5 *** 8.02 -  0.10
Platelet Crit 
Pet % .331 -  0 .0 4 7 **** .412 -  0.012
Table 3 The effects of D-pen treatm ent in Rheumatoid Patients on 
E.S.R. and p la te le t parameters showing good or j)oor clinical 
responders. The results are expressed as mean -  S.D. 
Statistical analysis shows:- a significant difference between 
Resp vs Non-Resp* (P < 0.03); Resp vs Non-Resp**
(P < 0.01); Resp vs N on-resp*** (P < 0.01) and Resp vs 
N o n -R esp **** (P < 0 .01).
-141-
Results at 18 months for the responder group were 
363-73x10^/1, compared to mean pre drug levels of 
586168x10^/1 and non responder group 482129x10^/1. The 
change in the responder group was significantly greater than 
in the non responder group (P < 0.01).
As illustrated in Table 3 the MPV values of the responder 
group mean had significantly increased to 8.6210.25 fl after 
D-pen treatment, compared to month 0 pre-D-pen treatment MPV 
7.58*0.44 fl (P < 0.001). However, the non responder MPV 
remained lower at 8.0210.10 fl nearer the pre treatment 
value, and again this level was significantly lower than the 
responder group (P < 0.01). Similarly therewasastatistical 
significance between platelet crit % values. Evaluation of 
results indicated responders to have a mean Pet of 0.331% 
compared to non responders 0.412$ (P < 0.01). The platelet 
crit had returned after D-pen treatment much nearer the 
control level mean 0.268$.
4.2 Plasma Beta-thromboglobulin (B-TG) levels
Until recently relatively few methods have been available for 
evaluating platelet function in vivo. However the isolation 
and characterisation of purified platelet proteins have been 
followed by development of a specific and sensitive 
radioimmunoassay of Beta thromboglobulin (B-TG) which may be 
used for monitoring the platelet release reaction in vivo.
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4.2.1 Calibration curve for total plasma B-TG assay
The calibration curve for total plasma B-TG is illustrated in 
Fig.4.3.a.It was determined by plotting the curve of 125i 
counts for the five known concentrations of standards against 
the B-TG concentration. The plasma levels of experimental 
B-TG were estimated by reading the average of duplicate 
counts and reading off their B-TG concentrations from the 
calibration curve (expressed as ng/ml B-TG). A performance 
check at this stage was (a) to determine the tine required to 
accumulate 10,000 counts in the 10 ng/ml standard tubes, this 
should not be greater than 4 minutes and 
(b)
Mean counts in tubes 1 & 2 (10 ng/ml)
Ratio = -------------------------------------------- = >1.7
Mean counts in tubes 7 & 8 (100 ng/ml)
This ratio should be greater than 1.7 and the background 
counts in the assay were subtracted in calculating this 
ratio. The above criteria were achieved in all experiments.
4.2.2 Total plasma Beta-thromboglobulin levels in normal 
controls, compared with pre D-pen treated (NSAIDs) 
and D-pen treated rheumatoid groups
The mean plasma concentration of B-TG for controls, pre D-pen 
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Fig.4.3.a The calibration curve for total Beta thromboglobulin
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32 -  12 10 -  51
R .A . Patients
Pre D-pen treatm ent 
0 weeks 
(n = 20)
62 -  3 0 * 2B -  128
R .A . Patients 
D-pen treated  
4 weeks 
(n = 11)
5 0 - 1 7 24 -  82
R .A . patients 
D-pen treated  
B weeks 
(n = 9)
44 -  16 30 -  78
Combined 
R .A . -  D-pen  
treated 4 + 8 weeks 
(n = 20)
47 -  16** 24 -  82
TABLE 4 Beta-thromboqlobulin levels of normal controls,
R .A . patients Pre D-pen treatm ent Week 0 , R .A . patients D-pen treatm ent 
Week 4, R .A . D-pen treatm ent Week B and combined data of Weeks 
4+8 D -pen treated. The results are expressed as mean -  S.D.
Statistical analysis shows:- a significant difference between Control 





Fig. 4.3.b Plasma beta-thromboglobulin levels in (A ) Normal Controls, 
(B) R .A . Patients Pre D-pen treatm ent week 0, (C) R .A . 
Patients D-pen Treated at 4 weeks, (D ) R .A . Patients 
D-pen treated at 8 weeks. Statistical analysis shows:- a 
significant difference between A vs B (P < 0.001).
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RA DISEASE A C TIV ITY  
SCORE
BETA THROMBOGLOBULIN  
LEVELS (ng/m l)
1 (n=0) -
2 (n=5) 59 t 16
IIcv_ 66 -  32
4 (n = l1) 62 -  35
Total RA (n=20) 62 -  30
Controls (n=20) 32 -  12
Table 5 Plasma beta-thromboglobulin levels at various stages of 
disease activity in rheumatoid arthritis Pre D-pen  
treatm ent. The results are expressed as mean -  S.D.
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The mean plasma concentration of B-TG in RA-NSAIDs patients 
with classical rheumatoid arthritis was found to be 6 3±30 
ng/ml (range 28-128 ng/ml). This was significantly greater 
(P < 0.001)than the levels found in healthy normal controls 
mean 32±12 ng/ml (range 10-51 ng/ml) as shown in Table 4. 
Following treatment with D-pen 250/mg day for 1 month, and 
375mg/day for 2 months, the B-TG levels were again determined 
in the rheumatoid group (Fig 4*3.b) The mean level of B-TG had 
fallen significantly to 47^16 ng/ml (range 24-82 ng/ml) 
(P < 0.05). Closer examination of the data revealed, that, 
before D-pen therapy 50$ of the RA group had B-TG levels 
similar to the control group and 50% were higher (Fig.4.3.h ). 
However, as shown in Table 5 this difference did not correlate 
with the severity of the disease, or with age, sex and 
duration of rheumatoid arthritis.
4.3 Platelet malonyldlaldehyde formation (MDA): An
indication of platelet hyperfunction
The formation of malonyldialdehyde, a metabolite of 
prostaglandin endoperoxides, has been studied in platelet 
rich plasmas in response to stimulation by ADP, adrenaline 
and collagen.
Platelet prostaglandin synthesis plays a key role in platelet 
aggregation and in the platelet release reaction. Therefore 
in view of the initial findings concerning platelet
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aggregation and their responses to ADP, adrenaline and 
collagen within the rheumatoid groups, a study was made on 
platelet suspensions from these groups to see if 
malonyldialdehyde generation was either impaired or 
increased by drugs used in rheumatoid arthritis 
especially D-pen.
4.3.1. Total platelet MDA generation in response to ADPV 
adrenaline and collagen in controls, RA-NSAIDs 
treated, RA-pre-D-pen and RA-D-pen treated 
patients
Using an LKB Ultrospec U.V. spectrophotometer and a 
thiobarbituric acid method for total MDA production peaks 
were seen at 532 nanometers. The addition of the aggregating 
agents ADP, adrenaline and collagen to the platelet rich 
plasma in the aggregometer induced the synthesis of MDA from 
platelets, whereas no increase in absorbance at 532 
nanometers (<0.02 0D nmol/10^) was observed when phosphate 
buffered saline was added to the platelet rich plasma in the 
test system.
Preliminary experiments with lower concentration of 
stimulating agents ADP 1 .5-5 /1 mol/1, adrenaline 5-10^imol/l, 
and collagen 1-3 jig/ml, induced only small but variable 
amounts of MDA in normal subjects. However, on increasing the 
concentrations to 10 ^umol/1 ADP, 20 /imol/1 adrenaline and
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4 /ig/ml collagen stable and reproducible levels of MDA 
production were obtained. Table 6 illustrates that although 
total MDA production by RA-platelets pre-D-pen was decreased 
with all three agonists, they did not vary significantly 
between patients showing marked differences in RA disease 
ac tivi ty.
Results of platelet MDA formation measured at 532 nanometers 
in the presence of ADP 10jumol/l are depicted in Fig.4.4.a. The 
normal control group who manifested normal platelet function 
without evidence for platelet hyperaggregability, generated 
values of platelet MDA mean 0. 182±0.017 nmol/10^ platelets. 
This was highly significantly different to the decreased 
values of MDA produced by RA-NSAIDs group mean 0.092^0.035 
nmol/10^ platelets and RA-D-pen group mean 0.080t0.021 
nmol/10^ platelets (P < 0.001), (P < 0.001) respectively.
Fig.4.4.b shows that NSAIDs, pre-D-pen and post-D-pen groups 
all produced significant decreases of total levels of MDA 
generation compared with healthy controls when induced by 
collagen 4 jjg/ml. MDA production for NSAIDs mean 0.071^0.035 
nmol/10^ platelets, pre-D-pen mean 0.049-0.029 nmol/10^ 
platelets and post D-pen mean 0.051±0.021 nmol/10^ platelets 
versus normal control mean 0 .085^0 . 027 nmol/ 1 0^ platele ts 
(P < 0.001).
As illustrated in Fig.4.4.c the generation of MDA in response
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RA DISEASE A C TIV ITY  
SCORE
MALONYJ D IALDEHYDE PRODUCTION  







1 (n=0) - - -
2 (n=5) .102 -  .029 .070 -  .039 .046 -  .028
3 (n=4) .088 -  .027 .075 -  .033 .055 -  .033
4 (n = l1) .095 -  .030 .067 -  .032 .047 -  .025
Total RA (n=20) .096 -  .029 .072 -  .036 .049 t .029
Controls (n=20) .182 -  .017 .166 -  .022 .085 -  .027
TABLE 6 M DA levels a t various stages of disease activity Pre D-pen  






























□  A. Normal 
0  a  R .A . NSAIDs 
P^C. R .A . Pre D-pen  





Fig* 4.4.a The effects of ADP KUy^iol/l on Malonyldialdehyde generation 
from platelets (n m o l/10 platelets of (A ) Normal control, (B) 
R .A . -  NSAIDs treated. (C) R .A .Pre D-pen (0 months), (D ) 
R.A. -  D-pen treated (3 months). The results are expressed 
as means -  S.D. (n = 20). Statistical analysis shows:- a 
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Fig. 4.4.b The effects of CollagenJtyjg/ml on Malonyldialdehyde generation 
from platelets (n m o l/10 platelets of (A ) Normal control, (B) 
R .A . -  NSAIDs treated, (C) R.A.Pre D-pen (0 months), (D )
R .A . -  D-pen treated (3 months). The results are expressed 
as means -  S.D. (n = 20). Statistical analysis shows:- a highly 
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Fig, 4.4.c The effects of Adrenalire 20pmol/l on Malonyldialdehyde generation 
from platelets (n m o l/10 platelets of (A ) Normal control, (B)
R .A . -  NSAIDs treated, (C) R .A . Pre D-pen (0 months), (D )
R .A . -  D-pen treated (3 months). The results are expressed 
as means -  S.D. (n = 20). Statisical analysis shows:- a highly 
significant difference between A vs B, C & D (P < 0.001).
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to adrenaline from platelets of RA-D-pen treated group were 
markedly depressed after 3 months mean 0.038±0.019 nmol/10^ 
platelets, compared with MDA production at 0 months pre-D-pen 
mean 0.072±0.036 nmol/10^ platelets (P < 0.001). There was 
also a significant difference in MDA levels between controls 
mean 0.160^0.022 nmol/10^ platelets and RA-NSAIDs mean 
0.07^0 .037 nmol/109 platelets (P < 0.001). These data 
parallel observations made in platelet aggregation 
experiments stimulated with adrenaline. Here, the platelet 
response to adrenaline had decreased rapidly over 1 - 3 months 
with almost total loss of sensitivity to the agonist (see 
Fig.4.5.b).
To be sure that only MDA produced by the cyclooxygenase 
pathway of arachidonic acid was measured and not any 
thiobarbituric acid reactive substance produced by the 
lipoxygenase pathway of arachidonic acid, acetylsalicylic 
acid (1mM) inhibition experiments were also performed 
according to the method of Takayama, Okuma & Uchino, (1980) 
(data not shown). Complete inhibition of the generation of 
thiobarbituric acid reactive material was found in ADP, 
adrenaline and collagen stimulated samples from all patients 
s tudied.
4.4 Platelet aggregation
Serial studies were performed on three groups of patients,
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twenty healthy controls, twenty RA-NSAID-treated and twenty 
patients before and after treatment with D-pen. Platelet rich 
suspensions were examined at monthly intervals for platelet 
aggregation as previously described in Chapter 2 (B) 2.1 and
2.2 and their responses to ADP, adrenaline and collagen 
recorded and plotted over a three month period.
4.4.1 Effects of D-pen treatment ( 0 - 3  months ) on ADP, 
adrenaline and collagen Induced platelet 
aggregation
As illustrated in Table 7» the various stages of disease 
activity pre-treatment had no significant effect on platelet 
aggregation responses. The result of the responses of patient 
groups to ADP are illustrated in Fig.4.5.a. The data shown 
were obtained with ADP concentrations equivalent to the ED^q 
of normal platelet responses. Healthy normal controls 
remained fairly constant over the time course averaging 
approximately 50? aggregation on each visit.
The RA NSAIDs group also showed very little change over the 
three months, but overall showed an increased sensitivity to 
ADP. However, in the RA group receiving D-pen aggregation 
responses decreased from an initial level at month 0 of 88? to 
72? at month 1 and 68? at month 3 thereby indicating a 
significant loss of sensitivity to ADP.(P < 0.001).
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As illustrated in Fig.4.5.b the responses to adrenaline of 
platelets from RA-D-pen patients showed a dramatic 
inhibition of platelet aggregation, falling from a response 
at month 0 of 78$ to 12$ at month 1 and 5$ at month 3 
(P < 0.001). When viewing the data of platelets from RA NSAIDs 
treated and normals there was little variation over the 3 
month period and only a minimal loss of sensitivity in the RA- 
NSAIDs was noted. Again the RA-NSAIDs showed an increased 
sensitivity to adrenaline at time 0. There was no apparent 
change in the control group. Several of these experiments 
were repeated after 18 months D-pen (data not shown) and the 
unresponsiveness of RA platelets to increasing 
concentrations of adrenaline remained.
As shown in Fig.4.5.c platelet aggregation stimulated with 
collagen 2.5 Jig/ml shows a significant change over the period 
0 - 3  months between the normal and RA-D-pen group with a 
progressive loss of sensitivity to collagen. The mean
platelet aggregation in the RA-D-pen group performed at month 
0 was 95$, and at 3 months the mean platelet aggregation had
decreased to 63$ almost the level of the normal controls.
This is highly significant (P < 0.001) The control group 
remained fairly consistent over this time period, whilst the 
RA-NSAIDs showed a minimal loss of sensitivity to the
collagen, mean level 94$ month 0, mean level 88$ month 3*
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1 (n=0) - - -
2 (n=5) 0.7A -  .30 1.70 -  1.07 1.08 -  .49
Itc 0.55 -  .19 1.87 -  1.23 0.80 -  .16
4 (n = l1) 0.50 -  .21 1.99 -  1.02 1.07 -  .33
Total RA (n=20) 0.57 -  .24 1.90 ~ 1.02 1.02 -  .35
Controls (n=20) 0.93 t .38 2.48 -  1.48 3.38 -  .99
Table 7 ADP, Adrenaline and Collagen ED™  concentration
required for Platelet Aggregation a t various stages of 
Disease Activ ity. The results are expressed as means 
-S.D.
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Fig.4.5.a Serial studies showing the effects of ED cq ADP 0.8|jmol/l on 
platelet aggregation (%) in (A ) Normal Healthy Controls,
(B) FLA. NSAIDs treated, (C) FLA. D-pen treated patients 
( 0 - 3  months). The results are expressed as mean -  S.D.
(n = 20). The S.D. bars are omitted for c larity . Statistical 
analysis shows:- a highly significant difference between Month 










•  A . Norm al H ealthy Controls
▼  B. FLA. -  NSAIDs treated
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Fig,4.5.b Serial studies showing the effects of ED^^ Adrenaline 2.0jjmol/l on 
platelet aggregation (%) in (A ) Normal Healthy Controls,
(B) FLA. NSAIDs treated, (C) R .A . D-pen treated patients 
( 0 - 3  months). The results are expressed as mean -  S.D.
(n = 20). The S.D. bars are om itted for c larity . Statistical 
analysis shows:- a highly significant difference between Month 










#  A. Norm al H ealthy Controls
▼  B. R .A . -  NSAIDs treated
O  C. R .A . -  D -pen  treated
Time in Months
Fig.4.b.c Serial studies showinq the effects of R )  Collagen 2.‘ju g /m l on 
platelet aggregation (%) in (A ) Normal Healthy Controls,
(B) R .A . NSAIDs treated, (C) R .A . D-pen treated patients 
( 0 - 3  months). The results are expressed as mean -  S.D.
(n = 20). The S.D. bars are om itted for c larity . Statistical 
analysis shows:- a highly significant difference between 
Month 0 vs Month 3 R .A . D -pen* (P < 0.001).
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4.5 Effects of D-Pen treatment on B-TG, MDA and platelet
aggregation in rheumatoid patients shoving good or 
poor clinical responses
Table 8 illustrates the changes in Beta-thromboglobulin 
levels, MDA production and ED^q 's for platelet aggregation 
indicating a good or poor clinical response. Levels of Beta- 
thromboglobulin in the responder group showed a significant 
decrease in total B-TG mean 43—13 ng/ml compared to the non 
responders mean 65^12 ng/ml (P < 0.05).
With MDA production there was no significant difference 
between the good or poor clinical response groups upon 
stimulation with ADP 10.0 fimol/1, collagen 4.0 yug/ml and 
adrenaline 20.0 pmol/1.
With EDjjq aggregation the responder group showed a slight 
increase in sensitivity to lower concentrations of ADP, mean 
0.69-0.28 jLtraol/1, compared to a non responder mean 0.75^0.17 
jumol/1. Adrenaline responses were absent both in the 
responder and non responder groups, whilst collagen showed a 
slight increase in sensitivity within the non responder group 
mean 1.40i0.37 yug/ml compared to responder group mean 
1.58±0.35 yug/ml. However, statistical analysis of these 











ADP 10.0pmol/l .079 -  .020 .083 -  .029
Adrenaline
20.0pmol/l .036 - .023 .045 -  .023
Collagen 4.0pg/ml .051 -  .021 .052 -  .023
ED cq for Platelet 
Aggregation
ADP pmol/1 0.69 -  .28 0.75 t .17
Adrenaline pmol/1 >100.00 >100.00
Collagen jug/ml 1.58 -  .35 1.40 -  .37
Mean dose of 
D-pen mg/day 406 -  97 593 t  120
TABLE 8 Levels of Beta-thromboglobulin, MDA and E D ^
platelet aggregation in D-pen treated rheumatoid 
patients showing good or poor clinical responses. 
Results are expressed as mean -  S.D. Statistical 
analysis shows:- a significant difference between 
B -TG  responder vs non-responder* (P < 0.05).
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CHAPTER FIVE:
RESULTS - IN VITRO STUDIES
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5.1 Human platelet alpha2 adrenoceptors
Adrenaline, acting via an alpha2 adrenergic receptor, 
stimulates platelets to aggregate and secrete, and 
potentiates the aggregation and secretion induced by 
unrelated agonists. Therefore platelets may be useful for 
studying changes in alpha2 adrenergic receptor numbers or 
functions in human diseases and in defining molecular events 
involved in alpha adrenergio actions. These receptors have 
been characterised by radioligand binding techniques using
(3h ) dihydroergocryptine (Boullin & Elliott, 1979); (^H)
\
clonidine (Shattil, McDonough, Turnbull & Insell, 1981); and 
by direct binding to intact human platelets of (^H) yohimbine 
(Boon, Elliott, Grahaeme-Smith, Outlaw & Stump, 1981).
The aim of this investigation was to examine alpha 2 receptor 
expression on blood platelets from RA patients treated with 
D-pen in view of the loss of aggregation to adrenaline seen in 
these cells in earlier experiments.
5-1*1 (3h) yohimbine binding assay for alpha2 adrenergic
receptors on normal, RA-HSAIDs, RA-D-pen treated 
platelets
Non specific binding was estimated by the addition of an 
excess (50/iM) of unlabelled phentolamine to one set of assay 
tubes containing incubation medium and dilutions of (3h )
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yohimbine. Specific binding was taken to be the total amount 
of (^H) yohimbine bound, minus the non specific binding in the 
presence of phentolamine after incubation at 37°C for twenty 
minutes.
5.1.2 Dissociation constant (KD ) of alpha2 adrenergic 
receptors on platelets in normal, RA-NSAIDs and 
RA-D-pen treated groups
Figs.5.1.a, and 5.1.b show the results of various 
concentrations of (3h ) yohimbine binding to normal intact 
platelets, RA-NSAIDs treated platelets and RA-D-pen treated 
platelets. Scatchard plots were derived from these data.
(3h ) yohimbine bound in a saturable manner to the intact 
platelets, and the Scatchard analysis indicated a single 
site. Non specific binding was 35 —50% of total binding at all 
concentrations of (^H) yohimbine tested. Fig.5.1.6 
illustrates plots for affinity of the platelet receptors (Kp) 
for the radioligand (3h ) yohimbine in the three groups, 
control (Kj)) mean 2.6±1.0 nmol/1, RA-NSAIDs mean 2.5-1.00 
nmol/1 and RA-D-pen mean 2.8— 1.1 nmol/1. There was no 
significant difference in these (Kjj) values, thereby 
indicating similar affinity for the receptor antagonist in 
the three groups studied.
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5.1.3 Scatchard plots of data showing binding sites per 
platelet of normals, RA-NSAIDs and RA-D-pen patients
In six separate experiments the saturation binding isotherm 
of (^H) yohimbine was compared with platelets from healthy 
controls, RA patients receiving NSAIDs and RA patients on D- 
pen. The maximum number of alpha2 receptor binding sites 
(Bmax) on the basis of (^H) yohimbine specific binding on 
intact human platelets was determined by Scatchard anaylsis 
as shown inFig.5.1.c and Fig.5•1•d • The results in Fig.5.1.f 
show that the mean number of binding sites for controls were 
49.9*6.1 sites/platelet fmol/108 , for RA-NSAIDs 47.2±8.9 
fmol/108 cells and in RA-D-pen treated 35.2i6.8 fmol/108 
cells. These results indicated that the number of alpha2 
receptor binding sites were significantly lower in RA-D-pen 
patients compared to normals, and indeed with RA-NSAIDs 
patients, (P<0.01,P<0.05) respectively.
Platelet aggregation studies were also performed with normal 
platelet rich plasma to demonstrate that the (8H) yohimbine 
could antagonise the response to adrenaline. As much as 6^ /uM 
yohimbine failed to aggregate platelets, but as little as 
0.03pM inhibited the initial rate and extent of platelet 
aggregation induced by 1 0/jM adrenaline. This inhibition was 
half maximal at 0.2yuM and maximal at 1pM.
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%  Normal Control Platelets 





















8 120 4 16 20 24
Free ( 5H ) Yohimbine (nM)
F ig .5.1.a P latelet Alpha? adrenoceptors. The equilibrium binding data 
of (^H ) Yohimbine for Normal and R .A . -  NSAIDs platelets  
as a function of p H )  Yohimbine concentration. One of six 
sim ilar experiments.
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#  Normal Control Platelets 



















Free ( V l )  Yohimbine (nM )
F ig -5.1. b Platelet Alpha 2 adrenoceptors. The equilibrium binding data 
of (V l)  Yohimbine as a function of (^H ) Yohimbine concent- 
tration for normal controls and RA patients D-pen treated.























#  Normal Control Platelets 
^  R .A . -  NSAIDs Treated Platelets
0 10 20 30 40 50
3 8( H ) Yohimbine Specifically Bound (Alpha9 sites/platelets fmols/10 )
Fig. 5.1.C Scatchard plot of data showinq binding sites per plate­
let of normal controls and R .A . -  NSAIDs treated  
patients. Fach value is the mean of triplicate deter­
minations. One of six sim ilar experiments.
-170-
•  Normal Control Platelets 
















3 0( H ) Yohimbine Specifically Bound (Alpha^ sites/platelets fmols/10 )
Fig. 5.1.d Scatchard plot of data showing binding sites per platelet 
of normal and R .A . D-pen treated patients. Each value 



















Fig. 5.1.e The dissociation constant of Alpha? adrenergic receptors on
platelets in (A ) Normal Controls, ^B ) R .A . -  NSAIDs treated  
(C ) R .A . -  D-pen treated. Saturation binding was performed 
w ith (^H ) yohimbine binding to intact platelets and the 
dissociation constant (K n ) determined from Scatchard plots. 



















Fig. 5 .1 .f The number of Alpha~ adrenergic receptors on platelets in 
(A ) Normal Controls, tB) R .A . NSAIDs treated, (c )
D-pen treated. Saturation binding was performed with 
(^ H ) Yohimbine to intact platelets and the maximum binding 
(Bmax ) determined from Scatchard plots. The bars represent 
mean values (n = 6 ). Statistical analysis shows:- a 
significant difference between A vs C (P < 0.01) and B vs C 
(P < 0 .05).
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5.2 In vitro studies with D-pen9 sodium aurothiomalate
and other thiol reactive compounds
The observations described in vivo for D-pen show a marked 
effect of the drug on platelet function and in view of these 
findings attempts were made to reproduce these same 
observations in vitro using drugs or other chemicals known to 
react with sulphydryl groups. These included D-pen, sodium 
aurothiomalate, pHMPSA and cysteine which were used at 
various concentrations and incubation times in the following 
experiments.
5.2.1 The effects of in vitro incubation time and 
concentration of D-pen on platelet aggregation 
inhibition to ADP9 adrenaline and collagen
In order to establish an optimum and maximum range for 
incubation times and concentrations of drugs used, 
preliminary experiments were performed with D-pen . The final 
range of incubation times selected were 10nins, 30mins and 60 
rains, with concentrations of D-pen 5^»g/ml, 10/ig/ml, and
20/ig/ml.
The results for in vitro D-pen are represented in Figs.5.2.a 
5.2.b and 5.2.c the total platelet aggregation inhibition to 
ADP, adrenaline and collagen are shown in Table 9. The graphs 
show D-pen caused both time and drug concentration dependent
-174-
inhibition of platelet aggregation. There was also an 
apparent increase in spontaneous aggregation with time. In 
the test systems D-pen affected responses to all three 
platelet agonists.
The effect was most marked with adrenaline, followed by ADP 
and collagen. However, in this in vitro regime D-pen did not 
bring about such dramatic inhibition as in the in vivo 
experiments. Clearly, from Table 9 the inhibitory effect of 
D-pen on platelet aggregation was most marked with 
adrenaline, followed by ADP and finally collagen. This 
pattern was maintained at all incubation times and drug 
concentrations examined.
Statistical analysis of all the in vitro aggregation 
inhibition studies gave parallel results Irrespective of 
incubation times or D-pen concentrations used. Examples of 
these were, adrenaline versus ADP at 5 minutes incubation and 
5jig/ml D-pen (P < 0.01), ADP versus collagen (P < 0.05), 
adrenaline versus collagen (P < 0.01), with similar P values 
obtained at 30 minutes and 60 minutes incubation and at 
10jig/ml and 20jig/ml concentrations of D-pen. The rank order 
noted with these agonists parallels the observed changes to 


























IN C U B A TIO N  TIM E 10 M IN U TES
• nn I O  Normal controls (no D -pen)
IUU~i n  ADP 2.5p mol/1
90-
Collagen
Adrenaline 5^ i mol/1
Final concentration of D-pen in pg/ml
Fig.5.2.a The effects of in vitro incubation (37°C 10 mins) of various 
concentrations of D-penicillam ine on % inhibition of platelet 
aggregation using agonists (1 ) ADP 2.5/u mol/1 (2 ) Collagen 4ug/m l, 
(3 ) Adrenaline 5jj mol/1 -t- controls (no D-penicillam ine). The 
results are expressed as means (n = 10). The s.d. bars are 

























INCUBATION TIME 30 MINUTES
D Normal controls (no D -pen)
□ ADP 2.5jj mol/1 
I  Collagen tyjg/ml 











0 5 10 15 20
Final concentration of D-pen in pg/ml
Fig. 5.2.b The effects of in vitro incubation (37°C 30 mins) of various 
concentrations of D-penicillam ine on % inhibition of platelet 
aggregation using agonists (1 ) ADP 2.5^j mol / I  (2 ) Collagen 4ug/m l, 
(3 ) Adrenaline 5p rnol/I + controls (no D -penicillam ine). The 
results are expressed as means (n = 10). The s.d. bars are 
om itted for c larity .
























IN C U B A TIO N  T IM E  60 M IN U TES
Normal controls (no D-pen) 
ADP 2.5p mol/1 
Collagen ^ug/ml 









5 100 15 20
Final concentration of D-pen in }jg/ml
Fig. 5.2.c The effects of in vitro incubation (37 C 60 mins) of various 
concentrations of D-penicillam ine on % inhibition of platelet 
aggregation using agonists (1) ADP 2.5^ j mol /I (2 ) Collagen 4ug/m l, 
(3 ) Adrenaline 5j j  mol/1 ♦ controls (no D-penlcillarnine). The 
results are expressed as means (n -  10). The s.d. bars are 
om itted for c larity .
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2 6 - 6  
42 t  7 
51 t  6 
1 5 - 4
B
2 0 - 6  
2 8 - 5  
41 t 7 
1 2 - 3
C
3 8 - 6
4 8 - 6
60 t 10 







3 9 - 5  
5 0 - 7  
63 1 8 
2 0 - 6
22 -  4 
3 1 - 6  
4 9 - 7  
1 9 - 4
4 5 - 6  
5 5 - 9  
75 1 6 







5 0 - 8
6 6 - 7
7 3 - 8
3 0 - 7
3 8 - 8  
49 -  10 
5 7 - 9  
2 8 - 6
60 - 15 
8 5 - 7  
90 t 5 







TABLE 9 Comparing the Inhibition of p latelet aggregation by Pre 
Incubation of D-penicillam ine 10, 30 and 60 minutes at 
various concentrations versus p latelet agonists ADP 
2.5jLimol/l, Collagen 4pg/ml and Adrenaline 5jumol/l. The 
results are expressed as means -  S.D. Statistical analysis 
shows:- a significant difference between A vs C (P < 0.01); 
A vs B (P < 0.05) and B vs C (P < 0.01), (see text).
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5-2.2 The effects of in vitro incubation time and 
concentration of Sodium aurothiomalate on platelet 
aggregation inhibition to ADP, adrenaline and 
collagen
A variety of enzyme systems are influenced by gold, 
particularly those requiring free SH groups. Comparisons of 
sodium aurothiomalate with D-pen (both sulphydryl compounds) 
have led to the intriguing proposal that they may act by a 
common mechanism. The observations found in in vivo and in 
vitro experiments with D-pen were extended to study sodium 
aurothiomalate in vitro and to compare these findings. The 
ability of sodium aurothiomalate to inhibit platelet 
aggregation was investigated at various incubation times and 
at different drug concentrations.
Preliminary experiments were performed in order to establish 
the optimal times and final drug concentration ranges needed 
to evaluate platelet aggregation inhibition with sodium 
aurothiomalate. Following these initial experiments 
incubation times selected were 10 mins, 30 mins, and 60 mins, 
and concentrations of sodium aurothiomalate 0.5^ig/ml, 
1.5/ig/ml, 3pg/ml and 5^ig/ml (final concentration).
The results shown in Figs 5-3.a, 5.3.b and 5.3.c illustrate 
that sodium aurothiomalate reacted in a similar manner to D- 

























IN C U B A TIO N  10 M IN U TES
Normal controls (No Aurothiomalate) 
ADP 2.5p mol/1 
Collagen 4pg/ml 











0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
Final Concentration of Sodium Aurothiomalate in jljg/m l
Fig,5.3.aThe effects of in vitro incubation (37°C 10 mins) of various
concentrations of Sodium Aurothiomalate on % inhibition of 
platelet aggregation using agonists (1 ) ADP 2.^u m o l/lt 
(2 ) Collagen 4pg/ml, (3) Adrenaline 5p mol/l + controls (no 
Sodium Aurothiom alate). The results are expressed as means 

























IN C U B A TIO N  30 M IN U TES
Normal controls (No Aurothiomalate) 












0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
Final Concentration of Sodium Aurothiomalate in pg/ml
Fig.5.3.b The effects of in vitro incubation (37°C 30 mins) of various 
concentrations of Sodium Aurothiomalate on % inhibition of 
platelet aggregation using agonists (1 ) ADP 2.5/j mol/1,
(2 ) Collagen 4pg/m I, (3 ) Adrenaline 5p mol/1 + controls (no 
Sodium Aurothiom alate). The results are expressed as means 
(n = 10). The s.d. bars are omitted for c larity .
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IN C U B A TIO N  60 M IN U TES
100-
Normal controls (No Aurothiomalate) 
ADP 2.5p mol/1 
Collagen ^ jg /m l 
Adrenaline mol/1
■5 80
0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 5 5.5
Final Concentration of Sodium Aurothiomalate in /jg /m l
Fig.5.3.c The effects of in vitro incubation (37 C 60 mins) of various 
concentrations of Sodium Aurothiomalate on %  inhibition of 
platelet aggregation using agonists (1 ) ADP 2.5^ mol/1,
(2 ) Collagen 4/jg/m l, (3) Adrenaline 5/j mol/1 + controls (no 
Sodium Aurothiomalate). The results are expressed as means 
(n = 10). The s.d. bars are om itted for c larity .
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TABLE 1U Comparing the Inhibition of platelet aggregation by Pre 
Incubation of Aurothiomalate 10, 30 and 60 minutes at 
various concentrations versus platelet agonists ADP 
2.5jjm ol/l, Collagen fyig/ml and Adrenaline 5jjm ol/l.
The results are expressed as means -  S.D.
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dependent inhibition of platelet aggregation. Responses to 
adrenaline were mean 40±6?6 at 10 mins, ADP mean 30±6? at 10 
mins and collagen mean 2826$ at 10 mins. However, the 
important observation seen in these in vitro experiments was 
that the same pattern of response in order of magnitude was 
noted irrespective of final drug concentrations 
(adrenaline>> ADP> collagen). These observed results 
correlated very well with the experimental findings for D-pen 
in vitro.
5*2*3 The effects of pHMPSA and L-cysteine singly or in 
combination, on platelet aggregation inhibition of 
normal platelets stimulated with ADP, adrenaline and 
collagen
In the previous in vitro experiments inhibition of platelet 
aggregation related to D-pen treatment indicates a possible 
thiol blockade of SH groups on RA platelets. Since blood 
platelets contain SH groups on their surface receptors 
experiments were broadend using fresh healthy normal 
platelets incubated with pHMPSA a non penetrating SH blocking 
agent. This was to determine whether any platelet aggregation 
inhibition developed after the addition of pHMPSA when 
stimulated by the agonists ADP, adrenaline and collagen, and 
to assess whether this inhibition was due to a blockade of the 
platelet surface SH groups as related to the D-pen effect.
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Initial experiments were performed using various times of 
incubation and concentrations of pHMPSA. However higher 
concentrations appeared to damage the platelet membrane and 
sensitivity of the platelets in the test system was impaired 
resulting in no data being generated. The established final 
concentration used in the experiments with pHMPSA and L- 
cysteine was (10“**M) and incubation time was exactly 1 minute 
prior to stimulation with either ADP, adrenaline or collagen. 
Standardisation of aggregation was accomplished by examining 
the aggregation pattern at 5, 10, 15» 20, 25 and 30 mins
respec tively.
Figs.5.4.a, 5.4.b and 5.4.c show that the blocking of surface 
SH groups of fresh normal platelets by incubation with the SH 
blocking agent pHMPSA (10"^M) resulted in maximum inhibition 
(>90S») of platelet aggregation for ADP, adrenaline and 
collagen, and that the addition of L-cysteine did not restore 
the platelets to a normal aggregation response. Platelet 
aggregation was observed over a 30 minute period at 5 minute 
intervals, but as shown in Fig.5.4.a inhibition was almost 
maximal in 5 minutes. Untreated controls showed some 


























O Control PRP 
□ PRP + pHMPSA
*  PRP + L-Cysteine











25 3010 15 205
Time in Minutes
Fig .5.4 .a  The effects of p-hydroxymercuriphenylsulphonate (pHMPSA) 100 j^liM, 
and L-Cysteine lOOpM, singly or in combination on the % inhibition 
of Platelet aggregation of normal c itrated platelet rich plasma 
( PRP) produced by A.D.P. 2.5pm ol/l, compared to non treated
( PRP). The results are expressed as mean -  S.D. (n = 5).
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□ PRP + pHMPSA
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Time in minutes
Fig .5.4.b The effects of p-hydroxymercuriphenylsulphonate (pHMPSA) 100 juM, 
and L-Cysteine 100 ^iM, singly or in combination on the % inhibition 
of Platelet aggregation of normal citrated platelet rich plasma 
( PRP) produced by Adrenaline 5pmol/l, compared to non treated  
( PRP). The results are expressed as mean -  S.D. (n =5).
The S.D. bars are om itted for c larity.
























O Control PRP 
□ PRP + pHMPSA
*  PRP ♦ L-Cysteine
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Time in Minutes
Fig .5.4.C The effects of p-hydroxymercuriphenylsulphonate (pHMPSA) lOOpM, 
and L-Cysteine lOOpM, singly or in combination on the % inhibition 
of Platelet aggregation of normal citrated p latelet rich plasma 
( PRP) produced by Collagen 4M0/m l, compared to non treated
( PRP). The results are expressed as mean- S.D. (n = 5).
The S.D. bars are om itted for c larity.
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5.2.4 The effects of dithiothreitol on fresh RA-D-pen 
treated platelets and the consequent responses of 
platelet aggregation to adrenaline
The aim of this investigation was to determine if the altered 
platelet aggregation response found with RA-D-pen treated 
platelets could be restored by the addition of 
dithiothreitol, a powerful reducing agent able to reverse any 
blocking of SH - groups on the rheumatoid platelets. 
Experimental evidence suggests that the thiol-disulphide 
status of platelets is causally related to aggregation and 
that agents react with thiol groups such as pHMPSA inhibit 
aggrega tion.
Various initial experiments were performed to determine 
incubation times, concentration of dithiothreitol and 
adrenaline to be used in normal and patient groups. From these 
observations the incubation times performed were 1 minute, 2 
minutes, and 5 minutes. Final concentrations of 
di thio threitol were 0.5 mM and 1 .0 mM and the concentration of 
adrenaline for stimulating platelet aggregation was 5/amol/l.
The results in Table 1 1 show that in vitro pre-incubation of 
RA-D-pen platelets with DTT brought about a significant 
restoration of the response to adrenaline. Aggregation 
responses increased from a mean 121356 platelet aggregation to 
a mean level of 5611156 in RA-D-pen platelets + DTT 0.5 mM and
-1 90-
mean of 6 1—1 2>6 with 1.0 mM DTT. Although their aggregability 
was not restored to the mean values of normal controls 88±8?S, 
the increase was still highly significant (P < 0.01). These 
results are suggestive of a possible thiol blockade by D-pen 
affecting platelet surfaces. Addition of higher 
concentrations of DTT caused a progressive but slow platelet 
aggregation within the test system, starting after a lag 




R .A . D-pen  
treated
No DTT  
(n=5)

















No DTT  
(n=5)
1 Minute 1 2 - 3 56 -II * 61 t  12 83 ^ 8 00 CD 1 + 00 • «
2 Minutes 1 6 - 4 49 t  7 51 i  8 03 0 1 
+ 
00 85 -  10
5 Minutes 9 - 4 42 t  9 45 t  9 7 1 - 9 7 6 - 9
Incubation time 
Dithiothreitol 
(D T T )
% Platelet aggregation responses to agonist 
5p mol/1 Adrenaline
Table 11 The e ffec t of D ithiothreitol (D T T ) 0.5m M, l.OmM on
Platelet aggregation responses to 5jj mol/1 of Adrenaline 
in R .A . D-pen treated patients compared to normal 
controls. The results are expressed as mean -  S.D. 
(n=5). Statistical analysis shows:- a significant 
difference between R .A . D-pen (no D TT) vs R .A .
D-pen (+ D T T )*  (P < 0.01) and R .A . D-pen (no D TT) 





The results presented In this thesis reveal a significant 
number of abnormal platelet parameters in patients with 
rheumatoid arthritis, Including an increase in total number 
and a higher degree of platelet activity ( increased B-TG and 
hypersensitivity to platelet agonists in vitro). These 
observations together with a higher platelet turnover are 
consistent with an Increased thrombocytosis in rheumatoid 
arthritis. These findings are discussed in the first part of 
this chapter.
Following treatment with D-penicillamine (D-pen) the 
observations of increased thrombocytosis returned to a more 
normal level, but with clear cut differences in the platelet 
response. There was total abolition of the aggregatory 
response to adrenaline, with reduced sensitivity to both ADP 
and collagen, platelet alpha2 adrenoceptors were also 
reduced. These findings will be examined and discussed in the 
second part of this chapter.
Hole of platelets in rheuaatoid arthritis
Thrombocytosis is a common finding in patients with active 
and early rheumatoid arthritis (Bean, 1965; Pazdur & Kopec, 
1970; Selroos, 1972; Hutchinson, Davis & Jayson, 1975; 
Hernandez, Rowan, Kennedy & Buchanan, 1975; Valenti, 
Chianese, Tirrl & Giordono, 1979; Colli, Maderna, Tremoli, 
Colombo & Canesi, 1982). Its presence has been observed in a 
significant proportion of patients and appears to correlate
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with disease activity ( Hutchinson, Davis & Jayson, 1975)* 
However, the mechanism underlying the peripheral 
thrombocytosis occurring in rheumatoid arthritis has not 
been elucidated. This present study confirms the findings of 
thrombocytosis in rheumatoid arthritis, but of greater 
importance lends supportive evidence that the rheumatoid 
platelets have both abnormal platelet parameters and 
functions.
In principle an elevated platelet count in disease may be 
attributable to either Increased life span, increased 
production or changed distribution of platelets within the 
circulation. As will be discussed, the platelet changes 
observed in rheumatoid arthritis in this study would support 
the theory that the elevated platelet count is due to 
increased production involving excess utilisation and 
consumption during the inflammatory process.
At one stage thrombocytosis in rheumatoid arthritis had been 
attributed as secondary to blood loss and iron deficiency 
anaemia. Pazdur & Kopec, (1970) and Hutchinson, Davis & 
Jayson, (1975) proved that there was no correlation between 
the Increase of platelet count and degree of anaemia. Indeed, 
although observations in this study showed a mean lower 
haemoglobin level in all three disease states, there was no 
apparent correlation between the anaemia and thrombocytosis. 
Normo-or hypercellularity of bone marrow is known to occur in 
the majority of rheumatoid patients (Selroos, 1972); and the
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life span of circulating platelets is determined by 
physiological senescence and by random destruction of 
thrombocytes taking part in continuous repair of microdamage 
to the vessel walls, or in inflammatory repair.
The investigation presented in this thesis on platelets and 
platelet parameters demonstrates that the major population 
of platelets in rheumatoid arthritis is young and small 
(microthrombocytes) which are functionally more active than 
ordinary or older platelets. These platelet populations 
showed in aggregation experiments an increased sensitivity 
to low concentrations of ADP and especially collagen. These 
findings are consistent with the hypothesis that platelet 
changes are due to Increased platelet turnover leading to 
young and hyperactive platelets, with old "spent" platelets 
being also present in the circulation. Platelet numbers and 
parameters were measured and a significant difference noted 
with platelet count, mean platelet volume and platelet crit 
in the rheumatoid groups compared to normal. These additional 
observations also support the theory that the major platelet 
populations in active rheumatoid arthritis are young, small 
and hypersensitive.
When platelet sizing techniques became available it was 
appreciated that there were considerable differences in 
platelet sizes. The mean platelet volume is known to Increase 
somewhat with time post-venesection (Giles, 1981); and the 
platelet crit Increases similarly. However, as conditions
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for collecting blood and performing the analysis were the 
same for all groups in this study, similar time-dependent 
changes in the mean platelet volume and platelet crit would be 
expected to have occurred in all the samples.
Histograms showing platelet volume distribution were plotted 
and by measuring their relative surface area the percentage 
of microthrombocytes and megathrombocytes present were 
calculated. The rheumatoid groups all showed an increased 
percentage of microplatelets and a lower number of 
megathrombocytes resulting in a mean platelet volume lower 
than that found in normal subjects. In the normal population a 
non-linear inverse relation between platelet count and mean 
platelet volume has been found (Levin & Bessman 1983), the low 
mean platelet volume found in rheumatoid thrombocytosis may 
be an extrapolation of this relation. The introduction of 
density gradient techniques by Karpatkin ( 1969) demonstrated 
differing populations of platelets which he believed to 
result primarily from an ageing process, the lighter 
platelets being the younger and the cells becoming more dense 
as they grew older. He supported this theory by pulse 
labelling experiments using (75ge) Selenomethionine. 
However, more recent experiments using cohort labelling 
suggest that this is not the case (Paulus, Breton-Gorius, 
Kinet-Denoel & Boniver, 197*1; Penington, Streatfield & 
Roxburgh, 1 976 ; Corash & Shafer, 1982). These studies suggest 
that platelets of varying density are released 
simultaneously from the bone marrow, thus making the
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possibility that differences between the three types of 
megakaryocytes represent a major source of heterogeneity of 
platelets. The data presented with mean platelet volume 
analysis would support this postulate in that different 
megakaryocyte ploidy classes release platelets of varying 
densities that are not altered in the circulation. Thus, the 
less dense platelets found in rheumatoid arthritis derived 
from megakaryocytes with higher ploidy, 32-64n, (Firkin, 
1985) and accompanied with thrombocytosis may be extremely 
important. They, therefore, may function in adhesion and 
aggregation, or in providing fibrillar bayonet type 
platelets that are important for their interaction with other 
cells in promoting inflammation and the formation of fibrin 
(Firkin, 1985).
Blood platelets may participate in the initiation and 
progression of rheumatoid arthritis in two ways. First, where 
platelets accumulate locally at points of endothelial 
injury, microthrombl (containing platelet aggregates and 
fibrin) are formed and may therefore be predisposed to 
enhanced platelet destruction, hence a shortened survival 
(Vollersten, Fuster, Conn, Luthra, McDuffie, Bowie & 
Ilstrup, 1982). Moreover, the increased turnover of 
fibrinogen in rheumatoid arthritis (Conn, McDuffie, Kazmier, 
Schroeter & Sun, 1 976) and deposits of fibrin may be 
considered indicative of occult activation of intravascular 
coagulation in this disease, thus arguing against 
prolongation of platelet survival (Bennett, Eddie-Quartey &
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Holt, 1972; Selroos & Wegelius, 1973; Hutchinson, Davis & 
Jayson, 1975).
The hypothesis that blood platelets continuously release the 
contents of their storage granules while in the circulation 
has been proposed (OfBrien, 1978). This hypothesis is 
supported by various conditions in which there is a reduction 
of the intra-cellular components of platelets. For example in 
cases of disseminated intravascular coagulation platelets 
continue to circulate even though there is evidence for a 
reduction in their spheric granules (Pareti, Capitanio & 
Mannucci, 1976). A similar mechanism may be operating in 
rheumatoid arthritis especially as beta-thromboglobulin is 
only produced in the alpha granules (Ludlam, 1979).
Using a radioimmunoassay, measurements of beta 
thromboglobulin in the rheumatoid patients showed a 
significant Increase in plasma levels compared with healthy 
controls. According to Ludlam, Moore, Bolton, Pepper & Cash 
(1975); Ludlam, (1979); Zahavl & Kakkar, (1980) the plasma 
concentration of B-TG is assumed to reflect platelet release 
reaction, as well as platelet turnover (Doyle, Chesterman, 
Cade, McGready, Rennie & Morgan, 1980). It is a platelet- 
specific marker and shows direct evidence of enhanced in vivo 
platelet activity and release reaction. This increase in 
platelet production may have some relevance to rheumatoid 
arthritis in that platelet activation either induced by 
circulating immune complexes or increased sensitivity to
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collagen, may promote both platelet aggregation and release 
from these platelets of cationic inflammatory mediators such 
as cathepsin, thromboxane A2 an  ^connective tissue activator 
peptide (Castor, Ritchie, Scott & Whitney, 1977; Smith & 
Castor, 1978), which may contribute to the rheumatoid 
vascular inflammatory state. This suggestion can be 
explained by a binding of IgG-containing immune complexes via 
the platelet Fc receptor associated with phagocytosis and 
will in turn lead to platelet release and the formation of 
circulating platelet aggregates, which are subsequently 
sequestered in the spleen. This possibility suggested, is 
supported by observations discussed by Pfueller & Luscher, 
( 1972) .
Secondly, exposure of the subendothelium stimulates the 
platelets to release subcellular constituents including ADP 
and beta-thromboglobulin (Holmsen, 1975); and to synthesise 
thromboxane A2 from arachidonic acid (Marcus, 1978). It is 
interesting to note that the increased sensitivity of 
rheumatoid platelets to ADP and particularly collagen 
observed in this project may have important consequences 
leading to tissue damage, especially of endothelial cells, or 
impaired fibrinolytic mechanisms in rheumatoid arthritis.
Structural determinants both in the collagen molecule and on 
the platelet membrane that mediate both adhesion and 
aggregation may well help to accelerate this process. An 
understanding of the interaction of the physiological
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agonists, for example, collagen, ADP and adrenaline with 
platelet membranes and the mechanism of platelet activation 
induced by these agonists, may prove to be very important in 
the pathogenesis of disease states. Most of these agonists 
have been reported to rely upon fibrinogen (elevated in most 
rheumatoid patients) binding to platelet receptors as an 
essential requirement for platelet agregatlon (Bennett & 
Vilaire, 1 979; Peerschke, 1 982) and collagen appears to play 
a vital role in the interaction between subendothelium and 
platelets. This interaction is thought to be crucial to the 
physiology of the primary haemostatic plug as well as to the 
role of platelets in disease states.
Collagen induced platelet aggregation is a complex process 
thought to involve several different mechanisms (Nyman, 
1977)* This author has shown that collagen from various 
sources as well as different concentrations are capable of 
activating aspirin inhibited platelets, thus suggesting that 
there are at least two mechanisms of collagen induced 
platelet activation, one dependent, and the other 
independent of arachidonic acid metabolism. This is 
supported by Best, Holland, Jones & Russell, (1980) who 
postulated that collagen can apparently induce aggregation 
and secretion via two pathways, one involving thromboxane 
production, the other by a direct mechanism independent of 
thromboxane biosynthesis.
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In this context, drugs that Inhibit platelet cyclooxygenase 
activity such as aspirin and other NSAID*s have attracted a 
great deal of attention since they were first shown to inhibit 
release reaction and some platelet aggregation. However, 
more recent studies (Kinlough-Rathbone, Cazenave, Packham & 
Mustard, 1980) have shown that although aspirin inhibits 
aggregation it does not affect platelet adhesion to collagen 
or the release reaction of adherent platelets. At high doses 
aspirin in fact blocks endothelial prostacyclin synthesis 
and can therefore potentiate platelet aggregation in vivo. 
Since the collagen-induced release reaction is also 
unaffected by systems that remove ADP, it has been suggested 
that platelets adhering to collagen may be capable of 
undergoing the release reaction by a third pathway which is 
independent of prostaglandins and thromboxane formation and 
release of ADP (Kinlough-Rathbone, Cazenave, Packham & 
Mustard, 1980). The increased sensitivity found in 
rheumatoid platelets to concentrations of collagen may 
therefore imply enhanced activity of this pathway in 
sustaining Inflammation.
In addition to these compounds, activated platelets release 
another important mitogenic factor, platelet derived growth 
factor (PDGF). This can induce the migration of smooth muscle 
cells, and stimulation of the normal endothelium adjacent to 
the damaged area. This can result in the synthesis of 
prostacyclin, a potent inhibitor of platelet aggregation, 
hence the balanced equilibrium that normally exists between
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vessel wall endothelium and platelets break downf more 
platelets are stimulated resulting in increased inflammatory 
mediators being released and hence thrombocytosis.
Although the lipid composition and architecture of the 
platelet plasma membrane undoubtedly are critical in 
pathophysiological processes, precise relationships between 
platelet membrane, lipid structure and platelet function 
remain unknown. Interaction of the platelet plasma membrane 
with either particulate stimuli (subendothelial collagen) or 
soluble stimuli (ADP, adrenaline) initiate profound changes 
in membrane lipids including (a) the development of 
procoagulant activity, so called platelet factor 3» which is 
thought to be associated with absorption of activated factor 
V on the platelet surface (Marcus, 1978); (b) an increase in 
the turnover of phospholipids, including phosphatidyl 
inositol (Marcus, 1978); and (c) the hydrolysis and 
mobilisation of arachidonic acid from phospholipids with 
consequent synthesis of biological active elcosanoids 
(Marcus, 1 978).
Thus the platelet is a cell evolved to maintain the integrity 
of the vascular compartment and as would be expected has an 
intimate association with humoral and cellular elements in 
the blood concerned with repair, defence and nutrition, 
although the functional attributes and properties may be more 
Important for some aspects compared to others. Nevertheless, 
the platelet should not be thought of as a cell in isolation,
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it has a particular affinity and integration with cellular 
elements of the vessel wall and humoral elements concerned 
with maintenance, surveillance and repair of vascular 
integrity and more peripherally with the inflammatory 
response and the body's defence system. In this respect, 
alterations to platelets in numbers, parameters, increased 
turnover and sensitivity may have important implications in 
the rheumatoid disease process.
Indeed, the therapeutio effect of D-pen in diseases such as 
rheumatoid arthritis could be to inhibit those stimuli by 
altering platelet function at the membrane and receptor level 
in conjunction with impairment of neutrophil polymorphs, 
monocytes, macrophages and lymphocytes.
Effects of D-penicillamine on platelets in rheumatoid 
arthritis.
D-pen is a valuable drug used for the treatment of the 
autoimmune disease-rheumatoid arthritis (Multicentre trial 
group, 1973)• The explanation for its capacity to suppress 
rheumatoid inflammatory disease, however, remains generally 
unclear. D-pen has been shown to have wide ranging activity in 
a variety of in vitro biological systems. The relevance of 
these activities to its clear clinical anti-rheumatic 
activity has been discussed at length but with few positive 
conclusions.
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Following D-pen therapy the results presented in this thesis 
reveal a trend to more normal platelet function, presumably 
secondary to improvement in disease activity. Initial 
observations showed rheumatoid platelets after treatment 
with D-pen to have Impaired aggregation responses to ADP, and 
collagen with almost total inhibition of the adrenaline 
response. This dramatic effect prompted the investigation of 
alpha2 adrenoceptor function on blood platelets and the 
interaction of D-pen with the platelet surface in vitro.
According to the generally accepted concept, platelets 
normally circulate in a "resting" state and are recruited for 
functional performance by contact with a foreign surface, or 
by being acted upon by specific soluble agents functioning as 
activators. The activation which follows is mediated by 
specific reactions at the membrane level leading to the 
products of Intracellular "second messengers" that transfer 
initial contaot into a functional response. It follows from 
this that the properties of the plasma membrane, its 
receptors and of the intracellular organelle membranes are 
highly relevant to these functions.
D-pen can modulate mononuclear cell functions via effects on 
cell membranes. Since these are poorly understood this 
present study has investigated the effects of D-pen therapy 
on platelets, cells with well defined receptors coupled to a 
clear cut response-aggregation. Human platelets can take up 
and respond to adrenaline and other catecholamines.
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Adrenaline activates platelets by binding to specific alpha 2 
adrenergic receptors, by inhibiting adenylate cyclase and by 
promoting Ca2+ translocation. An understanding of the 
mechanism of platelet-adrenaline interaction is important in 
order to study the nature of peripheral alpha2 adrenoceptors 
and their pharmacological manipulation, also the coupling of 
the adrenergic stimulus to its receptor and the intracellular 
responses leading to platelet activation. As will be 
discussed, following D-pen therapy platelet aggregation in 
response to adrenaline showed almost total inhibition, 
perhaps this may be due to an effect on alpha2 adrenoceptors.
In an attempt to relate drug effects more directly to alpha2 
receptors radio-ligand binding studies using (3H)yohimbine 
were performed. Most of the binding studies on alpha2 
adrenergic receptors have been performed with lysed platelet 
membrane preparations which precludes the study of the 
coupling between ligand binding and the function of intact 
platelets. However, in this study intact, discoid functional 
platelets were used as proposed by the method of Boon, Elliot, 
Grahame-Smith, Outlaw & Stump, (1981) thus removing any 
anomaly of lysed ruptured platelet membranes interfering 
with receptor mechanisms. Radioligand binding is a technique 
that allows one to quantify adrenergic receptors 
(independent of any response mediated by those receptors ) 
and allows a direct test of the hypothesis that D-pen is 
possibly associated with altered adrenergic receptors. 
Alpha2 adrenoceptor binding capacity was moderately
decreased in the RA-D-pen treated platelets compared to both 
healthy and RA-NSAID platelets. This reduction in receptor 
number could contribute to the reduced response to adrenaline 
mediated platelet aggregation found in RA-D-pen treated 
platelets. The intact aggregatory response to ADP and the 
absence of a gross reduction in the aggregation response to 
collagen are against a generalised effect of circulating 
anti-aggregatory prostaglandins or other factors. However, 
there is a marked dissociation between the modest reduction 
of alpha2 receptors binding sites and the virtually total 
inhibition of the aggregatory response to adrenaline in a 
functional study. This may be due to several different 
factors:- including, (a) altered adrenaline concentrations, 
(b) (^Hjyohimbine binding may not accurately reflect
adrenaline binding or (c) alpha2 adrenoceptors are 
ineffectively coupled to post receptor mechanisms.
Concentrations of adrenaline required to produce aggregation 
in platelet rich plasma are several orders of magnitude 
higher than those found in the circulation in vivo. Partly for 
this reason, the physiological relevance of this receptor 
mediated response is undetermined as the factors responsible 
for inter and intra individual variation in platelet 
responsiveness to adrenaline have not been fully assessed. 
Studies which have reported altered adrenaline aggregation 
of platelets with sex, age and ischaemic heart disease have 
used different methods of assessing the aggregation, and 
often using only a single concentration of agonist without
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full evaluation of overall dose response relationships 
(O'Brien, 1964b; Yokoyama, Kawishima, Sakamoto, Akita, 
Okada, Mizutani & Fukuzaki, 1 983)•
Alternatively, the receptors labelled by (^H) yohimbine may 
represent only a proportion of the population of functional 
alpha2 adrenoceptors. Thus, the concentration of binding 
sites identified by (^H) dihydroergocryptine which 
pharmacologically appear to have characteristics of alpha2 
adrenoceptors is two fold greater than those labelled with 
(^H) yohimbine in the same platelet membrane (Motulsky & 
Insel, 1982). Another possible explanation is that (^H) 
dihydroergocryptine is not selective for alpha2 adrenoceptor 
subtype and may also label other receptor populations. 
Morever, it is associated with a high level of non -specific 
binding to membrane components compared to my non-specific 
binding studies with (^H) yohimbine. However, it is not 
possible to make any definite statements regarding such 
differences between adrenaline functional aggregation and 
alpha 2 receptors until further information is available 
regarding the labelling of alpha2 receptors with (^H) 
yohimbine and (^H) dihydroergocryptine.
Observations that inhibition of the alpha receptor with (3h) 
yohimbine blocked the adrenaline effect is in keeping with 
the reports of other investigators who showed that the action 
of adrenaline on platelets is mediated through an alpha2 
receptor (Scrutton & Wallis; 1981). However, Yu & Latour,
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( 1 977 ) » and Kerry & Scrutton/( 1 9 8 3 ) conclude that the effect 
of adrenaline is possibly dependent upon a balance between 
alpha receptor agonists inhibiting adenylate cyclase and 
beta receptor agonists stimulating it. Alternatively a 
recent report by Figures, Strimpler, Scearce, Mills, 
Wachtfogel, Colman & Colman, (1984) show that adrenaline 
increases the binding of ADP to platelets and indicates that 
this has to be considered as another pathway by which 
adrenaline may exert its potentiating effect on ADP, the main 
pivot for platelet aggregation.
The dissociation between alpha2 adrenoceptor status assessed 
by (^HJyohimbine binding and functional aggregation may have 
yet another explanation. Only part of the adrenaline induced 
aggregation response may be directly dependent on alpha2 
adrenoceptor stimulation. A recent study by Connolly & 
Limbird; (1983) indicates that whilst increased Na+ 
concentration enhances platelet aggregation induced by 
adrenaline, there is no effect of Na+ on adrenaline Induced 
inhibition of PGE stimulated cyclic AMP production in Intact 
platelets. This differential modulatory influence suggest 
that at least part of the stimulus response coupling 
mechanism for the functional response to adrenaline is 
separate from that for adrenaline induced, alpha2 mediated 
inhibition of cyclic AMP production which is the only direct 
primary biochemical consequence of alpha2 adrenoceptor 
activation so far identified in the platelet.
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An understanding of the interaction of physiological 
agonists e.g. ADPy adrenaline and collagen with platelet 
membrane receptors and the mechanism of platelet activation 
induced by these agonists may prove to be important in the 
pathogenesis of many disease processes.
The catalytic unit of the adenylate-cyclase system is known 
to be regulated by membrane-bound receptors via guanine 
nucleotide regulatory (G) proteins (Rodbell, 1980). In 
platelets, agonists such as prostacyclin bind to the 
receptors and stimulate the catalytic unit of the enzyme via a 
stimulating (G) protein. However, other agonists for 
example, adrenaline, inhibit the catalytic unit, and do so 
via specific receptors which activate an inhibitory G protein 
(Gi); (Hildebrandt, Sekura, Codina, Iyenger, Manclark &
Blrnbaumer; 1983). Both effects are enhanced by GTP and 
inhibited by N-ethylmaleimide an SH-blocking agent (Jakobs, 
Lasch, Minuth, Aktories and Schultz, 1982). Treatment with N- 
ethylmaleimide prevents inhibition of adenylate cyclase and 
stimulation of GTPase by adrenaline in platelets without, 
however, significantly altering either uninhibited levels of 
adenylate cyclase activity or the extent of affinity for 
(3H)yohimbine. Thus under these conditions N-ethylmaleimide 
uncouples the alpha2 adrenoceptors from adenylate cyclase 
(Jakobs, Lasch, Minuth, Aktories & Schultz, 1982). One can 
postulate that D-pen may be uncoupling the receptor 
mechanisms in a similar way and thus blocking the action of 
adrenaline.
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Similarly reductions of sensitivity to ADP were noted 2-3 
months post D-pen therapy and one may postulate that this 
effect arises by a similar mechanism on the Gi protein. If * 
true, there must be a different coupling chemistry for alpha2 
adrenoceptor and ADP receptor to Gi protein, or adrenaline 
response is synergistically involved with both alpha2 
adrenoceptors and Gi protein effects. This hypothesis would 
help to explain the difference found between ADP and 
adrenaline responses in the aggregation inhibition 
experiments.
The in vitro functional response may not accurately reflect 
platelet alpha2 adrenoceptor function in vivo where the role 
of adrenaline may be to promote aggregation induced by a 
number of other influences acting in concert. It is possible 
that measurement of total concentration of alpha2 
adrenoceptors may be too crude an estimate of adrenoceptor 
status. Thus, it has been demonstrated that the alpha2 
adrenoceptor, in common with other adenylate-cyclase linked 
receptors, may exist in two interconvertible agonist 
affinity states (U*Prichard, Mitrius, Kahn & Perry, 1982). It 
is possible that the guanine nucleotide sensitive high 
affinity state may relate more directly to the functional 
activity of the receptor. Hence subtle changes in these 
affinity states of the adrenoceptor may be more relevant in 
relationship to adrenaline induced aggregation.
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Other workers indicate that aggregation and dense granule 
secretion are separate steps in the sequence of responses, 
only distinguished by different thresholds of concentration 
of the intracellular messengers. Such a proposal has 
previously been described wthe basic platelet reaction " 
(Holmsen, 1974; Holmsen, 1978; Holmsen, 1980) in which one 
and the same second messenger triggers responses. At present 
several intracellular messengers are believed to function 
such as Ca2+, diacylglycerol and inositol-1-4-5- 
triphosphate (Berridge;1984).
It is possible that adrenaline may affect the level of one or 
more intracellular messengers, for example, it is known that 
adrenaline lowers cAMP, perhaps diacylglycerol inositol-1- 
4-5- triphosphate and/or Ca2+ are also decreased or increased 
respectively, thereby controlling the different threshold 
for aggregation and secretion. Perhaps this process is having 
a dramatic effect on platelet aggregation associated with 
inflammatory events found in rheumatoid arthritis. 
Although the synergistic stimulation by adrenaline of 
thrombin induced platelet aggregation has been well 
documented ( 0 1 Brien^l 964b). the mechanism remains unknown. In 
platelet rich plasma, adrenaline induces a primary and 
secondary aggregation and secretion without causing shape 
change. Of these adrenaline induced responses only the 
primary aggregation is independent of the cyclooxygenase 
pathway (Scrutton & Wallis^ 1981). Adrenaline could be 
regarded as proaggregatory (positive agonist interaction ),
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by enhancing the synthesis of thromboxane A2 , or 
alternatively, by decreasing the level of intracellular cAMP 
(Jakobs, Saur & Schultz, 1976; Aktories & Jakobs, 1981; 
Cameron & Ardlie, 1 982). The abolition of adrenaline mediated 
function by D-pen could suppress any such reaction that 
required the synergistic action of this hormone. These 
findings may be relevant to the enhanced aggregation found in 
rheumatoid arthritis which diminished following treatment 
with D-pen, and loss of aggregatory response adrenaline >> 
ADP >> collagen.
Some recent studies have shown that the level of 
intracellular free Ca2 + in platelets may be regulated through 
the level of cAMP ( Zavoico & Feinstein, 1984). Another 
possibility is that diacylglycerol and Ca2+ function as 
synergistical second messengers, and that adrenaline changes 
the ratio between them. In order to elucidate the mechanisms 
of adrenaline action further studies are required in which 
synergistically induced aggregation and secretion, and 
alteration in intracellular free Ca2+, cAMP and phospholipid 
metabolism are measured simultaneously.
Despite extensive studies on the mechanism of action of 
adrenaline, the cellular events leading to its end function, 
for example, activation of contractile proteins are largely 
unknown. Presumably, after receptor stimulation platelet 
aggregation can be amplified by other mechanisms such as ADP 
release or thromboxane A2 synthesis, so that platelet
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aggregation does not directly reflect receptor involvement, 
such a concept could explain the discrepancy found between 
the loss of adrenaline - induced functional aggregation 
compared to the modest reduction in platelet alpha2 receptors 
in RA-D-pen platelets.
In this study assessment was made of the ability of 
adrenaline, ADP and collagen to induce malonyldialdehyde 
(MDA) release from the platelets of normal, RA-NSAID and RA- 
D-pen treated subjects. MDA is a major breakdown product of 
the metabolism of arachidonic acid to prostaglandin and 
thromboxane. Compared with normal controls MDA production 
was reduced both in the RA-NSAID and RA-D-pen treated 
platelets. This was not surprising as all patients had at some 
stage received various NSAID’s which are known inhibitors of 
cyclooxygenase. It is interesting to note that the MDA 
levels of the NSAID’s group and the pre-D-pen treated group 
(also NSAID's) showed a significant difference. A possible 
explanation for this is that five more patients in the pre-D- 
pen group were receiving indomethacin, a potent inhibitor of 
the cyclooxygenase pathway compared to the NSAIDfs group who 
included only two patients who had been prescribed this drug, 
no patient was receiving aspirin. The difference between the 
other NSAID's and aspirin is that aspirin irreversibly 
acetylates the platelet enzyme cyclooxygenase resulting in 
no MDA formation, since platelets cannot resynthesize 
cyclooxygenase the defect persists for their whole life cycle 
unlike the effect on other NSAID's where the effect only lasts
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several hours. Particularly low levels of MDA were found with 
adrenaline stimulation of RA-D-pen platelets. The degree of 
reduction in MDA concentration paralleled the loss of alpha2 
adrenoceptor response but was much less than the total 
inhibition of platelet aggregation in response to 
adrenaline, these results may be due to involvement of the Gi 
protein. It is known that adrenaline induces both primary and 
secondary aggregation of human blood platelets in vitro 
(Mills & Roberts; 1 967)• Secondary aggregation is thought to 
be mediated by ADP released from dense granules and, or, 
products of arachidonic acid metabolism, whereas primary 
aggregation seems to result from adrenaline stimulation of 
platelet alpha£ receptors. It would therefore seem that 
aggregation although mediated by the arachidonic acid 
pathway is quite capable of functioning by another pathway.
Current knowledge of platelets participating in the 
inflammatory process suggests that they participate by their 
functions of adhesion, release of endogenous platelet 
specific proteins and aggregation. The inhibitory effect of a 
drug can cause Impairment of any or all of these aspects of 
platelet function. I elected to study the effect on D-pen on 
platelet function using an in vitro aggregation technique 
because it encompassed platelet specific functions of 
membrane receptor regognition of agonists, release reaction 
and platelet aggregation. Addition of drug to normal 
platelets in vitro allowed a better control of experimental 
variables, such as donor selection, platelet count,
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incubation conditions, drug concentrations and solution 
stability. The in vitro studies agreed with earlier 
observations made ex vivo of inhibition of aggregation by D- 
pen, but the overall results were less specific with 
inhibition of both ADP and collagen as well as the adrenaline 
response. The latter was however more markedly affected than 
the other agonists. Differences betwen in vivo and in vitro 
experiments could relate specifically to the disease state or 
to the abnormal platelet parameters and turnover found in 
rheumatoid arthritis. It was also noted that longer 
incubations did not result in a significant increase or 
decrease in the inhibitory response. This suggests that D-pen 
inhibits platelet function by interacting with the platelet 
membrane where the drug may interfere with the binding of 
agonists to the specific receptors residing in platelet 
surface glycoproteins.
Indeed, in vitro experiments with both D-pen and sodium 
aurothiomalate (both sulphydryl compounds) showed 
inhibition of platelet aggregation with a similar pattern to 
that observed with D-pen in vivo. Thus supporting the theory 
that D-pen is possibly acting as a thiol blocker of SH-groups 
on the platelet surface. However, blockade of platelet cell 
surface SH-groups using the irreversible cell surface SH 
blocker pHMPSA produced a non-specific pattern of inhibition 
for platelet aggregation with all three agonists despite 
using a wide range of concentrations. The addition of L- 
cysteine only had a minimal effect in restoring aggregation,
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presumably pHHPSA is too potent a chemical for platelet 
receptor membranes resulting in non-specificity. However, 
good evidence for D-pen binding and blocking to platelet 
receptor mechanisms was achieved with dithiothreitol.
D-pen functioning on receptor mechanisms was determined with 
in vitro experiments using dithiothreitol (DTT) a powerful 
reducing agent, which largely restored the response to 
adrenaline. The most likely explanation for this process is 
that D-pen binds reversibly with the SH groups on the platelet 
surface forming disulphides. The addition of DTT appears to 
reverse this effect, removing the D-pen block and restoring 
the alpha2 receptor function. The DTT had no apparent 
detrimental effect on intracellular metabolism.
Concluding remarks
It is tempting to postulate that the loss of adrenaline 
response on platelets following D-pen treatment may have a 
modulatory effect on general platelet aggregation acting 
synergistically, thus modifying inflammation in rheumatoid 
arthritis. There may also be a general effect of D-pen on Gi 
proteins and thereby on adenylate cyclase activity. Gi 
protein is widely distributed and involved in regulating many 
cells. Potentially therefore, it may have a major impact on 
many cell types. Thirdly, D-pen may be acting on alpha2 
receptors in other sites in the body, but no evidence for this 
as yet. However, other inflammatory cells express alpha2
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receptors including lymphocytes and polymorphonuclear 
neutrophils (Sanders & Munson, 1985). All these theories 
remain purely speculative, further studies are obviously 
very important.
From these observations there is some indication that blood 
platelets might be involved in the pathogenesis and 
progression of rheumatoid arthritis. In this respect use of 
drugs like D-pen that, among other actions, inhibit platelet 
aggregation seem appropriate.
A combination of physiological stimuli may well be the 
modulatory mechanism in vivo. Exploration of synergistic 
actions on inhibition of platelet activation should be 
undertaken to determine how many of the parallel activation 
pathways need to be blocked, in order to prevent the 
complications which promote endothelial damage and 
inflammation. Such synergy between alpha2 adrenoceptors and 
other stimuli could be important in regulating other cells 
relevant to the pathogenesis of rheumatoid arthritis. The 
unravelling of these pathways has significant implications 
for therapeutic intervention with pathological states such 
as rheumatoid arthritis as well as for the understanding of 
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